Protoxin-ii variants and methods of use

ABSTRACT

The present invention relates to Protoxin-II variants, polynucleotides encoding them, and methods of making and using the foregoing.

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a Continuation of co-pending application Ser. No.15/060,158 filed Mar. 3, 2016, which claims the benefit of priorityunder 35 U.S.C. §119(e) to U.S. Provisional Application 62/127,339,filed Mar. 3, 2015, the disclosure of each are herein incorporated byreference in their entirety.

FIELD OF THE INVENTION

The present invention relates to Protoxin-II variants, syntheticpolynucleotides encoding them, and methods of making and using theforegoing.

BACKGROUND OF THE INVENTION

Voltage-gated sodium channels (VGSC) are present in all excitable cellsincluding cardiac and skeletal muscle cells and central and peripheralneurons. In neuronal cells, sodium channels are responsible foramplifying sub-threshold depolarizations and generating the rapidupstroke of the action potential. As such, sodium channels are essentialto the initiation and propagation of electrical signals in the nervoussystem. Aberrant sodium channel function is thought to underlie avariety of medical disorders (Hübner and Jentsch, Hum Mol Genet11:2435-45, 2002), including epilepsy (Yogeeswari et al., Curr DrugTargets 5:589-602, 2004), arrhythmia (Tfelt-Hansen et al., J CardiovascElectrophysiol 21:107-15, 2010), myotonia (Cannon and Bean, J ClinInvest 120:80-3, 2010), and pain (Cregg et al., J Physiol 588:1897-904,2010). Sodium channels are typically a complex of various subunits, theprinciple one being the pore-forming alpha-subunit, which is alonesufficient for function.

Nine known members of the family of voltage-gated sodium channel alphasubunits exist in humans, Nav1.1-Nav1.9. The Nav1.x subfamily can bepharmacologically subdivided into two groups, the tetrodotoxin(TTX)-sensitive and TTX-resistant. Nav1.7, (a.k.a. PN1 or hNE) isencoded by the SCN9A gene, is TTX-sensitive and is primarily expressedin peripheral sympathetic and sensory neurons. Nav1.7 accumulates atnerve fiber endings and amplifies small sub-threshold depolarizationsand acts as a threshold channel that regulates excitability.

Nav1.7 function is implicated in various pain states, including acute,inflammatory and/or neuropathic pain. In man, gain of function mutationsof Nav1.7 have been linked to primary erythermalgia (PE), a diseasecharacterized by burning pain and inflammation of the extremities (Yanget al., J Med Genet 41:171-4, 2004), and paroxysmal extreme paindisorder (PEPD) (Fertleman et al., Neuron 52:767-74, 2006). Consistentwith this observation, non-selective sodium channel blockers lidocaine,mexiletine and carbamazepine can provide symptomatic relief in thesepainful disorders (Legroux-Crespel et al., Ann Dermatol Venereol130:429-33, 2003; Fertleman et al., Neuron 52:767-74, 2006).

Loss-of-function mutations of Nav1.7 in humans cause congenitalindifference to pain (CIP), a rare autosomal recessive disordercharacterized by a complete indifference or insensitivity to painfulstimuli (Cox et al., Nature 444:894-8, 2006; Goldberg et al, Clin Genet71:311-9, 2007; Ahmad et al., Hum Mol Genet 16:2114-21, 2007).

Single nucleotide polymorphisms in the coding region of SCN9A have beenassociated with increased nociceptor excitability and pain sensitivity.For example, a polymorphism rs6746030 resulting in R1150W substitutionin human Nav1.7 has been associated with osteoarthritis pain, lumbardiscectomy pain, phantom pain, and pancreatitis pain (Reimann et al.,Proc Natl Acad Sci USA 107:5148-53, 2010). DRG neurons expressing theR1150W mutant Nav1.7 display increased firing frequency in response todepolarization (Estacion et al., Ann Neurol 66:862-6, 2009). A disablingform of fibromyalgia has been associated with SCN9A sodium channelpolymorphism rs6754031, indicating that some patients with severefibromyalgia may have a dorsal root ganglia sodium channelopathy(Vargas-Alarcon et al., BMC Musculoskelet Disord 13:23, 2012).

In mice, deletion of the SCN9A gene in nociceptive neurons leads toreduction in mechanical and thermal pain thresholds and reduction orabolition of inflammatory pain responses (Nassar et al., Proc Natl AcadSci USA 101:12706-11, 2004). Ablating SCN9A in all sensory neuronsabolished mechanical pain, inflammatory pain and reflex withdrawalresponses to heat. Deleting SCN9A in both sensory and sympatheticneurons abolished mechanical, thermal and neuropathic pain, andrecapitulated the pain-free phenotype seen in humans with Nav1.7loss-of-function mutations (Minett et al., Nat Commun 3:791, 2012).Nav1.7 inhibitors or blockers may therefore be useful in the treatmentof a wide range of pain associated with various disorders.

Spider venoms are known to contain a large number of sodium channelblocking peptides, including Huwentoxin-IV (HwTx-IV) (Peng et al., JBiol Chem 277:47564-71, 2002), Protoxin-I, Protoxin-II (Middleton etal., Biochemistry 41:14734-47, 2002) and Phrixotoxin-III (Bosmans etal., Mol Pharmacol 69:419-29, 2006). There is a need for identificationof additional Nav1.7 blockers for treatment of a wide range of painindications. In particular, there is a need for new Nav1.7 blockers withselectivity for Nav1.7 over other voltage gated sodium channel isoforms.

SUMMARY OF THE INVENTION

One embodiment of the invention is an isolated Protoxin-II variant,wherein the Protoxin-II variant inhibits human Nav1.7 activity with anIC₅₀ value of about 1×10⁻⁷ M or less, about 1×10⁻⁸ M or less, about1×10⁻⁹ M or less, about 1×10⁻¹⁰ M or less, about 1×10⁻¹¹ M or less, orabout 1×10⁻¹² M or less, wherein the IC₅₀ value is measured using aFLIPR® Tetra membrane depolarization assay using fluorescence resonanceenergy transfer (FRET) in the presence of 25×10⁻⁶ M3-veratroylveracevine in HEK293 cells stably expressing human Nav1.7,wherein the Protoxin-II variant has a W7Q and/or a W30L substitution.

Another embodiment of the invention is an isolated Protoxin-II variantcomprising the amino acid sequence of SEQ ID NOs: 30, 40, 44, 52, 56,56, 59, 65, 78, 109, 110, 111, 114, 117, 118, 119, 120, 121, 122, 123,124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137,138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151,152, 153, 154, 155, 156, 157, 158, 159, 162, 165, 166, 167, 168, 169,170, 171, 172, 173, 174, 175, 177, 178, 179, 180, 182, 183, 184, 185,186, 189, 190, 193, 195, 197, 199, 206, 207, 208, 209, 210, 211, 212,213, 214, 215, 216, 217, 218, 224, 226, 227, 231, 232, 243, 244, 245,247, 249, 252, 255, 258, 261, 263, 264, 265, 266, 269, 270, 271, 272,273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286,287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300,301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314,315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 332, 334,335, 336, 337, 339, 340, 341, 342, 346, 351, 358, 359, 364, 366, 367,368, 369, 370, 371, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417,418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430 or 431.

Another embodiment of the invention is an isolated Protoxin-II variantcomprising the amino acid sequence that is 90%, 91%, 92%, 93%, 94%, 95%,96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO:422 (GPYCQKWMQTCDSERKCCEGMVCRLWCKKKLL-COOH); wherein the amino acidsequence has Q at position 7 and L at position 30, when residuenumbering is according to SEQ ID NO: 1; and the polypeptide inhibitshuman Nav1.7 activity with an IC₅₀ value of about 30×10⁻⁹ M or less,wherein the IC₅₀ value is measured using a FLIPR® Tetra membranedepolarization assay using fluorescence resonance energy transfer (FRET)in the presence of 25×10⁻⁶ M 3-veratroylveracevine in HEK293 cellsstably expressing human Nav1.7.

Another embodiment of the invention is an isolated fusion proteincomprising the Protoxin-II variant of the invention conjugated to ahalf-life extending moiety.

Another embodiment of the invention is an isolated polynucleotideencoding the Protoxin-II variant of the invention.

Another embodiment of the invention is an vector comprising the isolatedpolynucleotide of the invention. Another embodiment of the invention isa host cell comprising the vector of the invention.

Another embodiment of the invention is a method of producing theisolated Protoxin-II variant of the invention, comprising culturing thehost cell of the invention and recovering the Protoxin-II variantproduced by the host cell.

Another embodiment of the invention is a pharmaceutical compositioncomprising the isolated Protoxin-II variant or fusion protein of theinvention and a pharmaceutically acceptable excipient.

Another embodiment of the invention is a method of treatingNav1.7-mediated pain in a subject, comprising administering to a subjectin need thereof an effective amount of the Protoxin-II variant or thefusion protein of the invention to treat the pain.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows the genus amino acid sequence of Protoxin-II variants thatinhibit Nav1.7 with an IC₅₀ value of 30 nM or less in a FLIPR Tetraassay. Residue numbering is according to wild-type Protoxin-II of SEQ IDNO: 1. Genus SEQ ID NO: 403.

FIGS. 2A and 2B show the IC₅₀ values for Nav1.7 and Nav1.6 inhibition ina QPatch assay, and selectivity of each variant calculated by ratio ofIC₅₀(Nav1.6)/IC₅₀(Nav1.7) obtained in QPatch assay. SE: standard error.

FIGS. 3A, 3B and 3C show the sequences and the genus sequence ofProtoxin-II variants that inhibit Nav1.7 with an IC₅₀ value of 30 nM orless in a FLIPR Tetra assay, and are over 30-fold selective over Nav1.6.Selectivity of each variant was calculated by ratio ofIC₅₀(Nav1.6)/IC₅₀9 av1.7) obtained in QPatch assay. Residue numbering isaccording to wild-type Protoxin-II of SEQ ID NO: 1.

FIG. 4A shows efficacy of NV1D3034 (NV1D3034-OH) (SEQ ID NO: 78) againstCFA-induced thermal hyperalgesia assessed by measurement of pawwithdrawal latency in the Hargreaves test before (pre-CFA) and after CFAinjection (0) and 1-day after peptide administration (1). ***P<0.001 vs.PBS, two-way ANOVA followed by Bonferroni's multiple comparison.

FIG. 4B shows efficacy of NV1D3034 (NV1D3034-OH) (SEQ ID NO: 78) inCFA-induced thermal hyperalgesia expressed as percent MPE (maximumpossible effect) (MPE %) at each dose on day1 following peptideadministration. *P<0.05 vs PBS, one-way ANOVA followed by Bonferroni'smultiple comparison.

FIG. 5A shows efficacy of NV1D3368 (NV1D3368-OH) (SEQ ID NO: 198)against CFA-induced thermal hyperalgesia assessed by measurement of pawwithdrawal latency in the Hargreaves test before (pre-CFA) and after CFAinjection (0) and 1-day after peptide administration (1). **P<0.01 and****P<0.0001 vs. PBS, two-way ANOVA followed by Bonferroni's multiplecomparison

FIG. 5B shows efficacy of NV1D3368 (NV1D3368-OH) (SEQ ID NO: 198) inCFA-induced thermal hyperalgesia expressed as percent MPE (MPE %) ateach dose on day1 following peptide administration. *P<0.05 and **P<0.01vs PBS, one-way ANOVA followed by Bonferroni's multiple comparison.

FIG. 6A shows efficacy of NV1D2775-OH (SEQ ID NO: 56) againstCFA-induced thermal hyperalgesia assessed by measurement of pawwithdrawal latency in the Hargreaves test before (pre-CFA) and after CFAinjection (0) and 1-day after peptide administration (1). ****P<0.0001vs. PBS, two-way ANOVA followed by Bonferroni's multiple comparison.

FIG. 6B shows efficacy of NV1D2775-OH (SEQ ID NO: 56) in CFA-inducedthermal hyperalgesia expressed as percent MPE (MPE %) at each dose onday1 following peptide administration. ***P<0.001 and ****P<0.0001 vsPBS, one-way ANOVA followed by Bonferroni's multiple comparison.

FIG. 6C shows efficacy of NV1D2775-OH (SEQ ID NO: 56) againstCFA-induced tactile allodynia. Tactile thresholds of hind paw before(pre-CFA) and after CFA (0) and 1-day after peptide administration (1).****P<0.0001 vs. PBS, two-way ANOVA followed by Bonferroni's multiplecomparison.

FIG. 6D shows efficacy of NV1D2775-OH (SEQ ID NO: 56) againstCFA-induced tactile allodynia expressed as percent MPE (MPE %) on day1following peptide. ***P<0.001 vs PBS, one-way ANOVA followed byBonferroni's multiple comparison.

FIG. 7A shows time course of NV1D2775-OH mediated reversal of thermalhyperalgesia in the CFA model as assessed by measurement of pawwithdrawal latency in the Hargreaves test before and after CFA and atvarious time points post-peptide administration. **P<0.01 vs. PBS,two-way ANOVA followed by Bonferroni's multiple comparison. Shaded areasindicate compound delivery period (0-24 hr).

FIG. 7B shows time course of NV1D2775-OH mediated reversal of tactileallodynia in the CFA model as assessed by measurement of tactilethreshold before and after CFA and at various time points post-peptideadministration. **P<0.01 vs. PBS, two-way ANOVA followed by Bonferroni'smultiple comparison. Shaded areas indicate compound delivery period(0-24 hr).

FIG. 8 shows that NV1D2775-OH produced significant analgesia in thehotplate test. Thermal withdrawal latency was evaluated at 50 and 55° C.pre- and post-pump implantation. Pump implantation had no impact on thelatency in the control PBS group. One day after pump, NV1D2775-OHtreated-mice exhibited prolonged latency compared to the PBS group.*P<0.05 and ****P<0.0001 vs. PBS, one-way ANOVA followed by Bonferroni'smultiple comparison.

FIG. 9 shows that NV1D2775-OH pretreatment protected animals fromcarrageenan-induced thermal hyperalgesia. Paw withdrawal latencies weremeasured pre- and on day1 post-pump before intraplantar carrageenaninjection. Latencies were measured again at 2, 3 and 4 hr followingcarrageenan.

FIG. 10 shows the surface representation of the NMR structure of thewild type Protoxin-II. A hydrophobic face shown on left includesresidues W5, M6, W7, L23 and W24. A selectivity face is shown on theright and includes residues S11, E12, K14, E17, G18, L29 and W30.Residue numbering according to SEQ ID NO: 1.

FIG. 11A shows efficacy of the Protoxin-II variant 63955918 SEQ ID NO:422) after a single intrathecal (IT) administration in the tail flicktest. Tail withdrawal latency to a thermal stimulus was measured at theindicated time post-peptide administration.

FIG. 11B shows efficacy of the Protoxin-II variant 63955918 SEQ ID NO:422) in the tail flick test expressed as percent area under the curve(AUC %) in the first 120 min after a single intrathecal (IT)administration. ***P<0.001 and ****P<0.0001 vs PBS, one-way ANOVAfollowed by Bonferroni's multiple comparison.

FIG. 11C shows efficacy of the Protoxin-II variant 63955918 SEQ ID NO:422) after a single intrathecal (IT) administration in the hot platetest (52.5° C.). The latency of a nociceptive response on a hot platewas measured at the indicated time post-peptide administration.

FIG. 11D shows efficacy of the Protoxin-II variant 63955918 SEQ ID NO:422) in the hot plate test expressed as percent area under the curve(AUC %) in the first 120 min after a single intrathecal (IT)administration. ***P<0.001 and ****P<0.0001 vs PBS, one-way ANOVAfollowed by Bonferroni's multiple comparison.

FIG. 11E shows efficacy of the Protoxin-II variant 63955918 SEQ ID NO:422) in the formalin test. Injection of formalin into the rat hindpawinduced a bi-phasic flinching behavior. Total number of flinches inPhase I (0-10 min post formalin) and Phase II (11-60 min post formalin)was measured by an automated device. No statistics were performed in E)due to small group size.

FIG. 12A shows efficacy of NV1D2775-OH after a single intrathecal (IT)administration in the tail flick test. Tail withdrawal latency to athermal stimulus was measured at the indicated time post-peptideadministration.

FIG. 12B shows efficacy of NV1D2775-OH in the tail flick test expressedas percent area under the curve (AUC %) in the first 120 min after asingle intrathecal (IT) administration. *P<0.05 and **P<0.01 vs PBS,one-way ANOVA followed by Bonferroni's multiple comparison.

FIG. 12C shows efficacy of NV1D2775-OH after a single intrathecal (IT)administration in the hot plate test (52.5° C.). The latency of anociceptive response on a hot plate was measured at the indicated timepost-peptide administration.

FIG. 12D shows efficacy of NV1D2775-OH in the hot plate test expressedas percent area under the curve (AUC %) in the first 120 min after asingle intrathecal (IT) administration. **P<0.01 and ****P<0.0001 vsPBS, one-way ANOVA followed by Bonferroni's multiple comparison.

FIG. 12E shows efficacy of NV1D2775-OH in the formalin test. Injectionof formalin into the rat hindpaw induced a bi-phasic flinching behavior.Total number of flinches in Phase I (0-10 min post formalin) and PhaseII (11-60 min post formalin) was measured by an automated device.**P<0.01 vs PBS, phase I, *P<0.05 vs PBS, phase II, one-way ANOVAfollowed by Bonferroni's multiple comparison.

FIG. 13A shows efficacy of NV1D3034-OH after a single intrathecal (IT)administration in the tail flick test. Tail withdrawal latency to athermal stimulus was measured at the indicated time post-peptideadministration.

FIG. 13B shows efficacy of NV1D3034-OH in the tail flick test expressedas percent area under the curve (AUC %) in the first 120 min after asingle intrathecal (IT) administration. ***P<0.005 vs PBS, t-test.

FIG. 13C shows efficacy of NV1D3034-OH after a single intrathecal (IT)administration in the hot plate test (52.5° C.). The latency of anociceptive response on a hot plate was measured at the indicated timepost-peptide administration.

FIG. 13D shows efficacy of NV1D3034-OH in the hot plate test expressedas percent area under the curve (AUC %) in the first 120 min after asingle intrathecal (IT) administration. **P<0.01 vs PBS, t-test.

FIG. 13E shows efficacy of NV1D3034-OH in the formalin test. Injectionof formalin into the rat hindpaw induced a bi-phasic flinching behavior.Total number of flinches in Phase I (0-10 min post formalin) and PhaseII (11-60 min post formalin) was measured by an automated device.*P<0.05 vs PBS, phase I, **P<0.01 vs PBS, phase II, t-test.

DETAILED DESCRIPTION OF THE INVENTION

All publications, including but not limited to patents and patentapplications, cited in this specification are herein incorporated byreference as though fully set forth.

As used herein and in the claims, the singular forms “a,” “and,” and“the” include plural reference unless the context clearly dictatesotherwise.

Unless defined otherwise, all technical and scientific terms used hereinhave the same meaning as commonly understood by one of ordinary skill inthe art to which an invention belongs. Although any compositions andmethods similar or equivalent to those described herein can be used inthe practice or testing of the invention, exemplary compositions andmethods are described herein.

The term “polypeptide” means a molecule that comprises at least twoamino acid residues linked by a peptide bond to form a polypeptide.Small polypeptides of less than 50 amino acids may be referred to as“peptides”. Polypeptides may also be referred as “proteins”.

The term “polynucleotide” means a molecule comprising a chain ofnucleotides covalently linked by a sugar-phosphate backbone or otherequivalent covalent chemistry. Double and single-stranded DNAs and RNAsare typical examples of polynucleotides.

The term “complementary sequence” means a second isolated polynucleotidesequence that is antiparallel to a first isolated polynucleotidesequence and that comprises nucleotides complementary to the nucleotidesin the first polynucleotide sequence.

The term “vector” means a non-natural polynucleotide capable of beingduplicated within a biological system or that can be moved between suchsystems. Vector polynucleotides typically contain a cDNA encoding aprotein of interest and additional elements, such as origins ofreplication, polyadenylation signal or selection markers, that functionto facilitate the duplication or maintenance of these polynucleotides ina biological system. Examples of such biological systems may include acell, virus, animal, plant, and reconstituted biological systemsutilizing biological components capable of duplicating a vector. Thepolynucleotide comprising a vector may be DNA or RNA molecules or ahybrid of these.

The term “expression vector” means a vector that can be utilized in abiological system or a reconstituted biological system to direct thetranslation of a polypeptide encoded by a polynucleotide sequencepresent in the expression vector.

The term “variant” as used herein refers to a polypeptide or apolynucleotide that differs from wild type Protoxin-II polypeptide ofSEQ ID NO: 1 or the polynucleotide encoding the wild type Protoxin-IIhaving the sequence of SEQ ID NO: 107 by one or more modifications forexample, substitutions, insertions or deletions of nucleotides or aminoacids.

Throughout the specification, residues that are substituted in theProtoxin-II variants are numbered corresponding to their position in thewild-type Protoxin-II of SEQ ID NO: 1. For example, “Y1A” in thespecification refers to the substitution of tyrosine at residue positionthat corresponds to the position 1 in the wild type Protoxin-II of SEQID NO:1 with alanine.

“Complementary DNA” or “cDNA” refers to a well-known syntheticpolynucleotide that shares the arrangement of sequence elements found innative mature mRNA species with contiguous exons, with the interveningintrons present in genomic DNA are removed. The codons encoding theinitiator methionine may or may not be present in cDNA. cDNA may besynthesized for example by reverse transcription or synthetic geneassembly.

“Synthetic” or “non-natural” as used herein refers to a polynucleotideor a polypeptide molecule not present in nature.

“Nav1.7” (also referred to as hNE or PN1) or “hNav1.7” as used hereinrefers to the well-known human sodium channel protein type 9 subunitalpha having a sequence shown in GenBank accession number NP 002968.1and in SEQ ID NO: 79.

The term “wild type Protoxin-II” or “wild type ProTx-II” as used hereinrefers to the tarantula Thrixopelma pruriens (Peruvian green velvettarantula) toxin peptide having the amino acid sequenceYCQKWMWTCDSERKCCEGMVCRLWCKKKLW-COOH (SEQ ID NO: 1) as described inMiddleton et al., Biochemistry 41(50):14734-47, 2002.

The term “recombinant Protoxin-II” or recombinant ProTx-II″ as usedherein refers to the recombinant Protoxin-II obtained from expressionand subsequent cleavage of a Protoxin-II fusion protein having thesequence of GPYCQKWMWTCDSERKCCEGMVCRLWCKKKLW-OH as shown in SEQ ID NO:2. Recombinant Protoxin-II incorporates a two amino acid N-terminalextension (residues G and P) when compared to the wild type Protoxin-II.

“Blocks human Nav1.7 activity” or “inhibits human Nav1.7 activity” asused herein refers to the ability of the Protoxin-II variant of theinvention to reduce membrane depolarization induced by veratridine(3-veratroylveracevine) with an IC₅₀ value of about 1×10⁻⁷ M or less ina FLIPR® Tetra membrane depolarization assay using fluorescenceresonance energy transfer (FRET), where veratridine-induceddepolarization is measured as a reduction in FRET signal usingDISBAC2(3) ([bis-(1,3-diethylthiobarbituric acid) trimethine oxonol]) asan acceptor and PTS18 (trisodium8-octadecyloxypyrene-1,3,6-trisulfonate) as a donor by exciting thedonor at 390-420 nm and measuring FRET at 515-575 nm in a cell linestably expressing human Nav1.7.

“FLIPR® Tetra membrane depolarization assay” as used herein is the assaydescribed in Example 3.

The term “substantially identical” as used herein means that the twoProtoxin-II variant amino acid sequences being compared are identical orhave “insubstantial differences”. Insubstantial differences aresubstitutions of 1, 2, 3, 4, 5, 6, or 7 amino acids in the Protoxin-IIvariant amino acid sequence that do not adversely affect peptideproperties. Amino acid sequences substantially identical to theProtoxin-II variants disclosed herein are within the scope of theapplication. In some embodiments, the sequence identity can be about80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%,94%, 95%, 96%, 97%, 98%, 99% or higher. Percent identity can bedetermined for example by pairwise alignment using the default settingsof the AlignX module of Vector NTI v.9.0.0 (Invitrogen, Carslbad,Calif.). The protein sequences of the present invention may be used as aquery sequence to perform a search against public or patent databases,for example, to identify related sequences. Exemplary programs used toperform such searches are the XBLAST or BLASTP programs(http_//www_ncbi_nlm/nih_gov), or the GenomeQuest™ (GenomeQuest,Westborough, Mass.) suite using the default settings.

Conventional one and three-letter amino acid codes are used herein asshown in Table 1.

TABLE 1 Amino acid Three letter code One letter code Alanine Ala AArginine Arg R Asparagine Asn N Aspartate Asp D Cysteine Cys C GlutamateGlu E Glutamine Gln Q Glycine Gly G Histidine His H Isoleucine Ile ILeucine Leu L Lysine Lys K Methionine Met M Phenylalanine Phe F ProlinePro P Serine Ser S Threonine Thr T Tryptophan Trp W Tyrosine Tyr YValine Val V

The present invention provides isolated Protoxin-II (ProTx-II) variantpolypeptides that inhibit human Nav1.7 activity, polynucleotidesencoding them, vectors, host cells, and methods of using thepolynucleotides and polypeptides of the invention. The polypeptides ofthe invention inhibit depolarization resulting from Nav1.7 activation,and therefore may be useful in the treatment of various conditionsassociated with pain and conditions associated with sensory orsympathetic neuron dysfunction.

The variants of the invention are potent inhibitors of Nav1.7. Thecurrent invention is based, at least in part, on the finding thatcertain residue substitutions in Protoxin-II enhance selectivity,synthetic yield and/or homogeneity without adversely affecting thepotency of the generated Protoxin-II variants, specifically W7 and M19,and additionally residues Y1 and S11, and further additionally residuesE12, R22 and (residue numbering according to SEQ ID NO: 1). For example,substitutions at positions W7 and W30 enhance the Protoxin-II variantfolding and improve yield. Substitutions at positions S11, E12, K14,E17, G18, L29 and W30 improve selectivity of the resulting Protoxin-IIvariants to Nav1.7.

One embodiment of the invention is an isolated Protoxin-II variant,wherein the Protoxin-II variant inhibits human Nav1.7 activity with anIC₅₀ value of about 1×10⁻⁷ M or less, about 1×10⁻⁸ M or less, about1×10⁻⁹ M or less, about 1×10⁻¹⁰ M or less, about 1×10⁻¹¹ M or less, orabout 1×10⁻¹² M or less, wherein the IC₅₀ value is measured using aFLIPR® Tetra membrane depolarization assay using fluorescence resonanceenergy transfer (FRET) in the presence of 25×10⁻⁶ M3-veratroylveracevine in HEK293 cells stably expressing human Nav1.7.

Another embodiment of the invention is an isolated Protoxin-II variant,wherein the Protoxin-II variant inhibits human Nav1.7 activity with anIC₅₀ value of about 1×10⁻⁷ M or less, about 1×10⁻⁸ M or less, about1×10⁻⁹ M or less, about 1×10⁻¹⁰ M or less, about 1×10⁻¹¹ M or less, orabout 1×10⁻¹² M or less, wherein the IC₅₀ value is measured using aFLIPR® Tetra membrane depolarization assay using fluorescence resonanceenergy transfer (FRET) in the presence of 25×10⁻⁶ M3-veratroylveracevine in HEK293 cells stably expressing human Nav1.7,wherein the Protoxin-II variant has a W7Q and a W30L substitution.

Another embodiment of the invention is an isolated Protoxin-II variantcomprising the sequenceX₁X₂X₃CX₄X₅WX₆QX₇CX₈X₉X₁₀X₁₁X₁₂CCX₁₃X₁₄FX₁₅CX₁₆LWCX₁₇KKLL (SEQ ID NO:432), wherein

-   -   X₁ is G, P, A or deleted;    -   X₂ is P, A or deleted;    -   X₃ is S, Q, A, R or Y;    -   X₄ is Q, R, K, A or S;    -   X₅ is K, S, Q or R;    -   X₆ is M or F;    -   X₇ is T, S, R, K or Q;    -   X₈ is D or T;    -   X₉ is S, A or R;    -   X₁₀ is E, R, N, K, T or Q;    -   X₁₁ is R or K;    -   X₁₂ is K, Q, S or A;    -   X₁₃ is E, Q or D;    -   X₁₄ is G or Q;    -   X₁₅ is V or S;    -   X₁₆ is R or T; and    -   X₁₇ is K or R;    -   optionally having an N-terminal extension or a C-terminal        extension,    -   wherein the polypeptide inhibits human Nav1.7 activity with an        IC₅₀ value of about 1×10⁻⁷ M or less,    -   wherein the IC₅₀ value is measured using a FLIPR® Tetra membrane        depolarization assay using fluorescence resonance energy        transfer (FRET) in the presence of 25×10⁻⁶ M        3-veratroylveracevine in HEK293 cells stably expressing human        Nav1.7.        Substitutions at Protoxin-II positions W7Q and W30L improve        refolding and yield of the resulting Protoxin-II variant.

In some embodiments, the N-terminal extension comprises the amino acidsequences of SEQ ID NOs: 372, 373, 374, 375, 376, 377, 378, 379, 380,381, 382, 383, 384 or 385.

In some embodiments, the C-terminal extension comprises the amino acidsequence of SEQ ID NOs: 374, 386, 387, 388, 389, 390, 391, 392, 393,394, 395, 396 or 397.

In some embodiments, the N-terminal and/or the C-terminal extension isconjugated to the Protoxin-II variant via a linker.

In some embodiments, the linker comprises the amino acid sequence of SEQID NOs: 383, 392, 398, 399, 400, 401 or 402.

In some embodiments, the N-terminal extension consists of the amino acidsequences of SEQ ID NOs: 372, 373, 374, 375, 376, 377, 378, 379, 380,381, 382, 383, 384 or 385.

In some embodiments, the C-terminal extension consists of the amino acidsequence of SEQ ID NOs: 374, 386, 387, 388, 389, 390, 391, 392, 393,394, 395, 396 or 397.

In some embodiments, the linker consists of the amino acid sequence ofSEQ ID NOs: 383, 392, 398, 399, 400, 401 or 402.

Another embodiment of the invention is an isolated Protoxin-II variantcomprising the sequenceX₁X₂X₃CX₄X₅WX₆QX₇CX₈X₉X₁₀X₁₁X₁₂CCX₁₃X₁₄FX₁₅CX₁₆LWCX₁₇KKLW (SEQ ID NO:403), wherein

-   -   X₁ is G, P, A or deleted;    -   X₂ is P, A or deleted;    -   X₃ is S, Q, A, R or Y;    -   X₄ is Q, R, K, A or S;    -   X₅ is K, S, Q or R;    -   X₆ is M or F;    -   X₇ is T, S, R, K or Q;    -   X₈ is D or T;    -   X₉ is S, A or R;    -   X₁₀ is E, R, N, K, T or Q;    -   X₁₁ is R or K;    -   X₁₂ is K, Q, S or A;    -   X₁₃ is E, Q or D;    -   X₁₄ is G or Q;    -   X₁₅ is V or S;    -   X₁₆ is R or T; and    -   X₁₇ is K or R;    -   optionally having an N-terminal extension or a C-terminal        extension,    -   wherein the polypeptide inhibits human Nav1.7 activity with an        IC₅₀ value of about 1×10⁻⁷ M or less,    -   wherein the IC₅₀ value is measured using a FLIPR® Tetra membrane        depolarization assay using fluorescence resonance energy        transfer (FRET) in the presence of 25×10⁻⁶ M        3-veratroylveracevine in HEK293 cells stably expressing human        Nav1.7.

The Protoxin-II variants of the invention are potent Nav1.7 inhibitors.Recombinant Protoxin-II (SEQ ID NO: 2) has an IC₅₀ value of about 4×10⁻⁹M for human Nav1.7 in a veratridine-induced depolarization inhibitionassay measuring decline in FRET (fluorescence resonance energy transfer)in cells stably expressing Nav1.7 using FLIPR® Tetra instrument(Molecular Devices) using experimental details described in Example 3. AProtoxin-II variant is “a potent” Nav1.7 inhibitor when the IC₅₀ valuein the assay described above and in Experiment 3 is about 30×10⁻⁹ M orless i.e. within 10 fold of recombinant Protoxin-II. For clarity, anIC₅₀ of 30×10⁻⁹ M is identical to IC₅₀ of 3.0×10⁻⁸ M.

The Protoxin-II variant polypeptides of the invention may be produced bychemical synthesis, such as solid phase peptide synthesis, on anautomated peptide synthesizer. Alternatively, the polypeptides of theinvention may be obtained from polynucleotides encoding the polypeptidesby the use of cell-free expression systems such as reticulocyte lysatebased expression systems, or by recombinant expression systems. Thoseskilled in the art will recognize other techniques for obtaining thepolypeptides of the invention. In an exemplary method, the Protoxin-IIvariants of the invention are generated by expressing them as humanserum albumin (HSA) fusion proteins utilizing a glycine-rich linker suchas (GGGGS)₄ (SEQ ID NO:80) or (GGGGS)₆ (SEQ ID NO: 81) coupled to aprotease cleavable linker such as a recognition sequence for HRV3Cprotease (Recombinant type 14 3C protease from human rhinovirus)LEVLFQGP (HRV3C linker) (SEQ ID NO: 82), and cleaving the expressedfusion proteins with the HRV3C protease to release the recombinantProtoxin-II variant peptides. Hexahistidine (SEQ ID NO: 108) or othertags may be used to facilitate purification using well known methods.

Protoxin-II variants of the invention may be purified using methodsdescribed herein. In an exemplary method, Protoxin-II variants of theinvention expressed as HSA fusion proteins and cleaved with HRV3Cprotease may be purified using sold phase extraction (SPE) as describedherein.

Generation of the Protoxin-II variants optionally having N-terminaland/or C-terminal extensions, and Protoxin-II variant fusion proteins istypically achieved at the nucleic acid level. The polynucleotides may besynthesized using chemical gene synthesis according to methods describedin U.S. Pat. Nos. 6,521,427 and 6,670,127, utilizing degenerateoligonucleotides to generate the desired variants, or by standard PCRcloning and mutagenesis. Libraries of variants may be generated bystandard cloning techniques to clone the polynucleotides encoding theProtoxin-II variants into the vector for expression.

The Protoxin-II variants may incorporate additional N- and/or C-terminalamino acids when compared to the wild type Protoxin-II of SEQ ID NO: 1,for example resulting from cloning and/or expression schemes. Forexample, cleavage from HSA after expression of the variant asHSA-linker-HRV3C cleavable peptide-Protoxin-II variant fusion proteinmay result in the incorporation of additional two residues to theN-terminus of each Protoxin-II variant, such as G and P.

The Protoxin-II variants of the invention are tested for their abilityto inhibit human Nav1.7 using methods described herein. An exemplaryassay is a veratridine-induced depolarization inhibition assay measuringdecline in FRET (fluorescence resonance energy transfer) in cells stablyexpressing Nav1.7. Another exemplary assay employs electrophysiologicalrecordings to measure changes in Nav1.7-mediated currents using wellknown patch clamp techniques and as described herein.

Another embodiment of the invention is an isolated Protoxin-II variantcomprising the amino acid sequence of SEQ ID NOs: 3, 4, 5, 6, 7, 8, 9,10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27,28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45,46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63,64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 109, 110,111, 112, 113, 114, 115, 116, 117, 118, 119, 121, 122, 123, 124, 125,126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139,140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153,154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167,168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181,182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195,196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209,210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223,224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237,238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251,252, 253, 254, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266,267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280,281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294,295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308,309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322,323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336,337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350,351, 352, 353, 354, 355, 35, 357, 358, 359, 360, 361, 362, 363, 364,365, 366, 367, 368 369, 370, 371, 408, 409, 410, 411, 412, 413, 414,415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428,429, 430 or 431.

The Protoxin-II variants of the invention may inhibit human Nav1.7 withan IC₅₀ value of about 1×10⁻⁷ M or less, about 1×10⁻⁸ M about 1×10⁻⁹ orless, about 1×10⁻¹⁰ M or less, about 1×10⁻¹¹ M or less, or about 1×10⁻¹²M or less. Exemplary variants demonstrating the range of IC₅₀ values arevariants having amino acid sequences shown in SEQ ID NOs: 30, 40, 44,52, 56, 56, 59, 65, 78, 109, 110, 111, 117, 118, 119, 120, 121, 122,123, 124, 125, 126, 127, 128, 129, 131, 132, 133, 134, 135, 136, 137,138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151,152, 153, 154, 155, 156, 157, 158, 159, 162, 165, 166, 167, 168, 169,170, 171, 172, 173, 174, 175, 177, 178, 179, 180, 182, 183, 184, 185,186, 189, 190, 193, 195, 197, 199, 206, 207, 208, 209, 210, 211, 212,213, 214, 215, 216, 217, 218, 224, 226, 227, 231, 232, 243, 244, 245,247, 249, 252, 255, 258, 261, 263, 264, 265, 266, 269, 270, 271, 272,273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286,287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300,301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314,315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 332, 334,335, 336, 337, 339, 340, 341, 342, 346, 351, 358, 359, 364, 366, 367,368, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420,421, 422, 423, 424, 425, 426, 427, 428, 429, 430 or 431.

Table 2, Table 3 and Table 14 show the sequences of select Protoxin-IIvariants.

TABLE 2 Protoxin-II Protein variant SEQ name peptide name ID NO:Protein amino acid sequence wild type  1YCQKWMWTCDSERKCCEGMVCRLWCKKKLW-COOH NV1D12  2GPYCQKWMWTCDSERKCCEGMVCRLWCKKKLW-COOH NV1D748  3GPACQKWMWTCDSERKCCEGMVCRLWCKKKLW-COOH NV1D751  4GPQCQKWMWTCDSERKCCEGMVCRLWCKKKLW-COOH NV1D2292  5GPRCQKWMWTCDSERKCCEGMVCRLWCKKKLW-COOH NV1D750  6GPSCQKWMWTCDSERKCCEGMVCRLWCKKKLW-COOH NV1D1328  7GPYCQKWFWTCDSERKCCEGMVCRLWCKKKLW-COOH NV1D774  8GPYCQKWMQTCDSERKCCEGMVCRLWCKKKLW-COOH NV1D786  9GPYCQKWMWTCDAERKCCEGMVCRLWCKKKLW-COOH NV1D2300 10GPYCQKWMWTCDRERKCCEGMVCRLWCKKKLW-COOH NV1D791 11GPYCQKWMWTCDSKRKCCEGMVCRLWCKKKLW-COOH NV1D1332 12GPYCQKWMWTCDSNRKCCEGMVCRLWCKKKLW-COOH NV1D2512 13GPYCQKWMWTCDSERKCCEGFVCRLWCKKKLW-COOH NV1D1336 14GPYCQKWMWTCDSERKCCEGLVCRLWCKKKLW-COOH NV1D1337 15GPYCQKWMWTCDSERKCCEGMVCTLWCKKKLW-COOH NV1D2308 16GPYCQKWMWTCDSERKCCEGMVCRLWCRKKLW-COOH NV1G953 NV1D2670 17GPACQKWMQTCDSERKCCEGMVCRLWCKKKLW-COOH NV1G951 NV1D2674 18GPACQKWMWTCDAERKCCEGMVCRLWCKKKLW-COOH NV1G909 NV1D2664 19GPACQKWMWTCDSERKCCEGFVCRLWCKKKLW-COOH NV1G963 NV1D2671 20GPQCQKWMQTCDSERKCCEGMVCRLWCKKKLW-COOH NV1G949 NV1D2675 21GPQCQKWMWTCDAERKCCEGMVCRLWCKKKLW-COOH NV1G977 NV1D2665 22GPQCQKWMWTCDSERKCCEGFVCRLWCKKKLW-COOH NV1G957 NV1D2668 23GPRCQKWMQTCDSERKCCEGMVCRLWCKKKLW-COOH NV1G965 NV1D2672 24GPRCQKWMWTCDAERKCCEGMVCRLWCKKKLW-COOH NV1G973 NV1D2662 25GPRCQKWMWTCDSERKCCEGFVCRLWCKKKLW-COOH NV1G975 NV1D2669 26GPSCQKWMQTCDSERKCCEGMVCRLWCKKKLW-COOH NV1G971 NV1D2673 27GPSCQKWMWTCDAERKCCEGMVCRLWCKKKLW-COOH NV1G995 NV1D2663 28GPSCQKWMWTCDSERKCCEGFVCRLWCKKKLW-COOH NV1G961 NV1D2676 29GPYCQKWMQTCDAERKCCEGMVCRLWCKKKLW-COOH NV1G911 NV1D2666 30GPYCQKWMQTCDSERKCCEGFVCRLWCKKKLW-COOH NV1D2816 31GPACQKWFQTCDSERKCCEGMVCRLWCKKKLW-COOH NV1G905 NV1D2735 32GPACQKWMQTCDSERKCCEGFVCRLWCKKKLW-COOH NV1G919 NV1D2739 33GPACQKWMWTCDAERKCCEGFVCRLWCKKKLW-COOH NV1G979 NV1D2731 34GPACQKWMQTCDAERKCCEGMVCRLWCKKKLW-COOH NV1D2810 35GPQCQKWFQTCDSERKCCEGMVCRLWCKKKLW-COOH NV1G1099 NV1D2732 36GPQCQKWMQTCDAERKCCEGMVCRLWCKKKLW-COOH NV1G1011 NV1D2740 37GPQCQKWMWTCDAERKCCEGFVCRLWCKKKLW-COOH NV1D2819 38GPRCQKWFWTCDAERKCCEGMVCRLWCKKKLW-COOH NV1G1105 NV1D2729 39GPRCQKWMQTCDAERKCCEGMVCRLWCKKKLW-COOH NV1G1013 NV1D2733 40GPRCQKWMQTCDSERKCCEGFVCRLWCKKKLW-COOH NV1D2814 41GPSCQKWFQTCDSERKCCEGMVCRLWCKKKLW-COOH NV1D2820 42GPSCQKWFWTCDAERKCCEGMVCRLWCKKKLW-COOH NV1G983 NV1D2730 43GPSCQKWMQTCDAERKCCEGMVCRLWCKKKLW-COOH NV1G1003 NV1D2734 44GPSCQKWMQTCDSERKCCEGFVCRLWCKKKLW-COOH NV1G1009 NV1D2738 45GPSCQKWMWTCDAERKCCEGFVCRLWCKKKLW-COOH NV1D2851 46GPYCQKWFKTCDAERKCCEGMVCRLWCKKKLW-COOH NV1D2850 47GPYCQKWFQTCDAERKCCEGMVCRLWCKKKLW-COOH NV1G987 NV1D2667 48GPYCQKWMWTCDAERKCCEGFVCRLWCKKKLW-COOH NV1D2867 49GPACQKWFQTCDAERKCCEGMVCRLWCKKKLW-COOH NV1D2881 50GPACQKWFQTCDSERKCCEGFVCRLWCKKKLW-COOH NV1D2882 51GPACQKWFQTCDSERKCCEGLVCRLWCKKKLW-COOH NV1G899 NV1D2774 52GPACQKWMQTCDAERKCCEGFVCRLWCKKKLW-COOH NV1G1077 NV1D2902 53GPACQKWMQTCDAERKCCEGLVCRLWCKKKLW-COOH NV1D2861 54GPQCQKWFQTCDAERKCCEGMVCRLWCKKKLW-COOH NV1D2870 55GPQCQKWFQTCDSERKCCEGLVCRLWCKKKLW-COOH NV1G1007 NV1D2775 56GPQCQKWMQTCDAERKCCEGFVCRLWCKKKLW-COOH NV1G1067 NV1D2893 57GPQCQKWMQTCDAERKCCEGLVCRLWCKKKLW-COOH NV1D2887 58GPRCQKWFWTCDAERKCCEGFVCRLWCKKKLW-COOH NV1G1005 NV1D2772 59GPRCQKWMQTCDAERKCCEGFVCRLWCKKKLW-COOH NV1G1061 NV1D2896 60GPRCQKWMQTCDAERKCCEGLVCRLWCKKKLW-COOH NV1D2877 61GPSCQKWFQTCDSERKCCEGFVCRLWCKKKLW-COOH NV1D2878 62GPSCQKWFQTCDSERKCCEGLVCRLWCKKKLW-COOH NV1D2889 63GPSCQKWFWTCDAERKCCEGFVCRLWCKKKLW-COOH NV1D2889 64GPSCQKWFWTCDAERKCCEGFVCRLWCKKKLW-COOH NV1G1001 NV1D2773 65GPSCQKWMQTCDAERKCCEGFVCRLWCKKKLW-COOH NV1D2890 66GPSCQKWFWTCDAERKCCEGLVCRLWCKKKLW-COOH NV1G1109 NV1D2899 67GPSCQKWMQTCDAERKCCEGLVCRLWCKKKLW-COOH NV1D2905 68GPYCQKWFQTCDAERKCCEGFVCRLWCKKKLW-COOH NV1D2906 69GPYCQKWFQTCDAERKCCEGLVCRLWCKKKLW-COOH NV1D2921 70GPACQKWFQTCDAERKCCEGFVCRLWCKKKLW-COOH NV1D2922 71GPACQKWFQTCDAERKCCEGLVCRLWCKKKLW-COOH NV1D2909 72GPQCQKWFQTCDAERKCCEGFVCRLWCKKKLW-COOH NV1D2910 73GPQCQKWFQTCDAERKCCEGLVCRLWCKKKLW-COOH NV1D2913 74GPRCQKWFQTCDAERKCCEGFVCRLWCKKKLW-COOH NV1D2914 75GPRCQKWFQTCDAERKCCEGLVCRLWCKKKLW-COOH NV1D2917 76GPSCQKWFQTCDAERKCCEGFVCRLWCKKKLW-COOH NV1D2918 77GPSCQKWFQTCDAERKCCEGLVCRLWCKKKLW-COOH NV1G1153 NV1D3034 78GPQCQKWMQTCDRERKCCEGFVCTLWCRKKLW-COOH

TABLE 3 Protoxin-II variant SEQ Protein name peptide name ID NO:Protein amino acid sequence (-GP) NV1G1001 (-GP) NV1D2773 109SCQKWMQTCDAERKCCEGFVCRLWCKK KLW-COOH (-GP) NV1G1001- (-GP) NV1D2773-NH2110 SCQKWMQTCDAERKCCEGFVCRLWCKK NH-Me KLW-NH2 NV1G1007-NH2 NV1D2775-NH2111 GPQCQKWMQTCDAERKCCEGFVCRLWC KKKLW-NH2 NV1G1107-NH2 NV1D2890-NH2 112GPSCQKWFWTCDAERKCCEGLVCRLWC KKKLW-NH2 NV1G1137 NV1D2974 113GPQCQKWMQTCDAERKCCEGFSCTLWC KKKLW-COOH (-GP) N-Ac- (-GP) N-Ac- 114Ac-QCQKWMQTCDAERKCCEGFSCTLW NV1G1137-NH2 NV1D2974-NH2 CKKKLW-NH2(-GP) N-Ac- (-GP) N-Ac- 115 Ac-QCQKWMQTCDAERKCCEGFSCTLW NV1G1137-NV1D2974 CKKKLW-COOH NV1G1153 NV1D3034 116 GPQCQKWMQTCDRERKCCEGFVCTLWCRKKLW-COOH NV1G1153-NH2 NV1D3034-NH2 117 GPQCQKWMQTCDRERKCCEGFVCTLWCRKKLW-NH2 NV1G1153-NH- NV1D3034-NH-butyl 118 GPQCQKWMQTCDRERKCCEGFVCTLWCbutyl RKKLW-NH-butyl NV1G1153-NH- NV1D3034-NH-methyl 119GPQCQKWMQTCDRERKCCEGFVCTLWC methyl RKKLW-NH-methyl (-GP) N-Ac-(-GP) N-Ac- 120 Ac-QCQKWMQTCDRERKCCEGFVCTLW NV1G1153 NV1D3034CRKKLW-COOH (-GP) N-Ac- (-GP) N-Ac- 121 Ac-QCQKWMQTCDRERKCCEGFVCTLWNV1G1153-NH2 NV1D3034-NH2 CRKKLW-NH2 NV1G1818 NV1D3368 122GPQCQKWMQTCDRTRKCCEGFVCTLWC RKKLW-COOH NV1G1818-NH2 NV1D3368-NH2 123GPQCQKWMQTCDRTRKCCEGFVCTLWC RKKLW-NH2 NV1G1147 NV1D2969 124GPSCQKWMQTCDAERKCCEGFSCRLWC KKKLW-COOH NV1G1145 NV1D2970 125GPSCQKWMQTCDAERKCCEGFVCTLWC KKKLW-COOH NV1G1143 NV1D2971 126GPSCQKWMQTCDAERKCCEGFSCTLWC KKKLW-COOH NV1G1141 NV1D2972 127GPQCQKWMQTCDAERKCCEGFSCRLWC KKKLW-COOH NV1G1139 NV1D2973 128GPQCQKWMQTCDAERKCCEGFVCTLWC KKKLW-COOH NV1G1137 NV1D2974 129GPQCQKWMQTCDAERKCCEGFSCTLWC KKKLW-COOH NV1G1137-NH2 NV1D2974-NH2 130GPQCQKWMQTCDAERKCCEGFSCTLWC KKKLW-NH2 NV1G1517 NV1D3004 131GPQCQKWMQTCDRERKCCEGFVCRLWC KKKLW-COOH NV1G1515 NV1D3005 132GPQCQKWMQTCDANRKCCEGFVCRLWC KKKLW-COOH NV1G1519 NV1D3006 133GPQCQKWMQTCDARRKCCEGFVCRLWC KKKLW-COOH NV1G1513 NV1D3007 134GPQCQKWMQTCDAERKCCEGFVCRLWC RKKLW-COOH NV1G1523 NV1D3012 135GPQCQKWMQTCDRNRKCCEGFVCRLWC KKKLW-COOH NV1G1525 NV1D3013 136GPQCQKWMQTCDRRRKCCEGFVCRLWC KKKLW-COOH NV1G1255 NV1D3014 137GPQCQKWMQTCDRERKCCEGFVCTLWC KKKLW-COOH NV1G1187 NV1D3015 138GPQCQKWMQTCDRERKCCEGFVCRLWC RKKLW-COOH NV1G1257 NV1D3016 139GPQCQKWMQTCDANRKCCEGFVCTLWC KKKLW-COOH NV1G1221 NV1D3017 140GPQCQKWMQTCDARRKCCEGFVCTLWC KKKLW-COOH NV1G1521 NV1D3018 141GPQCQKWMQTCDANRKCCEGFVCRLWC RKKLW-COOH NV1G1531 NV1D3019 142GPQCQKWMQTCDARRKCCEGFVCRLWC RKKLW-COOH NV1G1239 NV1D3020 143GPQCQKWMQTCDAERKCCEGFVCTLWC RKKLW-COOH NV1G1583 NV1D3030 144GPQCQKWMQTCDRNRKCCEGFVCTLWC KKKLW-COOH NV1G1527 NV1D3031 145GPQCQKWMQTCDRRRKCCEGFVCTLWC KKKLW-COOH NV1G1511 NV1D3032 146GPQCQKWMQTCDRNRKCCEGFVCRLWC RKKLW-COOH NV1G1509 NV1D3033 147GPQCQKWMQTCDRRRKCCEGFVCRLWC RKKLW-COOH NV1G1231 NV1D3035 148GPQCQKWMQTCDANRKCCEGFVCTLWC RKKLW-COOH NV1G1211 NV1D3036 149GPQCQKWMQTCDARRKCCEGFVCTLWC RKKLW-COOH NV1G1267 NV1D3044 150GPQCQKWMQTCDRNRKCCEGFVCTLWC RKKLW-COOH NV1G1269 NV1D3045 151GPQCQKWMQTCDRRRKCCEGFVCTLWC RKKLW-COOH NV1G1215 NV1D3048 152GPQCQKWMQTCDAKRKCCEGFVCRLWC KKKLW-COOH NV1G1593 NV1D3050 153GPQCQKWMQTCDRKRKCCEGFVCRLWC KKKLW-COOH NV1G1263 NV1D3051 154GPQCQKWMQTCDAKRKCCEGFVCTLWC KKKLW-COOH NV1G1585 NV1D3052 155GPQCQKWMQTCDAKRKCCEGFVCRLWC RKKLW-COOH NV1G1623 NV1D3056 156GPQCQKWMQTCDRKRKCCEGFVCTLWC KKKLW-COOH NV1G1613 NV1D3057 157GPQCQKWMQTCDRKRKCCEGFVCRLWC RKKLW-COOH NV1G1259 NV1D3058 158GPQCQKWMQTCDAKRKCCEGFVCTLWC RKKLW-COOH NV1G1265 NV1D3062 159GPQCQKWMQTCDRKRKCCEGFVCTLWC RKKLW-COOH NV1G1273 NV1D3109 160GPQCQKWMWTCDARRKCCEGFVCTLWC RKKLW-COOH NV1G1225 NV1D3121 161GPQCQKWMWTCDRKRKCCEGFVCTLWC RKKLW-COOH NV1G1886 NV1D3249 162GPAAAAAQCQKWMQTCDAERKCCEGFV CRLWCKKKLW-COOH NV1G1633 NV1D3251 163GPAPAPAQCQKWMQTCDAERKCCEGFV CRLWCKKKLW-COOH NV1G1631 NV1D3252 164GPQCQKWMQTCDAERKCCEGFVCRLWC KKKLWAPAPA-COOH NV1G1885 NV1D3254 165GPQCQKWMQTCDAERKCCEGFVCRLWC KKKLWGGGGG-COOH NV1G1884 NV1D3256 166GPCCNCSSKWCRDHSRCCGRGSAPAPA PAPAPGSQCQKWMQTCDAERKCCEGFV CRLWCKKKLW-COOHNV1G1881 NV1D3257 167 GPQCQKWMQTCDAERKCCEGFVCRLWCKKKLWGSAPAPAPAPAPGSCCNCSSKW CRDHSRCC-COOH NV1G1879 NV1D3259 168GPQCQKWMQTCDAERKCCEGFVCRLWC KKKLWGSAPAPAPAPAPAPAPAPAPAPGSCCNCSSKWCRDHSRCCGR-COOH NV1G1883 NV1D3260 169GPCCNCSSKWCRDHSRCCGRGSAPAPA PAPAPAPAPAPAPAPGSQCQKWMQTCDAERKCCEGFVCRLWCKKKLW-COOH NV1G1880 NV1D3261 170GPQCQKWMQTCDAERKCCEGFVCRLWC KKKLWGSAPAPAPAPAPAPAPAPAPAPGSCCNCSSKWCRDHSRCC-COOH NV1G1882 NV1D3262 171GPCCNCSSKWCRDHSRCCGSAPAPAPA PAPAPAPAPAPAPGSQCQKWMQTCDAERKCCEGFVCRLWCKKKLW-COOH NV1G1776 NV1D3339 172GPQCRKWMQTCDRERKCCEGFVCTLWC RKKLW-COOH NV1G1775 NV1D3340 173GPQCKKWMQTCDRERKCCEGFVCTLWC RKKLW-COOH NV1G1768 NV1D3341 174GPQCTKWMQTCDRERKCCEGFVCTLWC RKKLW-COOH NV1G1777 NV1D3342 175GPQCAKWMQTCDRERKCCEGFVCTLWC RKKLW-COOH NV1G1770 NV1D3344 176GPQCEKWMQTCDRERKCCEGFVCTLWC RKKLW-COOH NV1G1767 NV1D3345 177GPQCSKWMQTCDRERKCCEGFVCTLWC RKKLW-COOH NV1G1769 NV1D3346 178GPQCQRWMQTCDRERKCCEGFVCTLWC RKKLW-COOH NV1G1774 NV1D3347 179GPQCQTWMQTCDRERKCCEGFVCTLWC RKKLW-COOH NV1G1771 NV1D3348 180GPQCQAWMQTCDRERKCCEGFVCTLWC RKKLW-COOH NV1G1778 NV1D3349 181GPQCQDWMQTCDRERKCCEGFVCTLWC RKKLW-COOH NV1G1773 NV1D3350 182GPQCQEWMQTCDRERKCCEGFVCTLWC RKKLW-COOH NV1G1779 NV1D3351 183GPQCQQWMQTCDRERKCCEGFVCTLWC RKKLW-COOH NV1G1772 NV1D3352 184GPQCQSWMQTCDRERKCCEGFVCTLWC RKKLW-COOH NV1G1868 NV1D3353 185GPQCQKWMQRCDRERKCCEGFVCTLWC RKKLW-COOH NV1G1824 NV1D3354 186GPQCQKWMQKCDRERKCCEGFVCTLWC RKKLW-COOH NV1G1863 NV1D3356 187GPQCQKWMQDCDRERKCCEGFVCTLWC RKKLW-COOH NV1G1826 NV1D3357 188GPQCQKWMQECDRERKCCEGFVCTLWC RKKLW-COOH NV1G1810 NV1D3358 189GPQCQKWMQQCDRERKCCEGFVCTLWC RKKLW-COOH NV1G1836 NV1D3359 190GPQCQKWMQSCDRERKCCEGFVCTLWC RKKLW-COOH NV1G1834 NV1D3360 191GPQCQKWMQTCRRERKCCEGFVCTLWC RKKLW-COOH NV1G1829 NV1D3361 192GPQCQKWMQTCKRERKCCEGFVCTLWC RKKLW-COOH NV1G1820 NV1D3362 193GPQCQKWMQTCTRERKCCEGFVCTLWC RKKLW-COOH NV1G1828 NV1D3363 194GPQCQKWMQTCARERKCCEGFVCTLWC RKKLW-COOH NV1G1827 NV1D3365 195GPQCQKWMQTCQRERKCCEGFVCTLWC RKKLW-COOH NV1G1857 NV1D3366 196GPQCQKWMQTCSRERKCCEGFVCTLWC RKKLW-COOH NV1G1823 NV1D3367 197GPQCQKWMQTCDRQRKCCEGFVCTLWC RKKLW-COOH NV1G1818 NV1D3368 198GPQCQKWMQTCDRTRKCCEGFVCTLWC RKKLW-COOH NV1G1811 NV1D3369 199GPQCQKWMQTCDREKKCCEGFVCTLWC RKKLW-COOH NV1G1853 NV1D3370 200GPQCQKWMQTCDRETKCCEGFVCTLWC RKKLW-COOH NV1G1817 NV1D3371 201GPQCQKWMQTCDREAKCCEGFVCTLWC RKKLW-COOH NV1G1814 NV1D3372 202GPQCQKWMQTCDREDKCCEGFVCTLWC RKKLW-COOH NV1G1831 NV1D3374 203GPQCQKWMQTCDREQKCCEGFVCTLWC RKKLW-COOH NV1G1819 NV1D3375 204GPQCQKWMQTCDRESKCCEGFVCTLWC RKKLW-COOH NV1G1859 NV1D3376 205GPQCQKWMQTCDRERRCCEGFVCTLWC RKKLW-COOH NV1G1825 NV1D3377 206GPQCQKWMQTCDRERTCCEGFVCTLWC RKKLW-COOH NV1G1821 NV1D3378 207GPQCQKWMQTCDRERACCEGFVCTLWC RKKLW-COOH NV1G1835 NV1D3379 208GPQCQDWMQTCDRERDCCEGFVCTLWC RKKLW-COOH NV1G1815 NV1D3380 209GPQCQEWMQTCDRERECCEGFVCTLWC RKKLW-COOH NV1G1833 NV1D3381 210GPQCQKWMQTCDRERQCCEGFVCTLWC RKKLW-COOH NV1G1812 NV1D3382 211GPQCQKWMQTCDRERSCCEGFVCTLWC RKKLW-COOH NV1G1782 NV1D3383 212GPQCQKWMQTCDRERKCCRGFVCTLWC RKKLW-COOH NV1G1783 NV1D3384 213GPQCQKWMQTCDRERKCCKGFVCTLWC RKKLW-COOH NV1G1785 NV1D3385 214GPQCQKWMQTCDRERKCCTGFVCTLWC RKKLW-COOH NV1G1784 NV1D3386 215GPQCQKWMQTCDRERKCCAGFVCTLWC RKKLW-COOH NV1G1780 NV1D3387 216GPQCQKWMQTCDRERKCCDGFVCTLWC RKKLW-COOH NV1G1781 NV1D3388 217GPQCQKWMQTCDRERKCCQGFVCTLWC RKKLW-COOH NV1G1786 NV1D3389 218GPQCQKWMQTCDRERKCCSGFVCTLWC RKKLW-COOH NV1G1851 NV1D3390 219GPQCQKWMQTCDRERKCCERFVCTLWC RKKLW-COOH NV1G1852 NV1D3391 220GPQCQKWMQTCDRERKCCEKFVCTLWC RKKLW-COOH NV1G1854 NV1D3392 221GPQCQKWMQTCDRERKCCETFVCTLWC RKKLW-COOH NV1G1860 NV1D3393 222GPQCQKWMQTCDRERKCCEAFVCTLWC RKKLW-COOH NV1G1789 NV1D3394 223GPQCQKWMQTCDRERKCCEDFVCTLWC RKKLW-COOH NV1G1787 NV1D3396 224GPQCQKWMQTCDRERKCCEQFVCTLWC RKKLW-COOH NV1G1856 NV1D3397 225GPQCQKWMQTCDRERKCCESFVCTLWC RKKLW-COOH NV1G1855 NV1D3398 226GPQCQKWMQTCDRERKCCEGFSCTLWC RKKLW-COOH NV1G1788 NV1D3399 227GPQCQKWMQTCDRERKCCEGFTCTLWC RKKLW-COOH NV1G1849 NV1D3400 228GPQCQKWMQTCDRERKCCEGFQCTLWC RKKLW-COOH NV1G1795 NV1D3401 229GPQCQKWMQTCDRERKCCEGFVCTLWC RRKLW-COOH NV1G1803 NV1D3403 230GPQCQKWMQTCDRERKCCEGFVCTLWC RAKLW-COOH NV1G1807 NV1D3408 231GPQCQKWMQTCDRERKCCEGFVCTLWC RKRLW-COOH NV1G1806 NV1D3409 232GPQCQKWMQTCDRERKCCEGFVCTLWC RKTLW-COOH NV1G1805 NV1D3410 233GPQCQKWMQTCDRERKCCEGFVCTLWC RKALW-COOH NV1G1809 NV1D3413 234GPQCQKWMQTCDRERKCCEGFVCTLWC RKQLW-COOH NV1G1850 NV1D3414 235GPQCQKWMQTCDRERKCCEGFVCTLWC RKSLW-COOH NV1G1793 NV1D3419 236GPQCQKWMQTCDRERKCCEGFVCTLWC RKKLD-COOH NV1G1822 NV1D3423 237GPQCQKWMQTCRRRRKCCEGFVCTLWC RKKLW-COOH NV1G1813 NV1D3424 238GPQCQKWMQTCKRKRKCCEGFVCTLWC RKKLW-COOH NV1G1840 NV1D3425 239GPQCQKWMQTCRRRDKCCEGFVCTLWC RKKLW-COOH NV1G1848 NV1D3426 240GPQCQKWMQTCKRKDKCCEGFVCTLWC RKKLW-COOH NV1G1841 NV1D3427 241GPQCQKWMQTCRRREKCCEGFVCTLWC RKKLW-COOH NV1G1844 NV1D3428 242GPQCQKWMQTCKRKEKCCEGFVCTLWC RKKLW-COOH NV1G1842 NV1D3430 243GPQCQDWMQTCDRERKCCKGFVCTLWC RKKLW-COOH NV1G1846 NV1D3431 244GPQCQEWMQTCDRERKCCKGFVCTLWC RKKLW-COOH NV1G1843 NV1D3432 245GPQCQEWMQTCDRERKCCRGFVCTLWC RKKLW-COOH NV1G1892 NV1D3439 246GPQCQKWMQTCDRERKCCEGFVCTLWC RKKLG-COOH NV1G1916 NV1D3465 247GPQCQKFMQTCDRERKCCEGFVCTLWC RKKLW-COOH NV1G1922 NV1D3466 248GPQCQKWMQTCDEERKCCEGFVCTLWC RKKLW-COOH NV1G1915 NV1D3467 249GPQCQKWMQTCDRERKCCGGFVCTLWC RKKLW-COOH NV1G1924 NV1D3470 250GPQCQKWMQTCDRERKCCEGLVCTLWC RKKLW-COOH NV1G1709 NV1D3510 251GPQCQKWMQTCDRERKCCEGFVCTLWC RKKLWAPAPASPGARAF-COOH NV1G1681 NV1D3511 252GPQCQKWMQTCDRERKCCEGFVCTLWC RKKLWSPGARAF-COOH NV1G1693 NV1D3512 253GPQCQKWMQTCDRERKCCEGFVCTLWC RKKLWAPAPAPAPAPDGPWRKM-COOH NV1G1705NV1D3513 254 GPQCQKWMQTCDRERKCCEGFVCTLWC RKKLWAPAPADGPWRKM-COOH NV1G1689NV1D3514 255 GPQCQKWMQTCDRERKCCEGFVCTLWC RKKLWDGPWRKM-COOH NV1G1711NV1D3515 256 GPQCQKWMQTCDRERKCCEGFVCTLWC RKKLWAPAPAPAPAPFGQKASS-COOHNV1G1685 NV1D3516 257 GPQCQKWMQTCDRERKCCEGFVCTLWC RKKLWAPAPAFGQKASS-COOHNV1G1697 NV1D3517 258 GPQCQKWMQTCDRERKCCEGFVCTLWC RKKLWFGQKASS-COOHNV1G1695 NV1D3518 259 GPQCQKWMQTCDRERKCCEGFVCTLWCRKKLWAPAPAPAPAPQRFVTGHFGGLY PANG-COOH NV1G1701 NV1D3519 260GPQCQKWMQTCDRERKCCEGFVCTLWC RKKLWAPAPAQRFVTGHFGGLYPANG- COOH NV1G1691NV1D3520 261 GPQCQKWMQTCDRERKCCEGFVCTLWC RKKLWQRFVTGHFGGLYPANG-COOHNV1G1679 NV1D3521 262 GPQCQKWMQTCDRERKCCEGFVCTLWCRKKLWAPAPAPAPAPRRRRRRRRRRR- COOH NV1G1683 NV1D3523 263GPQCQKWMQTCDRERKCCEGFVCTLWC RKKLWRRRRRRRRRRR-COOH NV1G1707 NV1D3524 264GPQCQKWMQTCDRERKCCEGFVCTLWC RKKLWAPAPAPAPAPYGRKKRRQRRR- COOH NV1G1713NV1D3525 265 GPQCQKWMQTCDRERKCCEGFVCTLWC RKKLWAPAPAYGRKKRRQRRR-COOHNV1G1687 NV1D3526 266 GPQCQKWMQTCDRERKCCEGFVCTLWC RKKLWYGRKKRRQRRR-COOHNV1G1699 NV1D3527 267 GPQCQKWMQTCDRERKCCEGFVCTLWC RKKLWAPAPAPAPAP-COOHNV1G1675 NV1D3528 268 GPQCQKWMQTCDRERKCCEGFVCTLWC RKKLWAPAPA-COOHNV1G1754 NV1D3529 269 GPRCQKWMQTCDAKRKCCEGFVCTLWC RKKLW-COOH NV1G1748NV1D3530 270 GPSCQKWMQTCDAKRKCCEGFVCTLWC RKKLW-COOH NV1G1747 NV1D3531271 GPYCQKWMQTCDAKRKCCEGFVCTLWC RKKLW-COOH NV1G1752 NV1D3532 272GPACQKWMQTCDAKRKCCEGFVCTLWC RKKLW-COOH NV1G1722 NV1D3533 273GPQCQKWMQTCDAKRKCCEGFSCTLWC RKKLW-COOH NV1G1744 NV1D3534 274GPRCQKWMQTCDAKRKCCEGFSCTLWC RKKLW-COOH NV1G1742 NV1D3535 275GPSCQKWMQTCDAKRKCCEGFSCTLWC RKKLW-COOH NV1G1723 NV1D3536 276GPYCQKWMQTCDAKRKCCEGFSCTLWC RKKLW-COOH NV1G1745 NV1D3537 277GPACQKWMQTCDAKRKCCEGFSCTLWC RKKLW-COOH NV1G1757 NV1D3538 278GPRCQKWMQTCDRNRKCCEGFVCTLWC RKKLW-COOH NV1G1762 NV1D3539 279GPSCQKWMQTCDRNRKCCEGFVCTLWC RKKLW-COOH NV1G1763 NV1D3540 280GPYCQKWMQTCDRNRKCCEGFVCTLWC RKKLW-COOH NV1G1728 NV1D3541 281GPACQKWMQTCDRNRKCCEGFVCTLWC RKKLW-COOH NV1G1730 NV1D3542 282GPQCQKWMQTCDRNRKCCEGFSCTLWC RKKLW-COOH NV1G1760 NV1D3543 283GPRCQKWMQTCDRNRKCCEGFSCTLWC RKKLW-COOH NV1G1727 NV1D3544 284GPSCQKWMQTCDRNRKCCEGFSCTLWC RKKLW-COOH NV1G1729 NV1D3545 285GPYCQKWMQTCDRNRKCCEGFSCTLWC LRKKLW-COOH NV1G1867 NV1D3546 286GPACQKWMQTCDRNRKCCEGFSCTLWC RKKLW-COOH NV1G1759 NV1D3547 287GPRCQKWMQTCDRERKCCEGFVCTLWC RKKLW-COOH NV1G1758 NV1D3548 288GPSCQKWMQTCDRERKCCEGFVCTLWC RKKLW-COOH NV1G1766 NV1D3549 289GPYCQKWMQTCDRERKCCEGFVCTLWC RKKLW-COOH NV1G1761 NV1D3550 290GPACQKWMQTCDRERKCCEGFVCTLWC RKKLW-COOH NV1G1726 NV1D3551 291GPRCQKWMQTCDRERKCCEGFSCTLWC RKKLW-COOH NV1G1721 NV1D3552 292GPSCQKWMQTCDRERKCCEGFSCTLWC RKKLW-COOH NV1G1765 NV1D3553 293GPYCQKWMQTCDRERKCCEGFSCTLWC RKKLW-COOH NV1G1764 NV1D3554 294GPACQKWMQTCDRERKCCEGFSCTLWC RKKLW-COOH NV1G1732 NV1D3555 295GPRCQKWMQTCDAERKCCEGFSCTLWC KKKLW-COOH NV1G1862 NV1D3556 296GPYCQKWMQTCDAERKCCEGFSCTLWC KKKLW-COOH NV1G1751 NV1D3558 297GPRCQKWMQTCDANRKCCEGFSCTLWC KKKLW-COOH NV1G1866 NV1D3559 298GPSCQKWMQTCDANRKCCEGFSCTLWC KKKLW-COOH NV1G1865 NV1D3560 299GPYCQKWMQTCDANRKCCEGFSCTLWC KKKLW-COOH NV1G1716 NV1D3561 300GPACQKWMQTCDANRKCCEGFSCTLWC KKKLW-COOH NV1G1724 NV1D3562 301GPRCQKWMQTCDARRKCCEGFSCTLWC KKKLW-COOH NV1G1717 NV1D3563 302GPSCQKWMQTCDARRKCCEGFSCTLWC KKKLW-COOH NV1G1743 NV1D3564 303GPYCQKWMQTCDARRKCCEGFSCTLWC KKKLW-COOH NV1G1720 NV1D3565 304GPACQKWMQTCDARRKCCEGFSCTLWC KKKLW-COOH NV1G1735 NV1D3566 305GPRCQKWMQTCDAERKCCEGFVCTLWC KKKLW-COOH NV1G1734 NV1D3568 306GPACQKWMQTCDAERKCCEGFVCTLWC KKKLW-COOH NV1G1741 NV1D3569 307GPRCQKWMQTCDARRKCCEGFVCTLWC KKKLW-COOH NV1G1719 NV1D3570 308GPSCQKWMQTCDARRKCCEGFVCTLWC KKKLW-COOH NV1G1718 NV1D3571 309GPYCQKWMQTCDARRKCCEGFVCTLWC KKKLW-COOH NV1G1725 NV1D3572 310GPACQKWMQTCDARRKCCEGFVCTLWC KKKLW-COOH NV1G1869 NV1D3573 311GPRCQKWMQTCDANRKCCEGFVCTLWC KKKLW-COOH NV1G1755 NV1D3574 312GPSCQKWMQTCDANRKCCEGFVCTLWC KKKLW-COOH NV1G1756 NV1D3575 313GPYCQKWMQTCDANRKCCEGFVCTLWC KKKLW-COOH NV1G1746 NV1D3576 314GPACQKWMQTCDANRKCCEGFVCTLWC KKKLW-COOH NV1G1733 NV1D3577 315GPRCQKWMQTCDAERKCCEGFSCRLWC KKKLW-COOH NV1G1738 NV1D3578 316GPYCQKWMQTCDAERKCCEGFSCRLWC KKKLW-COOH NV1G1737 NV1D3579 317GPACQKWMQTCDAERKCCEGFSCRLWC KKKLW-COOH NV1G1740 NV1D3580 318GPRCQKWMQTCDARRKCCEGFSCRLWC KKKLW-COOH NV1G1864 NV1D3581 319GPSCQKWMQTCDARRKCCEGFSCRLWC KKKLW-COOH NV1G1739 NV1D3582 320GPYCQKWMQTCDARRKCCEGFSCRLWC KKKLW-COOH NV1G1870 NV1D3583 321GPACQKWMQTCDARRKCCEGFSCRLWC KKKLW-COOH NV1G1715 NV1D3584 322GPRCQKWMQTCDANRKCCEGFSCRLWC KKKLW-COOH NV1G1753 NV1D3585 323GPSCQKWMQTCDANRKCCEGFSCRLWC KKKLW-COOH NV1G1750 NV1D3586 324GPYCQKWMQTCDANRKCCEGFSCRLWC KKKLW-COOH NV1G1750-NH2 NV1D3586-NH2 325GPYCQKWMQTCDANRKCCEGFSCRLWC KKKLW-NH2 NV1G1749 NV1D3587 326GPACQKWMQTCDANRKCCEGFSCRLWC KKKLW-COOH NV1G1871 NV1D3772 327GPQCQKWMQTCDRERKCCEGFVCTLWC RKKLWSHSNTQTLAKAPEHTG-COOH NV1G1839 NV1D3774328 GPSHSNTQTLAKAPEHTGAPAPAPAPA PAPAPAPAPAPQCQKWMQTCDRERKCCEGFVCTLWCRKKLW-COOH NV1G1877 NV1D3775 329 GPSHSNTQTLAKAPEHTGAPAPAPAPAPQCQKWMQTCDRERKCCEGFVCTLWCR KKLW-COOH NV1G1872 NV1D3777 330GPSHSNTQTLAKAPEHTGQCQKWMQTC DRERKCCEGFVCTLWCRKKLW-COOH NV1G1941 NV1D3782331 GPQCQKWMQTCDRERKCCEGFVCTLWC RKKAW-COOH NV1G1990 NV1D3788 332GPAAAAAQCQKWMQTCDRERKCCEGFV CTLWCRKKLW-COOH NV1G1991 NV1D3789 333GPAPAPAQCQKWMQTCDRERKCCEGFV CTLWCRKKLW-COOH NV1G1989 NV1D3791 334GPQCQKWMQTCDRERKCCEGFVCTLWC RKKLWAAAAA-COOH NV1G1993 NV1D3792 335GPQCQKWMQTCDRERKCCEGFVCTLWC RKKLWGGGGG-COOH NV1G1967 NV1D3793 336GPCCNCSSKWCRDHSRCCGRGSAPAPA PAPAPAPAPAPAPAPGSQCQKWMQTCDRERKCCEGFVCTLWCRKKLW-COOH NV1G1969 NV1D3795 337GPCCNCSSKWCRDHSRCCGSAPAPAPA PAPAPAPAPAPAPGSQCQKWMQTCDRERKCCEGFVCTLWCRKKLW-COOH NV1G1974 NV1D3796 338GPCCNCSSKWCRDHSRCCGSAPAPAPA PAPGSQCQKWMQTCDRERKCCEGFVCT LWCRKKLW-COOHNV1G1950 NV1D3797 339 GPQCQKWMQTCDRERKCCEGFVCTLWCRKKLWGSAPAPAPAPAPAPAPAPAPAP GSCCNCSSKWCRDHSRCC-COOH NV1G1948 NV1D3798340 GPQCQKWMQTCDRERKCCEGFVCTLWC RKKLWGSAPAPAPAPAPAPAPAPAPAPGSCCNCSSKWCRDHSRCCGR-COOH NV1G2057 NV1D3799 341GPQCQKWMQTCDRERKCCEGFVCTLWC RKKLWGSAPAPAPAPAPGSCCNCSSKW CRDHSRCC-COOHNV1G1954 NV1D3800 342 GPQCQKWMQTCDRERKCCEGFVCTLWCRKKLWGSAPAPAPAPAPGSCCNCSSKW CRDHSRCCGR-COOH NV1G1956 NV1D3801 343GPSPGARAFAPAPAPAPAPQCQKWMQT CDRERKCCEGFVCTLWCRKKLW-COOH NV1G1961NV1D3802 344 GPSPGARAFAPAPAQCQKWMQTCDRER KCCEGFVCTLWCRKKLW-COOH NV1G1960NV1D3803 345 GPSPGARAFQCQKWMQTCDRERKCCEG FVCTLWCRKKLW-COOH NV1G1977NV1D3804 346 GPDGPWRKMAPAPAPAPAPQCQKWMQT CDRERKCCEGFVCTLWCRKKLW- COOHNV1G1982 NV1D3805 347 GPDGPWRKMAPAPAQCQKWMQTCDRER KCCEGFVCTLWCRKKLW-COOHNV1G1984 NV1D3806 348 GPDGPWRKMQCQKWMQTCDRERKCCEG FVCTLWCRKKLW-COOHNV1G1985 NV1D3808 349 GPFGQKASSAPAPAQCQKWMQTCDRER KCCEGFVCTLWCRKKLW-COOHNV1G1983 NV1D3809 350 GPFGQKASSQCQKWMQTCDRERKCCEG FVCTLWCRKKLW-COOHNV1G1973 NV1D3810 351 GPQRFVTGHFGGLYPANGAPAPAPAPAPQCQKWMQTCDRERKCCEGFVCTLWCR KKLW-COOH NV1G1976 NV1D3811 352GPQRFVTGHFGGLYPANGAPAPAQCQK WMQTCDRERKCCEGFVCTLWCRKKLW- COOH NV1G1980NV1D3812 353 GPQRFVTGHFGGLYPANGQCQKWMQTC DRERKCCEGFVCTLWCRKKLW-COOHNV1G1952 NV1D3813 354 GPRRRRRRRRRRRAPAPAPAPAPQCQKWMQTCDRERKCCEGFVCTLWCRKKLW- COOH NV1G1957 NV1D3814 355GPRRRRRRRRRRRAPAPAQCQKWMQTC DRERKCCEGFVCTLWCRKKLW-COOH NV1G1981 NV1D3815356 GPRRRRRRRRRRRQCQKWMQTCDRERK CCEGFVCTLWCRKKLW-COOH NV1G1959 NV1D3818357 GPYGRKKRRQRRRQCQKWMQTCDRERK CCEGFVCTLWCRKKLW-COOH NV1G1986 NV1D3819358 GPAPAPAPAPAPQCQKWMQTCDRERKC CEGFVCTLWCRKKLW-COOH NV1G1968 NV1D3822359 GPGWCGDPGATCGKLRLYCCSGFCDSY TKTCKDKSSAGGGGSAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPGGGGSQCQK WMQTCDRERKCCEGFVCTLWCRKKLW- COOH NV1G1945NV1D3823 360 GPQCQKWMQTCDRERKCCEGFVCTLWC RKKLWGGGGSAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPGGGGSGWCGDPGAT CGKLRLYCCSGFCDSYTKTCKDKSSA- COOH NV1G1972NV1D3824 361 GPGWCGDPGATCGKLRLYCCSGFCDAY TKTCKDKSSAGGGGSAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPGGGGSQCQK WMQTCDRERKCCEGFVCTLWCRKKLW- COOH NV1G1946NV1D3825 362 GPQCQKWMQTCDRERKCCEGFVCTLWC RKKLWGGGGSAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPGGGGSGWCGDPGAT CGKLRLYCCSGFCDAYTKTCKDKSSA- COOH NV1G1970NV1D3826 363 GPGWCGDPGATCGKLRLYCCSGFCDCY TKTCKDKSSAGGGGSAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPGGGGSQCQK WMQTCDRERKCCEGFVCTLWCRKKLW- COOH NV1G1949NV1D3828 364 GPQCQKWMQTCDRERKCCEGFVCTLWC RKKLWGSGGGGSAPAPAPAPAPAPAPAPAPAPGGGGSGSCCNCSSKWCRDHSRC CGR-COOH NV1G1951 NV1D3829 365GPQCQKWMQTCDRERKCCEGFVCTLWC RKKLWGSGGGGSAPAPAPAPAPAPAPAPAPAPGGGGSGSCCNCSSKWCRDHSRC C-COOH NV1G1971 NV1D3830 366GPCCNCSSKWCRDHSRCCGRGSGGGGS APAPAPAPAPAPAPAPAPAPGGGGSGSQCQKWMQTCDRERKCCEGFVCTLWCRK KLW-COOH NV1G1975 NV1D3832 367GPCRTIGPSVCAPAPAPAPAPAPAPAP APAPQCQKWMQTCDRERKCCEGFVCTL WCRKKLW-COOHNV1G1978 NV1D3833 368 GPCRTIGPSVCAPAPAPAPAPQCQKWMQTCDRERKCCEGFVCTLWCRKKLW- COOH NV1G1979 NV1D3834 369GPCRTIGPSVCAPAPAQCQKWMQTCDR ERKCCEGFVCTLWCRKKLW-COOH NV1G2043 NV1D3835370 GPCRTIGPSVCQCQKWMQTCDRERKCC EGFVCTLWCRKKLW-COOH NV1G1955 NV1D3838371 GPQCQKWMQTCDRERKCCEGFVCTLWC RKKLWAPAPACRTIGPSVC-COOH

In some embodiments, the isolated Protoxin-II variant inhibits humanNav1.7 activity with an IC₅₀ value of about 3×10⁻⁸ M or less.

In some embodiments, the isolated Protoxin-II variant inhibits humanNav1.7 activity with an IC₅₀ value of between about 3×10⁻⁸ M to about1×10⁻⁹ M.

Another embodiment of the invention is an isolated Protoxin-II variantcomprising the amino acid sequenceGPQCX₁X₂WX₃QX₄Cx₅X₆X₇X₈X₉CCX₁₀X₁₁FX₁₂CX₁₃LWCX₁₄KKLL (SEQ ID NO: 433),wherein

-   -   X₁ is Q, R, K, A or S;    -   X₂ is K, S, Q or R;    -   X₃ is M or F;    -   X₄ is T, S, R, K or Q;    -   X₅ is D or T;    -   X₆ is S, A or R;    -   X₇ is E, R, N, K, T or Q;    -   X₈ is R or K;    -   X₉ is K, Q, S or A;    -   X₁₀ is E, Q or D;    -   X₁₁ is G or Q;    -   X₁₂ is V or S;    -   X₁₃ is R or T; and    -   X₁₄ is K or R.

Exemplary Protoxin-II variants that inhibit human Nav1.7 activity withan IC₅₀ value of about 30×10⁻⁹ M or less are variants comprising theamino acid sequences of SEQ ID NOs: 56, 78, 111, 114, 117, 118, 119,122, 123, 129, 130, 131, 132, 133, 134, 135, 136, 138, 139, 140, 141,142, 145, 146, 147, 149, 150, 151, 152, 153, 154, 156, 158, 159, 165,172, 173, 175, 177, 178, 183, 184, 185, 186, 189, 190, 193, 197, 199,207, 210, 211, 216, 217, 224, 266, 273, 282, 335, 408, 409, 410, 422,424, 425, 426, 427 and 428.

In some embodiments, the isolated Protoxin-II variant selectivelyinhibits human Nav1.7. The Protoxin-II variants of the invention may bemore selective towards Nav1.7 when compared to the recombinantProtoxin-II (SEQ ID NO: 2). In the QPatch electrophysiology assay,recombinant Protoxin-II has an IC₅₀ of about 2.2×10⁻⁹ M for Nav1.7 andan IC₅₀ of about 62×10⁻⁹ M for Nav1.6, and therefore the ratio of IC₅₀for Nav1.6 to IC₅₀ for Nav1.7 about 28 fold. “Selectivity” or“selective” or “more selective” or “selectively blocks” or “selectivelyinhibits” when used herein refers to a Protoxin-II variant that has aratio of IC₅₀ for Nav1.6 to IC₅₀ for Nav1.7 (IC₅₀(Nav1.6)/IC₅₀(Nav1.7))equal or over about 30. IC₅₀ for Nav1.6 may be assayed in a QPatchelectrophysiology assay using cell lines stably expressing Nav1.6 usingsimilar methods to those described for Nav1.7.

Residue positions in Protoxin-II that can be mutagenized to improveselectivity include residues 7, 11, 12, 14, 17, 18 and 19, andoptionally residues 1, 20, 22 and 26 (residue numbering according to SEQID NO: 1). Exemplary substitutions to improve selectivity are Y1Q, W7Q,S11R, S11A, E12T, M19F, V20S, R22T, and K26R. Exemplary Protoxin-IIvariants with improved selectivity are variants of SEQ ID NOs: 56, 59,65, 78, 111, 114, 117, 118, 119, 121, 122, 123, 129, 130, 133, 150, 190,217, 281, 324, 325 or 326.

Another embodiment of the invention is an isolated Protoxin-II variantcomprising the sequence GPX₁CQKWMQX₂CDX₃X₄RKCCX₅GFX₆CX₇LWCX₈KKLW (SEQ IDNO: 405); wherein

-   -   X₁ is Y, Q, A, S or R;    -   X₂ is T or S;    -   X₃ is S, R or A;    -   X₄ is E, T or N;    -   X₅ is E or Q;    -   X₆ is V or S;    -   X₇ is R or T; and    -   X₈ is K or R;

wherein the Protoxin-II variant inhibits human Nav1.7 activity with anIC₅₀ value of about 3×10⁻⁸ M or less, and selectively inhibits humanNav1.7.

In some embodiments, the isolated Protoxin-II variant comprises thesequence GPQCQKWMQX₁CDX₂X₃RKCCX₄GFX₅CX₆LWCX₈KKLW (SEQ ID NO: 406);wherein

-   -   X₁ is T or S;    -   X₂ is S, R or A;    -   X₃ is E, T or N;    -   X₄ is E or Q;    -   X₅ is V or S;    -   X₆ is R or T; and    -   X₇ is K or R.

Another embodiment is an isolated Protoxin-II variant comprising theamino acid sequence that is 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%or 99% identical to the amino acid sequence of SEQ ID NO: 422(GPYCQKWMQTCDSERKCCEGMVCRLWCKKKLL-COOH); wherein

-   -   the amino acid sequence has Q at position 7 and L at position        30, when residue numbering is according to SEQ ID NO: 1; and    -   the polypeptide inhibits human Nav1.7 activity with an IC₅₀        value of about 30×10⁻⁹ M or less, wherein the IC₅₀ value is        measured using a FLIPR® Tetra membrane depolarization assay        using fluorescence resonance energy transfer (FRET) in the        presence of 25×10⁻⁶ M 3-veratroylveracevine in HEK293 cells        stably expressing human Nav1.7.    -   Protoxin-II variants having substitutions W7Q and W30L have        improved folding, yield and selectivity when compared to the        wild type Protoxin-II.

Another embodiment is an isolated Protoxin-II variant comprising theamino acid sequence that is 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%or 99% identical to the amino acid sequence of SEQ ID NO: 78(GPQCQKWMQTCDRERKCCEGFVCTLWCRKKLW-COOH); wherein

-   -   the amino acid sequence has Q at position 1, Q at position 7 and        F at position 19, when residue numbering is according to SEQ ID        NO: 1;    -   the polypeptide inhibits human Nav1.7 activity with an IC₅₀        value of about 30×10⁻⁹ M or less, wherein the IC₅₀ value is        measured using a FLIPR® Tetra membrane depolarization assay        using fluorescence resonance energy transfer (FRET) in the        presence of 25×10⁻⁶ M 3-veratroylveracevine in HEK293 cells        stably expressing human Nav1.7; and the polypeptide selectively        inhibits Nav1.7.

In some embodiments, the isolated Protoxin-II variant has a freeC-terminal carboxylic acid, amide, methylamide or butylamide group,which are generated via routine synthetic methods.

Another embodiment of the invention is an isolated fusion proteincomprising the Protoxin-II variant of SEQ ID NOs: 3, 4, 5, 6, 7, 8, 9,10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27,28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45,46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63,64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 109, 110,111, 112, 113, 114, 115, 116, 117, 118, 119, 121, 122, 123, 124, 125,126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139,140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153,154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167,168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181,182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195,196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209,210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223,224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237,238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251,252, 253, 254, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266,267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280,281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294,295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308,309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322,323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336,337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350,351, 352, 353, 354, 355, 35, 357, 358, 359, 360, 361, 362, 363, 364,365, 366, 367, 368 369, 370, 371, 408, 409, 410, 411, 412, 413, 414,415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428,429, 430 or 431. Such second polypeptides may be well known leader orsecretory signal sequences, or synthetic sequences resulting for examplefrom cloning steps, or tags such as hexahistidine tag (SEQ ID NO: 108).Such second polypeptide may be a half-life extending moiety. In oneembodiment, the isolated fusion protein comprises the Protoxin-IIvariant of the invention conjugated to a half-life extending moiety.

Exemplary half-life extending moieties that can be used include wellknown human serum albumin, transthyretin (TTR), a thyroxine-bindingglobulin (TGB), albumin-binding domains, or an Fc or fragments thereof.Biologically suitable polymers or copolymers may also be used, forexample ethylene glycol or polyethylene glycol (PEG) molecules, such asPEG5000 or PEG20000, dextran, polylysine, fatty acids and fatty acidesters of different chain lengths, for example laurate, myristate,stearate, arachidate, behenate, oleate, arachidonate, octanedioic acid,tetradecanedioic acid, octadecanedioic acid, docosanedioic acid, and thelike, octane, or carbohydrates (dextran, cellulose, oligo- orpolysaccharides). These moieties may be direct fusions with theProtoxin-II variant polypeptides and may be generated by standardcloning and expression techniques. Alternatively, well known chemicalcoupling methods may be used to attach the moieties to recombinantlyproduced Protoxin-II variants of the invention.

In another embodiment, the half-life extending moiety of the fusionprotein of the invention is human serum albumin, albumin binding domain(ABD), or polyethylene glycol (PEG).

In another embodiment, the half-life extending moiety of is conjugatedto the Protoxin-II variant via a linker. Suitable linkers are well knownand include linkers having the sequence shown in SEQ ID NOs: 80 or 81.

Exemplary fusion proteins incorporating Protoxin-II variants of theinvention are those having the polypeptide sequence of SEQ ID NOs: 83,85, 87, 89, 91, 93, 95, 97, 99, 101 or 103.

Protoxin-II variants of the invention incorporating additional moietiesmay be compared for functionality by several well-known assays. Forexample, pharmacokinetic properties of Protoxin-II variants coupled toPEG may be evaluated in well known in vivo models.

Additional Protoxin-II variants and Protoxin-II variant fusion proteinsare within the scope of the invention. Additional substitutions to theProtoxin-II variants of the invention can be made as long as theresulting variant or the fusion protein retains similar characteristicswhen compared to the parent peptide. Exemplary modifications are forexample conservative substitutions that will result in Protoxin-IIvariants with similar characteristics to those of the parent molecules.Conservative replacements are those that take place within a family ofamino acids that are related in their side chains. Genetically encodedamino acids can be divided into four families: (1) acidic (aspartate,glutamate); (2) basic (lysine, arginine, histidine); (3) nonpolar(alanine, valine, leucine, isoleucine, proline, phenylalanine,methionine, tryptophan); and (4) uncharged polar (glycine, asparagine,glutamine, cysteine, serine, threonine, tyrosine). Phenylalanine,tryptophan, and tyrosine are sometimes classified jointly as aromaticamino acids. Alternatively, the amino acid repertoire can be grouped as(1) acidic (aspartate, glutamate); (2) basic (lysine, argininehistidine), (3) aliphatic (glycine, alanine, valine, leucine,isoleucine, serine, threonine), with serine and threonine optionallygrouped separately as aliphatic-hydroxyl; (4) aromatic (phenylalanine,tyrosine, tryptophan); (5) amide (asparagine, glutamine); and (6)sulfur-containing (cysteine and methionine) (Stryer (ed.), Biochemistry,2nd ed, WH Freeman and Co., 1981). Non-conservative substitutions can bemade to the Protoxin-II variants that involve substitutions of aminoacid residues between different classes of amino acids to improveproperties of the Protoxin-II variants and Protoxin-II variant fusionproteins. Whether a change in the amino acid sequence of a polypeptideor fragment thereof results in a functional homolog can be readilydetermined by assessing the ability of the modified polypeptide orfragment to produce a response in a fashion similar to the unmodifiedpolypeptide or fragment using the assays described herein. Peptides,polypeptides or proteins in which more than one replacement takes placecan readily be tested in the same manner.

Another embodiment of the invention is an isolated syntheticpolynucleotide comprising a polynucleotide encoding the Protoxin-IIvariant of the invention.

Certain exemplary synthetic polynucleotides are disclosed herein,however, other synthetic polynucleotides which, given the degeneracy ofthe genetic code or codon preferences in a given expression system,encode the Protoxin-II variants and Protoxin-II variant fusion proteinsof the invention are also within the scope of the invention. Exemplarysynthetic polynucleotides are for example polynucleotide sequences shownin SEQ ID NOs: 84, 86, 88, 90, 92, 94, 96, 98, 100, 102 and 104, whichencode the Protoxin-II variant fusion proteins of the invention. Thoseskilled in the art can readily identify the polynucleotide segments inthe fusion proteins that encode the Protoxin-II variant itself. Thesynthetic polynucleotide sequences encoding the Protoxin-II variants orfusion proteins of the invention can be operably linked to one or moreregulatory elements, such as a promoter and enhancer, that allowexpression of the nucleotide sequence in the intended host cell. Thesynthetic polynucleotide may be a cDNA.

The polynucleotides of the invention may be produced by chemicalsynthesis such as solid phase polynucleotide synthesis on an automatedpolynucleotide synthesizer. Alternatively, the polynucleotides of theinvention may be produced by other techniques such as PCR basedduplication, vector based duplication, or restriction enzyme based DNAmanipulation techniques. Techniques for producing or obtainingpolynucleotides of known sequences are well known.

The polynucleotides of the invention may also comprise at least onenon-coding sequence, such as transcribed but not translated sequences,termination signals, ribosome binding sites, mRNA stabilizing sequences,introns and polyadenylation signals. The polynucleotide sequences mayalso comprise additional sequences encoding additional amino acids.These additional polynucleotide sequences may, for example, encode amarker or well-known tag sequences such as a hexa-histidine (SEQ ID NO:108) or a HA tag which facilitate the purification of fusedpolypeptides.

Another embodiment of the invention is a vector comprising thepolynucleotide of the invention. Such vectors may be plasmid vectors,viral vectors, vectors for baculovirus expression, transposon basedvectors or any other vector suitable for introduction of thepolynucleotide of the invention into a given organism or geneticbackground by any means. For example, polynucleotides encoding theProtoxin-II variants or the Protoxin-II variant fusion proteins of theinvention are inserted into an expression vector and may be operablylinked to control sequences in the expression vector to ensure efficientexpression, such as signal sequences, promoters (e.g. naturallyassociated or heterologous promoters), enhancer elements, andtranscription termination sequences, and are chosen to be compatiblewith the host cell chosen to express the Protoxin-II variant or theProtoxin-II variant fusion protein of the invention. Once the vector hasbeen incorporated into the appropriate host, the host is maintainedunder conditions suitable for high level expression of the proteinsencoded by the incorporated polynucleotides.

Suitable expression vectors are typically replicable in the hostorganisms either as episomes or as an integral part of the hostchromosomal DNA. Commonly, expression vectors contain selection markerssuch as ampicillin-resistance, hygromycin-resistance, tetracyclineresistance, kanamycin resistance or neomycin resistance to permitdetection of those cells transformed with the desired DNA sequences.

Suitable promoter and enhancer elements are known in the art. Forexpression in a bacterial cell, suitable promoters include, but are notlimited to, lacl, lacZ, T3, T7, gpt, lambda P and trc. For expression ina eukaryotic cell, suitable promoters include, but are not limited to,light and/or heavy chain immunoglobulin gene promoter and enhancerelements; cytomegalovirus immediate early promoter; herpes simplex virusthymidine kinase promoter; early and late SV40 promoters; promoterpresent in long terminal repeats from a retrovirus; mousemetallothionein-I promoter; and various art-known tissue specificpromoters. For expression in a yeast cell, a suitable promoter is aconstitutive promoter such as an ADH1 PGK1, ENO or PYK1 promoter and thelike, or a regulatable promoter such as a GAL1 or GAL10 promoter.Selection of the appropriate vector and promoter is well within thelevel of ordinary skill in the art.

Large numbers of suitable vectors and promoters are known to those ofskill in the art; many are commercially available for generatingrecombinant constructs. The following vectors are provided by way ofexample. Bacterial: pBs, phagescript, PsiX174, pBluescript SK, pBs KS,pNH8a, pNH16a, pNH18a, pNH46a (Stratagene, La Jolla, Calif., USA);pTrc99A, pKK223-3, pKK233-3, pDR540, and pRIT5 (Pharmacia, Uppsala,Sweden). Eukaryotic: pWLneo, pSV2cat, pOG44, PXR1, pSG (Stratagene)pSVK3, pBPV, pMSG and pSVL (Pharmacia).

An exemplary vector for expression of the Protoxin-II variants orProtoxin-II variant fusion proteins is a vector havingampicillin-resistance selection marker, CMV promoter, CMV intron, signalpeptide, neomycin resistance, f1 origin of replication, SV40polyadenylation signal, and cDNA encoding the Protoxin-II variant or theProtoxin-II variant fusion protein of the invention.

Another embodiment of the invention is a host cell comprising the vectorof the invention. The term “host cell” refers to a cell into which avector has been introduced. It is understood that the term host cell isintended to refer not only to the particular subject cell but also tothe progeny of such a cell. Because certain modifications may occur insucceeding generations due to either mutation or environmentalinfluences, such progeny may not be identical to the parent cell, butare still included within the scope of the term “host cell” as usedherein. Such host cells may be eukaryotic cells, prokaryotic cells,plant cells or archeal cells.

Escherichia coli, bacilli, such as Bacillus subtilis, and otherenterobacteriaceae, such as Salmonella, Serratia, and variousPseudomonas species, are examples of prokaryotic host cells. Othermicrobes, such as yeast, are also useful for expression. Saccharomyces(e.g., S. cerevisiae) and Pichia are examples of suitable yeast hostcells. Exemplary eukaryotic cells may be of mammalian, insect, avian orother animal origins. Mammalian eukaryotic cells include immortalizedcell lines such as hybridomas or myeloma cell lines such as SP2/0(American Type Culture Collection (ATCC), Manassas, Va., CRL-1581), NS0(European Collection of Cell Cultures (ECACC), Salisbury, Wiltshire, UK,ECACC No. 85110503), FO (ATCC CRL-1646) and Ag653 (ATCC CRL-1580) murinecell lines. An exemplary human myeloma cell line is U266 (ATTCCRL-TIB-196). Other useful cell lines include those derived from ChineseHamster Ovary (CHO) cells such as CHO-K1SV (Lonza Biologics,Walkersville, Md.), CHO-K1 (ATCC CRL-61) or DG44.

Introduction of a polynucleotide, such as a vector, into a host cell canbe effected by methods well known to those skilled in the art. Exemplarymethods are calcium phosphate transfection, DEAE-Dextran mediatedtransfection, microinjection, cationic lipid-mediated transfection andelectroporation.

Another embodiment of the invention is a method for producing theProtoxin-II variant of the invention comprising the steps of providing ahost cell of the invention; and culturing the host cell under conditionssufficient for the expression of at least one Protoxin-II variant of theinvention.

Host cells can be cultured under any conditions suitable for maintainingor propagating a given type of host cell and sufficient for expressing apolypeptide. Culture conditions, media, and related methods sufficientfor the expression of polypeptides are well known in the art. Forexample, many mammalian cell types can be aerobically cultured at 37° C.using appropriately buffered DMEM media while bacterial, yeast and othercell types may be cultured at 37° C. under appropriate atmosphericconditions in LB media.

In the methods of the invention, the expression of the Protoxin-IIvariant can be confirmed using a variety of well-known methods. Forexample, expression of a polypeptide can be confirmed using detectionreagents, such as using SDS-PAGE or HPLC.

Another aspect of the invention is a method of modulating the activityof Nav1.7 in a biological tissue, the method comprising contacting thebiological tissue expressing Nav1.7 with a Nav1.7-modulating amount ofthe Protoxin-II variant of the invention.

Methods of Treatment

Protoxin-II variants of the invention may be utilized in any therapywhere it is desired to treat, reduce or alleviate symptoms of pain orother disorders of sensory or sympathetic neuron dysfunction.

Pain treated with the Protoxin-II variants of the invention may be anytype of pain, such as chronic pain, acute pain, neuropathic pain,nociceptive pain, visceral pain, back pain, pain associated withinflammatory conditions, post-operative pain, thermal pain or painassociated with disease and degeneration.

Pain treated with the Protoxin-II variants of the invention may beNav1.7-mediated pain.

Nav1.7-mediated pain as used herein refers to pain resulting at leastpartially from increased Nav1.7 channel activity.

The methods of the invention may be used to treat an animal patientbelonging to any classification. Examples of such animals includemammals such as humans, rodents, dogs, cats and farm animals.

The pain and/or Nav1.7-mediated pain may result from one or more causes,such as peripheral neuropathy, central neuropathy, nerve compression orentrapment syndromes such as carpal tunnel syndrome, tarsus tunnelsyndrome, ulnar nerve entrapment, compression radiculopathy, lumbarspinal stenosis, sciatic nerve compression, spinal root compression,intercostal neuralgia, compression radiculopathy and radicular lowerback pain, spinal root lesions, neuritis, autoimmune diseases, generalinflammation, chronic inflammatory conditions, arthritis, rheumaticdiseases, lupus, osteoarthritis, general gastrointestinal disorders,colitis, gastric ulceration, duodenal ulcers, inflammatory boweldisorders, irritable bowel syndrome, pain associated with diarrhea,inflammatory eye disorders, inflammatory or unstable bladder disorders,psoriasis, skin complaints with inflammatory components, sunburn,carditis, dermatitis, myositis, neuritis, collagen vascular diseases,inflammatory pain and associated hyperalgesia and allodynia, neuropathicpain and associated hyperalgesia and allodynia, multiple sclerosis,demyelinating diseases, diabetes, diabetic neuropathy pain, causalgia,pain resulting from amputation or abscess, phantom limb pain, fracturepain, bone injury, direct trauma, HIV infection, acquired immunedeficiency syndrome (“AIDS”), small pox infection, herpes infection,exposure to toxins or other foreign particles or molecules, invasivecancer, cancer, chemotherapy, radiotherapy, hormonal therapy, burns,congenital defect, dental pain, gout pain, fibromyalgias, encephalitis,chronic alcoholism, hypothyroidism, uremia and vitamin deficiencies,trigeminal neuralgia, stroke, thalamic pain syndrome, general headache,migraine, cluster headache, tension headache, mixed-vascular andnon-vascular syndromes, sympathetically maintained pain, deafferentationsyndromes, asthma, epithelial tissue damage or dysfunction, disturbancesof visceral motility at respiratory, genitourinary, gastrointestinal orvascular regions, wounds, burns, allergic skin reactions, pruritis,vasomotor or allergic rhinitis, or bronchial disorders, dysmenorrhoea,pain during labor and delivery, dyspepsia, gastroesophageal reflux,pancreatitis, and visceralgia.

Other disorders of sensory or sympathetic neuron dysfunction that may bealleviated by the Protoxin-II variants of the invention include itch,cough and asthma. In mice, global deletion of the SCN9A gene leads tocomplete insensitivity to histamine-induced itch (Gingras et al.,American Pain Society Meeting Abstract 2013 and U.S. Pat. Publ. No.2012/0185956). This finding suggests that peptide Nav1.7 blockers mayhave utility in the treatment of itch, which may arise from varioussources, such as dermatological or inflammatory disorders; orinflammatory disorders such as renal or hepatobiliary disorders,immunological disorders, medication reactions and unknown/idiopathicconditions, including dermatitis, psoriasis, eczema, insect sting orbite. Nav1.7 is also expressed in sensory nerves innervating the airways(Muroi et al., J Physiol. 2011 Dec. 1; 589(Pt 23):5663-76; Muroi et al.,Am J Physiol Regul Integr Comp Physiol. 2013 Apr. 10), suggesting thatpeptide Nav1.7 blockers may be beneficial in the treatment of coughe.g., acute or chronic cough, or cough caused by irritation fromgastroesophageal reflux disease, and inflammatory diseases of theairways such as asthma and allergy-related immune responses,bronchospasm, chronic obstructive pulmonary disease, chronic bronchitis,emphysema, and hiccups (hiccoughs, singultus). Silencing Nav1.7 in vivoin nodose ganglia of guinea pigs using shRNA nearly abolished the coughreflex induced by mechanical probing (Muroi et al., Am J Physiol RegulIntegr Comp Physiol. 2013 Apr. 10).

One aspect of the invention is a method of alleviating or treating itch,cough or asthma in a subject by administering a therapeuticallyeffective amount of the Protoxin-II variant of the invention to asubject in need thereof for a time sufficient to alleviate the itch,cough or asthma.

Another aspect of the invention is a method of alleviating or treatingNav1.7-mediated itch, Nav1.7-mediated cough or Nav1.7-mediated asthma ina subject by administering a therapeutically effective amount of theProtoxin-II variant of the invention to a subject in need thereof for atime sufficient to alleviate the itch, cough or asthma.

Nav1.7-mediated itch as used herein refers to itch resulting at leastpartially from increased Nav1.7 channel activity.

Nav1.7-mediated cough as used herein refers to cough resulting at leastpartially from increased Nav1.7 channel activity.

Nav1.7-mediated asthma as used herein refers to asthma resulting atleast partially from increased Nav1.7 channel activity.

Protoxin-II variants of the invention may be tested for their effect inreducing or alleviating pain and/or Nav1.7-mediated pain using animalmodels described herein, and models such as the rat spinal nerveligation (SNL) model of neuropathic pain, carageenan induced allodyniamodel, the Freund's complete adjuvant (CFA)-induced allodynia model, thethermal injury model, the formalin model and the Bennett Model, andother models as described in U.S. Pat. Appl. No. 2011/0124711 and U.S.Pat. No. 7,998,980. Carageenan induced allodynia and CFA-inducedallodynia are models of inflammatory pain. The Bennett model provides ananimal model for chronic pain including post-operative pain, complexregional pain syndrome, and reflex sympathetic dystrophy.

Any of the foregoing animal models may be used to evaluate the efficacyof Protoxin-II variants of the invention inhibitor in treating painand/or NAv1.7-mediated pain. The efficacy of the Protoxin-II variants ofthe invention may be compared to a no treatment or placebo control.Additionally or alternatively, efficacy may be evaluated in comparisonto one or more known pain-relieving medicaments.

The present invention provides methods of treating Nav1.7-mediated painusing the Protoxin-II variants of the invention. It has been discoveredin the pending application by the inventors (U.S. Patent Application No.61/781,276) that administration of Nav1.7 blocking peptides areefficacious in treating and/or alleviating pain in various animal modelsof pain, contrary to what was disclosed and suggested in the literature.While peptide inhibitors of Nav1.7 have been shown to be potent and/orselective towards Nav1.7 in in vitro cell culture models usingoverexpressed Nav1.7 or on isolated neurons in which the blood-nervebarrier is subverted through desheathing or hypertonic saline injection,they have so far proven non-efficacious in in vivo animal models ofpain, where the lack of efficacy has been reported to result from theinability of the peptides to pass the blood-nerve barrier. Severalpublications describe lack of efficacy of Nav1.7 blocking peptides inanimal models of pain or in isolated nerves. For example Hackel et al.,Proc Natl Acad Sci 109:E2018-27, 2012, describes the inability ofProTx-II to inhibit action potential firing in isolated nerves unlessthe perineural barrier, which provides a diffusion barrier in thismodel, is compromised. ProTx-II was found non-efficacious in rodentmodels of acute and inflammatory pain; a likely explanation stated theinability of ProTx-II to cross the blood-nerve barrier (Schmalhofer etal., Mol Pharmacol 74:1476-1484, 2008). It has been proposed that Nav1.7peptide toxin blockers have poor oral bioavailability and they aredifficult to deliver to nerve endings, implying that their use astherapeutic agents remain limited (Dib-Hajj et al., Nature RevNeuroscience 14, 49-62, 2013).

Nav1.7 is expressed in the peripheral nervous system e.g., innociceptive dorsal root ganglions (DRG), most notably in nociceptivesmall-diameter DRG neurons, in particular in peripheral terminals in theskin, with little representation in the brain. Nav1.7 distribution (e.g.sensory ending) and physiology predispose it to a major role intransmitting painful stimuli.

One embodiment of the invention is a method of treating Nav1.7-mediatedpain by administering a therapeutically effective amount of theProtoxin-II variant of the invention to a subject in need thereof for atime sufficient to treat the Nav1.7-mediated pain.

The Protoxin-II variants of the invention Nav1.7 may be utilized in anytherapy where it is desired to treat Nav1.7-mediated pain or otherdisorders of sensory or sympathetic neuron dysfunction. “Treat” or“treatment” of pain is meant to include partially or completely toprevent, stop, inhibit, reduce, or delay the perception of pain.

In some embodiments, the Nav1.7-mediated pain is chronic pain, acutepain, neuropathic pain, nociceptive pain, visceral pain, back pain,post-operative pain, thermal pain, phantom limb pain, or pain associatedwith inflammatory conditions, primary erythemalgia (PE), paraoxysmalextreme pain disorder (PEPD), osteoarthritis, rheumatoid arthritis,lumbar discectomy, pancreatitis, fibromyalgia, painful diabeticneuropathy (PDN), post-herpetic neuropathy (PHN), trigeminal neuralgia(TN), spinal cord injuries or multiple sclerosis, or pain associatedwith disease and degeneration.

Neuropathic pain includes for example painful diabetic neuropathy (PDN),post-herpetic neuropathy (PHN) or trigeminal neuralgia (TN). Othercauses of neuropathic pain include spinal cord injuries, multiplesclerosis, phantom limb pain, post-stroke pain and HIV-associated pain.Conditions such as chronic back pain, osteoarthritis and cancer may alsoresult in the generation of neuropathic-related pain and thus arepotentially suitable for treatment with the Protoxin-II variants of theinvention.

In another embodiment, the Nav1.7-mediated pain is associated withprimary erythemalgia (PE), paraoxysmal extreme pain disorder (PEPD),osteoarthritis, rheumatoid arthritis, lumbar discectomy, pancreatitis orfibromyalgia.

In the methods of the invention, the Protoxin-II variants of theinvention may be conjugated to a second polypeptide to form a fusionprotein. Such fusion proteins are for example the well-known Fc fusionsor fusions to human serum albumin to extend half-life of the peptideinhibitors. The conjugation may be a direct conjugation via a linker,such as a glycine-serine rich linker. Such linkers are well known in theart. The Protoxin-II variants of the invention incorporating additionalmoieties may be compared for their Nav1.7 blocking ability and efficacyin treatment or reducing pain using well known methods and thosedescribed herein.

Other disorders of sensory or sympathetic neuron dysfunction that can betreated with the Protoxin-II variants of the invention, includingasthma, cough, heart-burn, itch, dermatitis, bladder instability, andReynaud's disease.

Pharmaceutical Compositions

The Protoxin-II variants of the invention may be formulated in apharmaceutically acceptable vehicle or carrier. One embodiment of theinvention is a pharmaceutical composition comprising the isolatedProtoxin-II variant of the invention and a pharmaceutically acceptableexcipient.

A suitable vehicle or carrier may be water for injection, physiologicalsaline solution or artificial cerebrospinal fluid, possibly supplementedwith other materials common in compositions for parenteraladministration. Neutral buffered saline or saline mixed with serumalbumin are further exemplary vehicles. These solutions are sterile andgenerally free of particulate matter, and may be sterilized byconventional, well-known sterilization techniques (e.g., filtration).The compositions may contain pharmaceutically acceptable excipients asrequired to approximate physiological conditions, such as pH adjustingand buffering agents, stabilizing, thickening, lubricating and coloringagents, etc. Suitable vehicles and their formulation and packaging aredescribed, for example, in Remington: The Science and Practice ofPharmacy (21st ed., Troy, D. ed., Lippincott Williams & Wilkins,Baltimore, Md. (2005) Chapters 40 and 41).

In the methods of the invention, the Protoxin-II variants of theinvention may be administered by peripheral administration. “Peripheraladministration” or “administered peripherally” means introducing anagent into a subject outside of the central nervous system. Peripheraladministration encompasses any route of administration other than directadministration to the spine or brain.

Peripheral administration can be local or systemic. Local administrationmay be used to concentrate the therapeutic to the site of action, suchas local administration to joints, spinal cord, surgical wounds, sitesof injury/trauma, peripheral nerve fibers, various organs (GI,urogenital, etc) or inflamed tissues. Systemic administration results indelivery of a pharmaceutical composition to essentially the entireperipheral nervous system of the subject and may also result in deliveryto the central nervous system depending on the properties of thecomposition.

Routes of peripheral administration encompass, without limitation,topical administration, intravenous or other injection, and implantedmini-pumps or other extended release devices or formulations.

Pharmaceutical compositions of the invention include formulationsinvolving the Protoxin-II variants of the invention in sustained- orcontrolled-delivery formulations. These formulations may be achievedthrough use of for example injectable microspheres, bio-erodibleparticles, microemulsions, nanoparticles, nanocapsules, macroemulsions,polymeric compounds (such as polyesters, polyamino acids, hydrogels,poly(lactic acid), polyglycolic acid or ethylene vinylacetatecopolymers), beads or liposomes, hyaluronic acid or implantable drugdelivery devices.

The Protoxin-II variants of the invention may be prepared for use forparenteral (subcutaneous, intramuscular or intravenous), intracerebral(intra-parenchymal), intracerebroventricular, intramuscular,intra-ocular, intra-arterial, intraportal, or intralesional routes; bysustained release systems or by implantation devices, or any otheradministration, particularly in the form of liquid solutions orsuspensions; for buccal or sublingual administration such as in the formof tablets or capsules; or intranasally such as in form of powders,nasal drops or aerosols or certain agents; transdermally in a form of agel, ointment, lotion, cream or dusting powder, suspension or patchdelivery system with chemical enhancers to either modify the skinstructure or to increase the drug concentration in the transdermalpatch, or with agents that enable the application of formulationscontaining proteins and peptides onto the skin (Int. Pat. Publ. No.WO98/53847), or applications of electric fields to create transienttransport pathways such as electroporation, or to increase the mobilityof charged drugs through the skin such as iontophoresis, or applicationof ultrasound such as sonophoresis (U.S. Pat. Nos. 4,309,989 and4,767,402). The composition also may be administered locally viaimplantation of a membrane, sponge or another appropriate material ontowhich the desired molecule has been absorbed or encapsulated.

In certain embodiments, where an implantation device is used, the devicemay be implanted into any suitable tissue or organ, and delivery of thedesired molecule may be via diffusion, timed-release bolus, orcontinuous administration.

The concentration of the Protoxin-II variants of the invention or otherpeptide inhibitors of Nav1.7 in such pharmaceutical formulation can varywidely, for example from about 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%,0.8%, 0.9%, 1.0%, 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, 1.6%, 1.7%, 1.8%, 1.9%,2%, or between 2% to 5%, up to as much as 15%, 20%, 30%, 40%, 50%, 60%or 70% by weight and will be selected primarily based on fluid volumes,viscosities and other factors, according to the particular mode ofadministration selected. The Protoxin-II variants of the invention canbe lyophilized for storage and reconstituted in a suitable vehicle priorto use. This technique has been shown to be effective with conventionalprotein preparations. Lyophilization and reconstitution techniques arewell known in the art.

An exemplary pharmaceutical compositions of the present invention maycomprise Tris buffer of about pH 7.0-8.5, or acetate buffer of about pH4.0-5.5, and may further include sorbitol, sucrose, Tween-20 and/or asuitable substitute thereof.

The appropriate therapeutically effective dose may be determined readilyby those skilled in the art. An effective dose refers to an amount ordosage sufficient to produce a desired result, i.e. to partially orcompletely prevent, stop, inhibit, reduce, or delay the perception ofpain associated with any painful medical condition. The effective amountmay vary depending on the specific vehicle and the Protoxin-II variantsof the invention selected, and is also dependent on a variety of factorsand conditions related to the subject to be treated and the severity ofthe pain. For example, factors such as age, weight and health of thesubject to be administered with the pharmaceutical compositions of theinvention as well as dose response curves and toxicity data obtained inpreclinical animal work could be among those considered. A determineddose may, if necessary, be repeated at appropriate time intervalsselected as appropriate by a physician or other person skilled in therelevant art (e.g. nurse, veterinarian, or veterinary technician) duringthe treatment period. The determination of an effective amount or atherapeutically effective amount for a given agent is well within theability of those skilled in the art.

Thus, a pharmaceutical composition of the invention for intramuscularinjection could be prepared to contain 1 ml sterile buffered water, andbetween about 1 ng to about 100 mg, about 50 ng to about 30 mg or about5 mg to about 25 mg of a Protoxin-II variant of the invention.Similarly, a pharmaceutical composition of the invention for intravenousinfusion could be made up to contain about 250 ml of sterile Ringer'ssolution, and about 1 mg to about 30 mg or about 5 mg to about 25 mg ofthe Protoxin-II variants of the invention. Actual methods for preparingparenterally administrable compositions are well known and are describedin more detail in, for example, “Remington's Pharmaceutical Science”,15th ed., Mack Publishing Company, Easton, Pa.

Further Embodiments of the Invention

Set out below are certain further embodiments of the invention accordingto the disclosures elsewhere herein. Features from embodiments of theinvention set out above described as relating to the invention disclosedherein also relate to each and every one of these further numberedembodiments.

-   -   1) An isolated Protoxin-II variant comprising the sequence        X₁X₂X₃CX₄X₅WX₆QX₇CX₈X₉X₁₀X₁₁X₁₂CCX₁₃X₁₄FX₁₅CX₁₆LWCX₁₇KKLW (SEQ        ID NO: 403), wherein        -   X₁ is G, P, A or deleted;        -   X₂ is P, A or deleted;        -   X₃ is S, Q, A, R or Y;        -   X₄ is Q, R, K, A or S;        -   X₅ is K, S, Q or R;        -   X₆ is M or F;        -   X₇ is T, S, R, K or Q;        -   X₈ is D or T;        -   X₉ is S, A or R;        -   X₁₀ is E, R, N, K, T or Q;        -   X₁₁ is R or K;        -   X₁₂ is K, Q, S or A;        -   X₁₃ is E, Q or D;        -   X₁₄ is G or Q;        -   X₁₅ is V or S;        -   X₁₆ is R or T; and        -   X₁₇ is K or R;        -   optionally having an N-terminal extension or a C-terminal            extension,        -   wherein the polypeptide inhibits human Nav1.7 activity with            an IC₅₀ value of about 1×10⁻⁷ M or less, wherein the IC₅₀            value is measured using a FLIPR® Tetra membrane            depolarization assay using fluorescence resonance energy            transfer (FRET) in the presence of 25×10⁻⁶ M            3-veratroylveracevine in HEK293 cells stably expressing            human Nav1.7.    -   2) The Protoxin-II variant of claim 1, wherein the N-terminal        extension comprises the amino acid sequence of SEQ ID NOs: 372,        373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384 or        385.    -   3) The Protoxin-II variant of claim 1 or 2, wherein the        C-terminal extension comprises the amino acid sequence of SEQ ID        NOs: 374, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396        or 397.    -   4) The Protoxin-II variant of claim 2 or 3, wherein the        N-terminal and/or the C-terminal extension is conjugated to the        Protoxin-II variant via a linker.    -   5) The Protoxin-II variant of claim 4, wherein the linker        comprises the amino acid sequence of SEQ ID NOs: 383, 392, 398,        399, 400, 401 or 402.    -   6) The isolated Protoxin-II variant of any of the claim 1-5,        comprising the amino acid sequence of SEQ ID NOs: 30, 40, 44,        52, 56, 56, 59, 65, 78, 109, 110, 111, 114, 117, 118, 119, 120,        121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133,        134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146,        147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159,        162, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 177,        178, 179, 180, 182, 183, 184, 185, 186, 189, 190, 193, 195, 197,        199, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217,        218, 224, 226, 227, 231, 232, 243, 244, 245, 247, 249, 252, 255,        258, 261, 263, 264, 265, 266, 269, 270, 271, 272, 273, 274, 275,        276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288,        289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301,        302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314,        315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 332,        334, 335, 336, 337, 339, 340, 341, 342, 346, 351, 358, 359, 364,        366, 367, or 368.    -   7) The isolated Protoxin-II variant of any of the claims 1-6,        that inhibits human Nav1.7 activity with an IC₅₀ value of about        3×10⁻⁸ M or less.    -   8) The isolated Protoxin-II variant of claim 7 that inhibits        human Nav1.7 activity with an IC₅₀ value of between about 3×10⁻⁸        M to about 1×10⁻⁹ M.    -   9) The isolated Protoxin-II variant of claim 7 or 8 comprising        the amino acid sequence        GPQCX₁X₂WX₃QX₄CX₅X₆X₇X₈X₉CCX₁₀X₁₁FX₁₂CX₁₃LWCX₁₄KKLW (SEQ ID NO:        404), wherein        -   X₁ is Q, R, K, A or S;        -   X₂ is K, S, Q or R;        -   X₃ is M or F;        -   X₄ is T, S, R, K or Q;        -   X₅ is D or T;        -   X₆ is S, A or R;        -   X₇ is E, R, N, K, T or Q;        -   X₈ is R or K;        -   X₉ is K, Q, S or A;        -   X₁₀ is E, Q or D;        -   X₁₁ is G or Q;        -   X₁₂ is V or S;        -   X₁₃ is R or T; and        -   X₁₄ is K or R.    -   10) The isolated Protoxin-II variant of claim 9, comprising the        amino acid sequence of SEQ ID NOs: 56, 78, 111, 114, 117, 118,        119, 122, 123, 129, 130, 131, 132, 133, 134, 135, 136, 138, 139,        140, 141, 142, 145, 146, 147, 149, 150, 151, 152, 153, 154, 156,        158, 159, 165, 172, 173, 175, 177, 178, 183, 184, 185, 186, 189,        190, 193, 197, 199, 207, 210, 211, 216, 217, 224, 266, 273, 282        or 335.    -   11) The isolated Protoxin-II variant of any of the claims 1-10,        wherein the variant selectively inhibits human Nav1.7.    -   12) The isolated Protoxin-II variant of claim 11, comprising the        sequence GPX₁CQKWMQX₂CDX₃X₄RKCCX₅GFX₆CX₇LWCX₈KKLW (SEQ ID NO:        405); wherein        -   X₁ is Y, Q, A, S or R;        -   X₂ is T or S;        -   X₃ is S, R or A;        -   X₄ is E, T or N;        -   X₅ is E or Q;        -   X₆ is V or S;        -   X₇ is R or T; and        -   X₈ is K or R.    -   13) The isolated Protoxin-II variant of claim 12, comprising the        amino acid sequence of SEQ ID NOs: 56, 59, 65, 78, 111, 114,        117, 118, 119, 121, 122, 123, 129, 130, 133, 150, 190, 217, 281,        324, 325 or 326.    -   14) The isolated Protoxin-II variant of claim 12, comprising the        sequence GPQCQKWMQX₁CDX₂X₃RKCCX₄GFX₅CX₆LWCX₈KKLW (SEQ ID NO:        406); wherein        -   X₁ is T or S;        -   X₅ is S, R or A;        -   X₃ is E, T or N;        -   X₄ is E or Q;        -   X₅ is V or S;        -   X₆ is R or T; and        -   X₇ is K or R.    -   15) An isolated Protoxin-II variant comprising the amino acid        sequence that is 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or        99% identical to the amino acid sequence of SEQ ID NO: 78        (GPQCQKWMQTCDRERKCCEGFVCTLWCRKKLW-COOH), wherein        -   a) the amino acid sequence has Q at position 1, Q at            position 7 and F at position 19, when residue numbering is            according to SEQ ID NO: 1;        -   b) the polypeptide inhibits human Nav1.7 activity with an            IC₅₀ value of about 30×10⁻⁹ M or less, wherein the IC₅₀            value is measured using a FLIPR® Tetra membrane            depolarization assay using fluorescence resonance energy            transfer (FRET) in the presence of 25×10⁻⁶ M            3-veratroylveracevine in HEK293 cells stably expressing            human Nav1.7; and        -   c) the polypeptide selectively inhibits Nav1.7.    -   16) The isolated Protoxin-II variant of any of the claims 1-15,        having a free C-terminal carboxylic acid, amide, methylamide or        butylamide group.    -   17) An isolated fusion protein comprising the Protoxin-II        variant of any of the claims 1-16 conjugated to a half-life        extending moiety.    -   18) The fusion protein of claim 17, wherein the half-life        extending moiety is human serum albumin (HSA), albumin binding        domain (ABD), Fc or polyethylene glycol (PEG).    -   19) An isolated polynucleotide encoding the Protoxin-II variant        of claim 12 or 15.    -   20) A vector comprising the isolated polynucleotide of claim 19.    -   21) A host cell comprising the vector of claim 20.    -   22) A method of producing the isolated Protoxin-II variant,        comprising culturing the host cell of claim 21 and recovering        the Protoxin-II variant produced by the host cell.    -   23) A pharmaceutical composition comprising the isolated        Protoxin-II variant of claim 1, 6, 12, 13 or 15 and a        pharmaceutically acceptable excipient.    -   24) A method of treating Nav1.7-mediated pain in a subject,        comprising administering to a subject in need thereof an        effective amount of the Protoxin-II variant of any of the claims        1-16 to treat the pain.    -   25) The method of claim 24, wherein pain is chronic pain, acute        pain, neuropathic pain, nociceptive pain, visceral pain, back        pain, post-operative pain, thermal pain, phantom limb pain, or        pain associated with inflammatory conditions, primary        erythemalgia (PE), paraoxysmal extreme pain disorder (PEPD),        osteoarthritis, rheumatoid arthritis, lumbar discectomy,        pancreatitis, fibromyalgia, painful diabetic neuropathy (PDN),        post-herpetic neuropathy (PHN), trigeminal neuralgia (TN),        spinal cord injuries or multiple sclerosis.    -   26) The method of claim 24, wherein the Protoxin-II variant is        administered peripherally.    -   27) The method of claim 24, wherein the Protoxin-II variant is        administered locally to a joint, spinal cord, surgical wound,        sites of injury or trauma, peripheral nerve fibers, urogenital        organs, or inflamed tissues.    -   28) The method of claim 24, wherein the subject is a human.    -   29) The Protoxin-II variant of any of the claims 1-16 for use in        treating pain in a subject in need thereof.    -   30) The Protoxin-II variant for use according to claim 29,        wherein pain is chronic pain, acute pain, neuropathic pain,        nociceptive pain, visceral pain, back pain, post-operative pain,        thermal pain, phantom limb pain, or pain associated with        inflammatory conditions, primary erythemalgia (PE), paraoxysmal        extreme pain disorder (PEPD), osteoarthritis, rheumatoid        arthritis, lumbar discectomy, pancreatitis, fibromyalgia,        painful diabetic neuropathy (PDN), post-herpetic neuropathy        (PHN), trigeminal neuralgia (TN), spinal cord injuries or        multiple sclerosis.    -   31) The Protoxin-II variant for use according to claim 29 or 30,        wherein the Protoxin-II variant is administered peripherally.    -   32) The Protoxin-II variant for use according to claim 29, 30 or        31, wherein the Protoxin-II variant is administered locally to a        joint, spinal cord, surgical wound, sites of injury or trauma,        peripheral nerve fibers, urogenital organs, or inflamed tissues.

The present invention will now be described with reference to thefollowing specific, non-limiting examples.

Example 1: Design and Generation of Protoxin-II Variants

Protoxin-II single position limited amino acid scanning librarysubstitution was designed to assess to what degree selectivity, peptideyield, and homogeneity can be improved.

Protoxin-II variants were designed as HRV3C protease cleavable HSAfusion proteins in the following format from N- to C-terminus:6xHis-HSA-linker-HRV3C cleavable peptide-Protoxin-II variant (“6xHis”disclosed as SEQ ID NO: 108); linker being (GGGGSGGGGSGGGGSGGGGS; SEQ IDNO: 80, HSA having the sequence of SEQ ID NO: 106, HRV3C cleavablepeptide having the sequence of SEQ ID NO: 82). Each Protoxin-II variant,after cleavage from HSA had a residual N-terminal GP from the cleavagesite.

The variants were characterized in membrane depolarization assays usingFLIPR® Tetra as described in Example 3 FLIPR® Tetra membranedepolarization assay, and in whole cell patch clamp experiments usingthe QPatch assay as described in Example 3.

Combinatorial libraries were designed to test for additive effects ofselect single position hits in an attempt to generate Nav1.7 antagonistswith further improved potency and selectivity profile compared to thenative peptide.

Construction of the Expression Vectors

The designed Protoxin-II variant genes were generated using syntheticgene assembly technology as described in U.S. Pat. No. 6,521,427. Theamino acid sequences of the designed peptide variants wereback-translated to DNA sequences using human high-frequency codons. TheDNA sequence of each variant gene, together with a portion of vector DNAincluding the DNA cloning sites, was synthesized as multipleoligonucleotides, some of which contained degenerate codons, andassembled into full-length DNA fragments. The assembled DNA fragmentswere amplified by PCR and PCR products were subsequently cloned as apool. Pooled PCR products were digested with the appropriate restrictionenzymes and cloned into the designed expression vector in such a manneras to fuse each toxin variant gene to the signal peptide and the fusionpartner (6xHis-HSA-linker-HRV3C cleavable peptide (“6xHis” disclosed asSEQ ID NO: 108) contained in the vector. Standard molecular biologytechniques were used to identify a positive clone for each designedvariant. The plasmid DNA from these positive clones was purified andsequence confirmed before expressing the Protoxin-II peptide variantfusion proteins using standard methods.

Protein Expression

HEK 293-F cells were maintained in 293 Freestyle™ media (Invitrogen Cat#12338) and split when the cell concentration was between 1.5 and2.0×10⁶ cells per ml. The cells were grown in suspension, shaking at 125RPM in a humidified incubator set at 37° C. and 8% CO₂. HEK 293F cellswere transiently transfected using a DNA/lipid complex after they werediluted to 1.0×10⁶ cells per ml. To generate the complex, 1.25 μg DNAper ml of transfection was diluted in 1.0 ml of OptiPro media(Invitrogen Cat #12309) and 1.25 ml of Freestyle™ Max transfectionreagent (Invitrogen Cat #16447) was diluted in 1.0 ml of OptiPro media.The DNA and Max transfection reagent were mixed together and incubatedfor 10 minutes at room temperature before adding to the cells.Transfected cells were placed in a humidified incubator set at 37° C.and 8% CO₂ for 4 days shaking at 125 RPM. The supernatant was separatedfrom the cells by centrifugation at 5,000×g for 10 minutes and filteredthrough a 0.2 μm filter (Corning; Cat #431153), then concentrated 10 and50 fold using an Amicon Ultra Concentrator 10K (Cat #UFC901096), andcentrifuging for approximately 10 minutes at 3,750×g.

Example 2: Purification of Protoxin-II Variants

Protoxin-II variants were expressed as HSA fusion proteins as indicatedin Example 1 and the Protoxin-II variant peptides were cleaved withHRV3C protease prior to purification. Two methodologies were tested forefficient purification of the Protoxin-II variants.

Protein Purification Purification of Protoxin-II Variants by RP-HPLC

The secreted proteins were purified from the expression supernatants viaIMAC using 1 ml HisTrap HP columns (GE Healthcare Cat#17-5247-01). Thechromatography method was run using an AKTA Xpress and protein waseluted from the column using a step gradient of Imidazole. Peakfractions were pooled and digested overnight with HRV 3C protease (1 μgprotease/150 μg fusion).

Cleaved peptide-fusion pools were further purified using a Dionex HPLCsystem with a reverse phase Phenomenex Luna 5 μm C18(2) column(Cat#00B-4252-P0-AX). Samples were eluted from the column with a 0-68%Acetonitrile (0.05% TFA) linear gradient. Elution fractions were pooled,lyophilized overnight and reconstituted in HEPES buffered saline, pH 7.4(10 mM HEPES, 137 mM NaCl, 5.4 mM KCl, 5 mM glucose, 2 mM CaCl₂, 1 mMMgCl₂).

Table 4 shows yields of Protoxin-II variants purified by RP-HPLC. Theaverage mg yield/L was 0.01615.

TABLE 4 Protoxin-II Protoxin-II Variant yield Variant yield Peptide ID(mg) Peptide ID (mg) NV1D816 0.0008 NV1D2496 0.0006 NV1D2511 0.0009NV1D2503 0.0030 NV1D2513 0.0034 NV1D766 0.0054 NV1D2504 0.0071 NV1D7700.0040 NV1D2260 0.0129 NV1D772 0.0015 NV1D2498 0.0079 NV1D792 0.0016NV1D2499 0.0076 NV1D815 0.0008 NV1D2512 0.0061 NV1D768 0.0060 NV1D22670.0095 NV1D2508 0.0017 NV1D2507 0.0000 NV1D2501 0.0008 NV1D2509 0.0000NV1D2296 0.0018 NV1D2305 0.0001 NV1D2292 0.0059 NV1D815 0.0021 NV1D7500.0023 NV1D2506 0.0001 NV1D748 0.0036 NV1D2505 0.0006 NV1D774 0.0050NV1D812 0.0001 NV1D786 0.0036 NV1D2510 0.0009 NV1D855 0.0008 NV1D7690.0031 NV1D2312 0.0011 NV1D2497 0.0038 NV1D1410 0.0074 NV1D2500 0.0004NV1D1415 0.0128 NV1D767 0.0004 NV1D751 0.0033 NV1D2502 0.0002

Purification of Protoxin-II Variants by Solid Phase Extraction (SPE)

The secreted proteins were purified from the expression supernatants viaIMAC using 1 ml HisTrap HP columns (GE Healthcare Cat#17-5247-01). Thechromatography method was run using an AKTA Xpress and protein waseluted from the column using a step gradient of Imidazole. Peakfractions were pooled and digested overnight with HRV3C protease (1 μgprotease/150 μg fusion). The cleaved sample was loaded into a 50 kDamolecular weight cut off centrifugal filter unit (Millipore UFC805096)and cleaved peptide collected in the filtrate fraction.

Peptide pools were loaded onto a 96-well solid phase extraction block(Agilent Bond Elut Plexa A3969030) for further purification, desalting,and concentration. Blocks were used in conjunction with a vacuummanifold (Whatman). Peptide samples were loaded and washed in 0.05% TFAin water and eluted with a step gradient of acetonitrile with 0.05% TFAin water. Elution fractions were then lyophilized overnight andreconstituted in HEPES buffered saline, pH 7.4 (10 mM HEPES, 137 mMNaCl, 5.4 mM KCl, 5 mM glucose, 2 mM CaCl₂, 1 mM MgCl₂).

Peptides were reconstituted in supplemented HEPES buffered saline, pH7.4 (10 mM HEPES, 137 mM NaCl, 5.4 mM KCl, 5 mM glucose, 2 mM CaCl₂, 1mM MgCl₂) and absorbance was measured at 280 nm. Concentration valueswere then calculated using each sample's extinction coefficient. 2 μg ofeach peptide were loaded onto an Invitrogen NuPAGE® Novex® Bis-Tris Gel15 well gel and run in MES buffer non-reduced.

Samples were analyzed on Agilent 1100 HPLC using 4-80% acetonitrile in0.05% TFA linear gradient with a Phenomenex Luna C18(2) analyticalcolumn (Cat#00A-4041-B0). Concentrations of all peptides were normalizedand 10 μl of each were injected for a total of 1.3 μg per sample.Absorbance at 220 nm was monitored and chromatograms analyzed were usingChromeleon software.

Table 5 shows yields (mg) of Protoxin-II variants purified by SPE. Theaverage mg yield/L was 0.05353.

The benefits of the SPE purification process are ease and throughput ofpurification since samples are processed in parallel in a 96-well blockrather than serially on RP-HPLC, and improvement in yield. There was, onaverage, more than 3-fold higher yield (mg/L) for variants purified bySPE versus RP-HPLC.

TABLE 5 Protoxin-II Protoxin-II Variant yield Variant yield Peptide ID(mg) Peptide ID (mg) NV1D12 0.0054 NV1D2734 0.0602 NV1D2659 0.0234NV1D2772 0.2050 NV1D2664 0.0060 NV1D2775 0.2225 NV1D2666 0.0225 NV1D27380.0512 NV1D2708 0.0721 NV1D2740 0.0373 NV1D2725 0.0144 NV1D2733 0.1913NV1D2739 0.0053 NV1D788 0.0000 NV1D2765 0.0097 NV1D757 0.0021 NV1D27480.0995 NV1D791 0.0007 NV1D2771 0.0103 NV1D2310 0.0011 NV1D2770 0.0121NV1D2308 0.0014 NV1D2778 0.0644 NV1D778 0.0019 NV1D2782 0.0202 NV1D22940.0000 NV1D2756 0.0466 NV1D856 0.0047 NV1D2759 0.0218 NV1D2309 0.0023NV1D2712 0.0558 NV1D846 0.0020 NV1D12 0.0127 NV1D2896 0.0504 NV1D26730.0625 NV1D2913 0.0203 NV1D2662 0.0433 NV1D2910 0.0253 NV1D2669 0.2661NV1D2893 0.0569 NV1D2665 0.0389 NV1D2909 0.0195 NV1D2731 0.2547 NV1D29170.0339 NV1D2767 0.0238 NV1D2914 0.0201 NV1D2730 0.2566 NV1D2922 0.0554NV1D2766 0.0198 NV1D2902 0.0061 NV1D2667 0.0050 NV1D2889 0.0022 NV1D27690.0142 NV1D2887 0.0025 NV1D2719 0.0675 NV1D2878 0.0272 NV1D2776 0.0633NV1D2877 0.0129 NV1D2663 0.0344 NV1D2851 0.0029 NV1D2709 0.1841 NV1D28500.0026 NV1D2720 0.0538 NV1D2820 0.0020 NV1D12 0.0095 NV1D2819 0.0015NV1D2773 0.1921 NV1D2814 0.0163 NV1D2810 0.0086 NV1D2918 0.0256 NV1D27320.0262 NV1D2921 0.0533 NV1D757 0.0026 NV1D2905 0.0126 NV1D791 0.0206NV1D2906 0.0189 NV1D2310 0.0085 NV1D2881 0.0207 NV1D2308 0.0179 NV1D28820.0223 NV1D778 0.0094 NV1D2869 0.0038 NV1D856 0.0247 NV1D2870 0.0187NV1D2309 0.0035 NV1D2867 0.0147 NV1D846 0.0043 NV1D2888 0.0045 NV1D28890.0107 NV1D2816 0.0133 NV1D2887 0.0061 NV1D2885 0.0025 NV1D2861 0.0469NV1D2974 0.0418 NV1D2729 0.1101 NV1D2972 0.1089 NV1D2890 0.0088 NV1D29710.0407 NV1D2899 0.0402 NV1D2970 0.0557 NV1D2804 0.0044 NV1D2969 0.0799

Example 3: Characterization of Protoxin-II Variants

Select Protoxin-II variants were characterized in membranedepolarization and whole cell patch clamp assays to assess their potencyand selectivity towards Nav1.7.

FLIPR® Tetra Membrane Depolarization Assay

The ability of the generated peptides to inhibit membrane depolarizationinduced by Nav1.7 agonist veratridine (3-Veratroylveracevine; Biomol,Catalog# NA125) was measured with a FRET (fluorescence resonance energytransfer) assay on FLIPR® Tetra using DISBAC2(3) (Invitrogen, K1018) asan electron acceptor and PTS18 (Trisodium8-octadecyloxypyrene-1,3,6-trisulfonate) (Sigma) as a donor by excitingthe donor at 390-420 nm and measuring FRET at 515-575 nm.

HEK293 cells stably expressing human Nav1.7 were cultured in DMEM/F-12media (1:1), supplemented with 10% fetal bovine serum, 1%penicillin/streptomycin, 400 μg/mL geneticin and 100 μM NEAAs (allreagents from Invitrogen). 50 μL of harvested cells were plated at25,000 cells/well into poly-lysine coated 384-well black clear bottomplates. The plates were incubated at room temperature (RT) for 15 minfollowed by an overnight incubation at 37° C. All incubations were donein the dark unless otherwise stated. The next day, the wells were washed4 times with assay buffer (137 mM NaCl, 4 mM KCl, 2 mM MgCl₂, 2 mMCaCl₂, 5 mM Glucose, 10 mM HEPES, pH 7.4), and resuspended in 25 μL ofassay buffer. 2× stock (6 μM) of the PTS18 dye was prepared bysuspending the dye in 10% pluronic F127 in DMSO at 1:1 (v/v ratio). 25μL of the 2×PTS18 stock was added into the wells and the cells werestained for 30 min at RT, after which the dye was washed off with theassay buffer. Peptides were suspended at 3× their final concentration inthe assay buffer containing 10 μM DISBAC2(3) and 400 μM VABSC-1 tosuppress background fluorescence (Sigma, cat#201987). 25 μL/well of thesuspended peptides were added into each well, and incubated for 60minutes at RT. Depolarization was induced by 25 μM final concentrationof veratridine (by adding 25 μL/well of 75 μM (3×) stock solution), andthe reduction in the mean intensity of FRET dye fluorescence wasmeasured 30-100 seconds after adding the agonist. A 1.3× dilution ofeach measured peptide occurred after adding veratridine by convention,the concentration at the beginning of the FLIPR® Tetra assay isreported.

Concentration-response curves of synthetic Protoxin-II (PeptideInternational) were constructed in each experimental series and wereused as controls. Fluorescence counts for each well were converted to %response by normalizing the signal to the difference between negativecontrol (response to agonist veratridine alone) and positive control(response to veratridine in the presence of 10 μM tetracaine) values.For measurements, “spatial uniformity correction” (all fluorescencetraces are normalized to the average initial starting intensity) and“subtract bias value” (subtract the initial starting intensity from eachtrace) were turned on in FLIPR® Tetra. Each data point represented theresponse in an individual well. All individual data points were used ina non-linear least-squares fitting procedure to find the best fit to aHill function using Origin (Microcal). IC₅₀ values were extracted fromthe resultant fitted curve. The mean responses of the positive (P) andnegative (N) controls were used to calculate the % response in a well asfollows: % response=100*(N−R)/(N−P).

Assay plates were accepted if the potency of control antagonists forthat day were within ±0.5 log units of their historical mean.

QPatch Assay

HEK293 cells stably expressing human Nav1.5 (SEQ ID NO: 105), Nav1.7(SEQ ID NO: 79) or Nav1.6 (SEQ ID NO: 407) were cultured in DMEM/F-12media (1:1), supplemented with 10% fetal bovine serum, 1%penicillin/streptomycin, 400 μg/mL Geneticin and 100 μM NEAAs (allreagents from Invitrogen). Cells were maintained at 37° C. and in 5% CO2and assayed upon reaching ˜50-90% confluency. CHO cells stablyexpressing human Nav1.6 in a tetracycline-inducible manner (SEQ ID NO:407) were cultured in HAMs F12, supplemented with 10% fetal bovineserum, 1% penicillin/streptomycin, 10 μg/mL Blasticidin and 400 μg/mLZeocin. Cells were maintained at 37° C. and in 5% CO2, and assayed uponreaching ˜50-90% confluency. Nav1.6 expression was induced with 1 μg/mlof tetracycline, 24-48 h prior to an experiment.

Before testing in QPatch HT (Sophion), cells were first dissociatedusing 0.05% trypsin (5 min at 37° C.), resuspended in CHO-S-SFM media(Life Technologies) and gently triturated to break up cell clumps. Celldensity was adjusted to 1-2×10⁶/mL with the same media and cells werethe transferred to a cell “hotel” in QPatch HT and used in experimentsfor several hours. For giga-ohm seal formation and whole-cell patchclamp recording, the extracellular solution contained 137 mM NaCl, 5.4mM KCl, 1 mM MgCl₂, 2 mM CaCl₂, 5 mM glucose, and 10 mM HEPES, pH=7.4and osmolarity=315 mOsm. The intracellular solution contained 135 mMCsF, 10 mM CsCl, 5 mM EGTA, 5 mM NaCl and 10 mM HEPES, pH=7.3 andosmolarity=290 mOsm. The voltage protocol used in the assay was asfollows. From a holding potential of −75 mV (Nav1.7), −60 mV (Nav1.6),or −105 mV (Nav1.5) cells were first hyperpolarized to −120 mV for 2 secand then depolarized to 0 mV for 5 ms before returning to the holdingpotential. This protocol was repeated once every 60 sec during liquidapplications (see below). Cells were otherwise held at the holdingpotential when the above voltage protocol was not executed. Uponestablishment of the whole-cell recording configuration, a total of fiveapplications of the extracellular solution (all containing 0.1% bovineserum albumin (BSA) with or without test compound, except for the lastapplication, which contained 1 μM TTX or 10 mM lidocaine as a positivecontrol) were made on to cells being recorded. The first liquidapplication contained only the control buffer (5 μl). The voltageprotocol was executed 10 times (for a total duration of 10 min) five secafter the application. The next three liquid applications (5 μl each)contained a test compound (same compound at the same concentration forall three applications) or control buffer (for control cells only). Fiveseconds after each of these applications, the voltage protocol was againexecuted 10 times (also once per min). The last application containedpositive (composed of three 10 μl sub-applications, each separated by 2sec), five seconds after which the same voltage protocol was executedtwice to obtain the baseline current. Currents were sampled at 25 kHzand filtered at 5 kHz with an 8-pole Bessle filter. The seriesresistance compensation level was set at 80%. For each cell, the peakcurrent amplitude at 0 mV for each current trace in the first fourliquid applications was first subtracted from that of the last trace inthe presence of positive control and then normalized to that of the lasttrace in the first (control buffer) application as % inhibition. Tocontrol for current rundown, this (% inhibition) value for each cell inthe presence of a test compound was further normalized to the average %inhibition value for control (typically 5-6) cells in the sameexperiment. The mean of the last two such values in the last compoundapplication (i.e., the corrected % inhibition value for eachconcentration of a test compound) were taken as the % inhibition valuefor each cell at the particular compound concentration tested. The %inhibition values for all cells tested at each compound concentrationwere averaged and used in concentration response calculations. Allexperiments were performed at room temperature (˜22° C.). Data areexpressed as mean±se. Wild type Protoxin-II was included in eachexperiment as a positive control. Data were accepted only if the potencyof Protoxin-II was within ±0.5 log units of its historical mean.

IC₅₀ values for Nav1.7 for select Protoxin-II variants obtained usingthe FLIPR® Tetra are shown in Table 6.

TABLE 6 Protoxin-II Protoxin-II hNav1.7 Variant variant Peptide TETRAProtein ID Peptide ID SEQ ID NO: IC₅₀ (nM) NV1D12_5 NV1D12 2 4.1 ± 3.6NV1G1045 NV1D791 11 4.8 ± 0.4 NV1D1332_1 NV1D1332 12 6.7 ± 0.5NV1D1336_1 NV1D1336 14 10.5 ± 1.2  NV1D1337_1 NV1D1337 15 10.3 ± 1.0 NV1G1049 NV1D2308 16 4.5 ± 0.4 NV1G953 NV1D2670 17 22.2 ± 3.3  NV1G951NV1D2674 18 4.0 ± 0.2 NV1G963 NV1D2671 20 31.5 ± 6.4  NV1G949 NV1D267521 4.3 ± 0.3 NV1G977 NV1D2665 22 4.9 ± 0.4 NV1G957 NV1D2668 23 17.5 ±2.6  NV1G965 NV1D2672 24 4.5 ± 0.3 NV1G973 NV1D2662 25 4.0 ± 0.4 NV1G975NV1D2669 26 18.4 ± 5.7  NV1G971 NV1D2673 27 4.3 ± 0.5 NV1G995 NV1D266328 4.2 ± 0.4 NV1G961 NV1D2676 29 26.5 ± 2.9  NV1G911 NV1D2666 30 66.5 ±36.7 NV1G1133 NV1D2816 31  667 ± 93.6 NV1G905 NV1D2735 32 60.0 ± 16.2NV1G979 NV1D2731 34 20.7 ± 7.2  NV1G1097 NV1D2810 35  339 ± 5750NV1G1099 NV1D2732 36  126 ± 26.9 NV1G1011 NV1D2740 37 3.6 ± 9.9 NV1G1105NV1D2729 39 8.0 ± 0.9 NV1G1013 NV1D2733 40 7.5 ± 2.9 NV1G1095 NV1D281441  754 ± 51.3 NV1G983 NV1D2730 43 25.5 ± 4.3  NV1G1003 NV1D2734 44 13.4± 0.8  NV1G1009 NV1D2738 45 2.6 ± 0.2 NV1G1129 NV1D2867 49 >1000NV1G1121 NV1D2881 50  488 ± 72.2 NV1G1123 NV1D2882 51  857 ± 65.7NV1G899 NV1D2774 52 50.5 ± 15.2 NV1G1103 NV1D2861 54 >1000 NV1G1127NV1D2870 55  784 ± 84.8 NV1G1007 NV1D2775 56 25.4 ± 2.0  NV1G1067NV1D2893 57 75.5 ± 10.5 NV1G1005 NV1D2772 59 15.6 ± 1.8  NV1G1061NV1D2896 60 80.3 ± 7.1  NV1G1085 NV1D2877 61  441 ± 73.3 NV1G1083NV1D2878 62  680 ± 40.7 NV1G1079 NV1D2889 64 12.1 ± 1.5  NV1G1001NV1D2773 65 18.8 ± 1.5  NV1G1107 NV1D2890 66 25.8 ± 4.2  NV1G1109NV1D2899 67 33.3 ± 6.7  NV1G1117 NV1D2905 68  713 ± 87.3 NV1G1119NV1D2906 69  940 ± 86.7 NV1G1115 NV1D2921 70  586 ± 71.7 NV1G1075NV1D2922 71  204 ± 45.7 NV1G1069 NV1D2909 72 97.1 ± 10.1 NV1G1065NV1D2910 73  441 ± 41.7 NV1G1063 NV1D2913 74 79.7 ± 9.3  NV1G1073NV1D2914 75 135 ± 7.8  NV1G1071 NV1D2917 76  197 ± 48.3 NV1G1113NV1D2918 77  983 ± 98.7 NV1G1153 NV1D3034 78 10.3 ± 2.1 

Select Protoxin-II variants were tested for selectivity against humanNav1.5 using QPatch. IC₅₀ values for both Nav1.7 and Nav1.5 for selectpeptides obtained using QPatch are shown in Table 7.

TABLE 7 Protoxin-II Protoxin-II hNav1.7 hNav1.5 Variant variant PeptideQPatch Protein ID Peptide ID SEQ ID NO: IC₅₀ (nM) IC₅₀ (nM) NV1D12_5NV1D12 2 2.2 ± 1.3 >1000 NV1G899 NV1D2774 52 18.7 ± 13.6 >3000 NV1G1007NV1D2775 56 4.0 ± 8.9 >3000 NV1G1005 NV1D2772 59 6.2 ± 3.2 >3000NV1G1001 NV1D2773 65 4.3 ± 3.3 >3000 NV1G1153 NV1D3034 78 4.3 ± 4.3>1000

Example 4. Generation and Characterization of Combinatorial Protoxin-IIVariants

Combinatorial libraries were designed to test for additive effects ofselect single position hits in an attempt to generate Nav1.7 antagonistswith further improved potency and selectivity profile compared to thenative peptide using several approaches.

A limited amino acid scan was conducted at all non-cysteine Protoxin-IIpositions using A, D, Q, R, K and S for diversification. In theseexperiments, Protoxin-II was expressed and tested as monovalent Fcfusion protein as described in Example 1. From this scan, substitutionsY1Q, W7Q, S11A, were identified that improved potency and/or selectivityof the resulting variants.

A full amino acid scan (excluding cys and trp) at positions M6 and M19was also conducted. M19F substitution was identified from this scan thatimproved potency and/or selectivity of the resulting variants.

Protoxin-II/Huwentoxin-IV single position chimeras were designedbidirectionally. The purpose of this library was to obtain Protoxin-IIvariants that retained potency and selectivity profile of the wild typeProtoxin-II and would achieve beneficial refolding properties associatedwith Huwentoxin-IV. Substitutions R22T and E12N were identified fromthis scan.

Peptide NV1G1153 was further engineered by diversifying position Y1 by alimited amino acid scan using R, K, T, A, D, E, Q and 5, and by chargecluster engineering, where all sets of charged residues in thethree-dimensional structure of the peptide (D10/E12, K4/E17,D10/E12/R13) were mutated.

N- and C-terminal extensions were introduced to select peptides,including NV1G1153 with the purpose of improving peptide distribution tothe site of action and of improving half-life of the peptides withoutsignificantly increasing the molecular weight of the resulting peptide.The N- and C-terminal extensions that were used are shown in Table 8 and9, respectively, and are described in Oi et. al., Neuroscience Letters434, 266-272, 2008; Whitney et. al., Nature Biotechnology 2011 29:4,352-356; Sockolosky et. al., (2012) 109:40, 16095-16100. Cellpenetrating peptides HIV Tat and polyarginine were also used. Variouslinkers were used to couple the Protoxin-II variant to the N- and/orC-terminal extensions. The linkers used are shown in Table 10.

Protoxin-II variants from each campaign were tested for their potencyand selectivity for Nav1.7 using methods described in Example 3. Theamino acid sequences of the variants that inhibited Nav1.7 with an IC₅₀value of 200 nM or less are shown in Table 3. Table 11 shows the aminoacid substitutions in select variant when compared to the wild typeProtoxin-II, and the IC₅₀ values for Nav1.7 inhibition in the FLIPRTetra assay.

TABLE 8 N-terminal extension Amino acid sequence SEQ ID NO: GPAAAAA 372GPAPAPA 373 GGGGG 374 GPCCNCSSKWCRDHSRCC 375 GPSPGARAF 376 GPDGPWRKM 377GPFGQKASS 378 GPCRTIGPSVC 379 GPSHSNTQTLAKAPEHTG 380 GPQRFVTGHFGGLYPANG381 GPGWCGDPGATCGKLRLYCCSGFCDSYTKTCKDKSSA 382 APAPAPAPAP 383GPYGRKKRRQRRR 384 GPRRRRRRRRRRR 385

TABLE 9 C-terminal extensions Amino acid sequence SEQ ID NO: CRTIGPSVC386 YGRKKRRQRRR 387 GGGGG 374 DGPWRKM 388 CCNCSSKWCRDHSRCC 389RRRRRRRRRRR 390 SHSNTQTLAKAPEHTG 391 APAPA 392 AAAAA 393 FGQKASS 394QRFVTGHFGGLYPANG 395 SPGARAF 396 GPGWCGDPGATCGKLRLYCCSGFCDAYTKTCKDKSSA397

TABLE 10 Linkers Amino acid sequence SEQ ID NO: GSAPAPAPAPAPGS 398GSAPAPAPAPAPAPAPAPAPAPGS 399 GGGGSAPAPAPAPAPAPAPAPAPAPAPAPAPAPA 400PGGGGS APAPA 392 GSGGGGSAPAPAPAPAPAPAPAPAPAPGGGGSGS 401 APAPAPAPAP 383APAPAPAPAPAPAPAPAPAP 402

TABLE 11 Protoxin-II Protein Nav1.7 variant SEQ ID IC₅₀ Protein namepeptide name NO: Substitutions (nM) SE NV1G1728 NV1D3541 281 Y1A, W7Q,S11R, E12N, M19F, 9.4 1.2 R22T, K26R NV1G1870 NV1D3583 321 Y1A, W7Q,S11A, E12R, M19F, 13.1 1.57 V20S NV1G1752 NV1D3532 272 Y1A, W7Q, S11A,E12K, M19F, 17.3 2 R22T, K26R NV1G1749 NV1D3587 326 Y1A, W7Q, S11A,E12N, M19F, 18.3 2.6 V20S NV1G1725 NV1D3572 310 Y1A, W7Q, S11A, E12R,M19F, 19.8 2.2 R22T NV1G1745 NV1D3537 277 Y1A, W7Q, S11A, E12K, M19F,21.4 4.1 V20S, R22T, K26R NV1G1720 NV1D3565 304 Y1A, W7Q, S11A, E12R,M19F, 23 2.8 V20S, R22T NV1G1761 NV1D3550 290 Y1A, W7Q, S11R, M19F,R22T, 25.8 2.7 K26R NV1G1746 NV1D3576 314 Y1A, W7Q, S11A, E12N, M19F,26.7 5.2 R22T NV1G979 NV1D2731 34 Y1A, W7Q, S11A 20.7 7.2 NV1G953NV1D2670 17 Y1A, W7Q 22.2 3.3 NV1G1519 NV1D3006 133 Y1Q, W7Q, S11A,E12R, M19F 4.03 1.05 NV1G1007- NV1D2775- 111 Y1Q, W7Q, S11A, M19F 5.060.473 NH2 NH2 NV1G1517 NV1D3004 131 Y1Q, W7Q, S11R, M19F 6.23 1.56 (-GP)N-Ac- (-GP) N-Ac- 114 Y1Q, W7Q, S11A, M19F, V20S, 6.43 1.06 NV1G1137-NV1D2974- R22T NH2 NH2 NV1G1776 NV1D3339 172 Y1Q, Q3R, W7Q, S11R, M19F,6.57 0.675 R22T, K26R NV1G1153- NV1D3034- 119 Y1Q, W7Q, S11R, M19F,R22T, 7.1 0.9 NH-methyl NH-methyl K26R (-GP) N-Ac- (-GP) N-Ac- 121 Y1Q,W7Q, S11R, M19F, R22T, 7.63 1.04 NV1G1153- NV1D3034- K26R NH2 NH2NV1G1523 NV1D3012 135 Y1Q, W7Q, S11R, E12N, M19F 7.74 0.904 NV1G1515NV1D3005 132 Y1Q, W7Q, S11A, E12N, M19F 7.83 1.38 NV1G1187 NV1D3015 138Y1Q, W7Q, S11R, M19F, K26R 8.86 2.28 NV1G1521 NV1D3018 141 Y1Q, W7Q,S11A, E12N, M19F, 9.79 2.91 K26R NV1G1267 NV1D3044 150 Y1Q, W7Q, S11R,E12N, M19F, 9.8 0.849 R22T, K26R NV1G1153 NV1D3034 78 Y1Q, W7Q, S11R,M19F, R22T, 10.3 2.14 K26R NV1G1836 NV1D3359 190 Y1Q, W7Q, T8S, S11R,M19F, 10.5 0.739 R22T, K26R NV1G1593 NV1D3050 153 Y1Q, W7Q, S11R, E12K,M19F 10.8 1.3 NV1G1215 NV1D3048 152 Y1Q, W7Q, S11A, E12K, M19F 11.1 1.05NV1G1868 NV1D3353 185 Y1Q, W7Q, T8R, S11R, M19F, 11.2 1.25 R22T, K26RNV1G1525 NV1D3013 136 Y1Q, W7Q, S11R, E12R, M19F 11.3 1.83 NV1G1775NV1D3340 173 Y1Q, Q3K, W7Q, S11R, M19F, 11.5 0.798 R22T, K26R NV1G1833NV1D3381 210 Y1Q, W7Q, S11RK14Q, M19F, 12.2 1.56 R22T, K26R NV1G1153-NV1D3034- 117 Y1Q, W7Q, S11R, M19F, R22T, 12.2 1 NH2 NH2 K26R NV1G1777NV1D3342 175 Y1Q, Q3A, W7Q, S11R, M19F, 12.8 2.67 R22T, K26R NV1G1259NV1D3058 158 Y1Q, W7Q, S11A, E12K, M19F, 12.9 1.29 R22T, K26R NV1G1511NV1D3032 146 Y1Q, W7Q, S11R, E12N, M19F, 13 203 K26R NV1G1527 NV1D3031145 Y1Q, W7Q, S11R, E12R, M19F, 13 1.36 R22T NV1G1265 NV1D3062 159 Y1Q,W7Q, S11R, E12K, M19F, 13.2 1.43 R22T, K26R NV1G1781 NV1D3388 217 Y1Q,W7Q, S11RE17Q, M19F, 13.5 1.14 R22T, K26R NV1G1824 NV1D3354 186 Y1Q,W7Q, T8K, S11R, M19F, 13.9 1.12 R22T, K26R NV1G1772 NV1D3352 184 Y1Q,K4S, W7Q, S11R, M19F, 14.2 2.01 R22T, K26R NV1G1509 NV1D3033 147 Y1Q,W7Q, S11R, E12R, M19F, 14.5 2.18 K26R NV1G1779 NV1D3351 183 Y1Q, K4Q,W7Q, S11R, M19F, 15.3 2.39 R22T, K26R NV1G1687 NV1D3526 266 Y1Q, W7Q,S11R, M19F, R22T, 15.4 K26R NV1G1269 NV1D3045 151 Y1Q, W7Q, S11R, E12R,M19F, 15.6 1.39 R22T, K26R NV1G1623 NV1D3056 156 Y1Q, W7Q, S11R, E12K,M19F, 16.2 2.99 R22T NV1G1859 NV1D3376 205 Y1Q, W7Q, S11R, K14R, M19F,16.3 2.53 R22T, K26R NV1G1153- NV1D3034- 118 Y1Q, W7Q, S11R, M19F, R22T,16.6 1.4 NH-butyl NH-butyl K26R NV1G1211 NV1D3036 149 Y1Q, W7Q, S11A,E12R, M19F, 17.2 1.55 R22T, K26R NV1G1885 NV1D3254 165 Y1Q, W7Q, S11A,M19F 17.5 2.45 NV1G1730 NV1D3542 282 Y1Q, W7Q, S11R, E12N, M19F, 17.72.5 V20S, R22T, K26R NV1G1263 NV1D3051 154 Y1Q, W7Q, S11A, E12K, M19F,17.9 1.78 R22T NV1G1818 NV1D3368 122 Y1Q, W7Q, S11R, E12T, M19F, 17.91.89 R22T, K26R NV1G1153 NV1D3034 116 Y1Q, W7Q, S11R, M19F, R22T, 18 2.5(synthetic) K26R NV1G1823 NV1D3367 197 Y1Q, W7Q, S11R, E12Q, M19F, 18.62.17 R22T, K26R NV1G1820 NV1D3362 193 Y1Q, W7Q, D10T, S11R, M19F, 20.12.32 R22T, K26R NV1G1811 NV1D3369 199 Y1Q, W7Q, S11R, R13K, M19F, 20.42.44 R22T, K26R NV1G1810 NV1D3358 189 Y1Q, W7Q, T8Q, S11R, M19F, 20.52.11 R22T, K26R NV1G1818- NV1D3368- 123 Y1Q, W7Q, S11R, E12T, M19F, 20.52.8 NH2 NH2 R22T, K26R NV1G1137 NV1D2974 129 Y1Q, W7Q, S11A, M19F, V20S,21.6 1.34 (synthetic) R22T NV1G1221 NV1D3017 140 Y1Q, W7Q, S11A, E12R,M19F, 21.9 2.48 R22T NV1G1722 NV1D3533 273 Y1Q, W7Q, S11A, E12K, M19F,22.4 3.5 V20S, R22T, K26R NV1G1767 NV1D3345 177 Y1Q, Q3S, W7Q, S11R,M19F, 22.4 2.52 R22T, K26R NV1G1769 NV1D3346 178 Y1Q, K4R, W7Q, S11R,M19F, 23.2 3.39 R22T, K26R NV1G1780 NV1D3387 216 Y1Q, W7Q, S11R, E17D,M19F, 23.7 2.85 R22T, K26R NV1G1886 NV1D3249 162 Y1Q, W7Q, S11A, M19F24.1 11.5 NV1G1812 NV1D3382 211 Y1Q, W7Q, S11R, K14S, M19F, 24.3 2.14R22T, K26R NV1G1857 NV1D3366 196 Y1Q, W7Q, D10S, S11R, M19F, 24.6 3.8R22T, K26R NV1G1821 NV1D3378 207 Y1Q, W7Q, S11R, K14A, M19F, 24.8 2.66R22T, K26R NV1G1993 NV1D3792 335 Y1Q, W7Q, S11R, M19F, R22T, 25.3 2.8K26R NV1G1007 NV1D2775 56 Y1Q, W7Q, S11A, M19F 25.4 2 NV1G1787 NV1D3396224 Y1Q, W7Q, S11R, G18Q, M19F, 26.4 3.17 R22T, K26R NV1G1257 NV1D3016139 Y1Q, W7Q, S11A, E12N, M19F, 26.6 3.1 R22T NV1G1153 NV1D3034 116 Y1Q,W7Q, S11R, M19F, R22T, 27.3 2.02 (synthetic) K26R NV1G1803 NV1D3403 230Y1Q, W7Q, S11R, M19F, R22T, 28.3 1.97 K26R, K27A (-GP) N-Ac- N-Ac- 115Y1Q, W7Q, S11A, M19F, V20S, 28.6 2.23 NV1G1137 NV1D2974 R22T NV1G1531NV1D3019 142 Y1Q, W7Q, S11A, E12R, M19F, 28.7 4.78 K26R NV1G1513NV1D3007 134 Y1Q, W7Q, S11A, M19F, K26R 29.6 9.17 NV1G1991 NV1D3789 333Y1Q, W7Q, S11R, M19F, R22T, 29.9 5.19 K26R NV1G1013 NV1D2733 40 Y1R,W7Q, M19F 7.54 2.9 NV1G1740 NV1D3580 318 Y1R, W7Q, S11A, E12R, M19F, 8.41.5 V20S NV1G1757 NV1D3538 278 Y1R, W7Q, S11R, E12N, M19F, 11.6 1.4R22T, K26R NV1G1741 NV1D3569 307 Y1R, W7Q, S11A, E12R, M19F, 11.9 0.8R22T NV1G1715 NV1D3584 322 Y1R, W7Q, S11A, E12N, M19F, 13.9 1.4 V20SNV1G1754 NV1D3529 269 Y1R, W7Q, S11A, E12K, M19F, 14.6 1.7 R22T, K26RNV1G1005 NV1D2772 59 Y1R, W7Q, S11A, M19F 15.6 1.8 NV1G1733 NV1D3577 315Y1R, W7Q, S11A, M19F, V20S 18.8 2.2 NV1G1744 NV1D3534 274 Y1R, W7Q,S11A, E12K, M19F, 20.6 2.2 V20S, R22T, K26R NV1G1724 NV1D3562 301 Y1R,W7Q, S11A, E12R, M19F, 23.6 2.7 V20S, R22T NV1G1735 NV1D3566 305 Y1R,W7Q, S11A, M19F, R22T 23.7 2.5 NV1G1760 NV1D3543 283 Y1R, W7Q, S11R,E12N, M19F, 23.8 1.9 V20S, R22T, K26R NV1G1759 NV1D3547 287 Y1R, W7Q,S11R, M19F, R22T, 26.5 2.1 K26R NV1G1751 NV1D3558 297 Y1R, W7Q, S11A,E12N, M19F, 26.7 3.4 V20S, R22T NV1G1726 NV1D3551 291 Y1R, W7Q, S11R,M19F, V20S, 29.3 3.8 R22T, K26R NV1G1105 NV1D2729 39 Y1R, W7Q, S11A 88.85E−01 NV1G957 NV1D2668 23 Y1R, W7Q 17.5 2.6 (-GP) (-GP) 109 Y1S, W7Q,S11A, M19F 9.47 1.28 NV1G1001 NV1D2773 (-GP) (-GP) 110 Y1S, W7Q, S11A,M19F 11.5 0.61 NV1G1001- NV1D2773- NH-methyl NH-methyl NV1G1003 NV1D273444 Y1S, W7Q, M19F 13.4 0.8 NV1G1864 NV1D3581 319 Y1S, W7Q, S11A, E12R,M19F, 14.6 1.7 V20S NV1G1748 NV1D3530 270 Y1S, W7Q, S11A, E12K, M19F,15.6 2.2 R22T, K26R NV1G1758 NV1D3548 288 Y1S, W7Q, S11R, M19F, R22T,17.6 1.9 K26R NV1G1727 NV1D3544 284 Y1S, W7Q, S11R, E12N, M19F, 17.8 2.2V20S, R22T, K26R NV1G1719 NV1D3570 308 Y1S, W7Q, S11A, E12R, M19F, 18.11.5 R22T NV1G1742 NV1D3535 275 Y1S, W7Q, S11A, E12K, M19F, 18.7 2.8V20S, R22T, K26R NV1G1001 NV1D2773 65 Y1S, W7Q, S11A, M19F 18.8 1.5NV1G1753 NV1D3585 323 Y1S, W7Q, S11A, E12N, M19F, 19.4 2.1 V20S NV1G1762NV1D3539 279 Y1S, W7Q, S11R, E12N, M19F, 19.4 1.8 R22T, K26R NV1G1755NV1D3574 312 Y1S, W7Q, S11A, E12N, M19F, 22.3 2.7 R22T NV1G1717 NV1D3563302 Y1S, W7Q, S11A, E12R, M19F, 22.4 2.4 V20S, R22T NV1G1866 NV1D3559298 Y1S, W7Q, S11A, E12N, M19F, 26.5 5.02 V20S, R22T NV1G1721 NV1D3552292 Y1S, W7Q, S11R, M19F, V20S, 28.1 3.7 R22T, K26R NV1G975 NV1D2669 26Y1S, W7Q 18.4 5.7 NV1G983 NV1D2730 43 Y1S, W7Q, S11A 25.5 4.3 NV1G1750-NV1D3586- 325 W7Q, S11A, E12N, M19F, V20S 4.23 0.33 NH2 NH2 NV1G1747NV1D3531 271 W7Q, S11A, E12K, M19F, R22T, 13 2.1 K26R NV1G1763 NV1D3540280 W7Q, S11R, E12N, M19F, R22T, 16 1.5 K26R NV1G1739 NV1D3582 320 W7Q,S11A, E12R, M19F, V20S 17.8 2.2 NV1G1750 NV1D3586 324 W7Q, S11A, E12N,M19F, V20S 20.5 2.2 NV1G1718 NV1D3571 309 W7Q, S11A, E12R, M19F, R22T 212.3 NV1G1865 NV1D3560 299 W7Q, S11A, E12N, M19F, V20S, 27.2 3.42 R22TNV1G1766 NV1D3549 289 W7Q, S11R, M19F, R22T, K26R 27.5 3.2 NV1G961NV1D2676 29 W7Q, S11A 26.5 2.9 NV1G951 NV1D2674 18 Y1A, S11A 4.03 0.2NV1G1011 NV1D2740 37 Y1Q, S11A, M19F 3.62 9.9 NV1G977 NV1D2665 22 Y1Q,M19F 4.9 0.4 NV1G949 NV1D2675 21 Y1Q, S11A 4.33 0.3 NV1G973 NV1D2662 25Y1R, M19F 4.03 0.4 NV1G965 NV1D2672 24 Y1R, S11A 4.5 0.3 NV1G1009NV1D2738 45 Y1S, S11A, M19F 2.57 0.2 NV1G995 NV1D2663 28 Y1S, M19F 4.190.4 NV1G1107- NV1D2890- 112 Y1S, M6F, S11A, M19L 9.12 1.17 NH2 NH2NV1G971 NV1D2673 27 Y1S, S11A 4.31 0.5 NV1G1782 NV1D3383 212 Y1Q, W7Q,S11R, E17R, M19F, 30.3 4.06 R22T, K26R, NV1G1990 NV1D3788 332 Y1Q, W7Q,S11R, M19F, R22T, 30.3 4.78 K26R, (-GP) N-Ac- (-GP) N-Ac- 120 Y1Q, W7Q,S11R, M19F, R22T, 30.4 2.96 NV1G1153- NV1D3034 K26R NV1G1786 NV1D3389218 Y1Q, W7Q, S11R, E17S, M19F, 30.8 4.48 R22T, K26R, NV1G1147 NV1D2969124 Y1S, W7Q, S11A, M19F, V20S 31 6.15 NV1G1764 NV1D3554 294 Y1A, W7Q,S11R, M19F, V20S, 31.4 3.3 R22T, K26R NV1G963 NV1D2671 20 Y1Q, W7Q 31.56.4 NV1G1835 NV1D3379 208 Y1Q, K4D, W7Q, S11R, M19F, 31.6 2.88 R22T,K26R NV1G1231 NV1D3035 148 Y1Q, W7Q, S11A, E12N, M19F, 32 4.9 R22T, K26RNV1G1743 NV1D3564 303 W7Q, S11A, E12R, M19F, V20S, 32.3 3.1 R22TNV1G1960 NV1D3803 345 Y1Q, W7Q, S11R, M19F, R22T, 32.3 5.33 K26RNV1G1924 NV1D3470 250 Y1Q, W7Q, S11R, M19L, R22T, 32.5 403 K26R NV1G1756NV1D3575 313 W7Q, S11A, E12N, M19F, R22T 33.2 3.9 NV1G1109 NV1D2899 67Y1S, W7Q, S11A, M19L 33.3 6.7 NV1G1818 NV1D3368 122 Y1Q, W7Q, S11R,E12T, M19F, 33.5 10.7 R22T, K26R NV1G1784 NV1D3386 215 Y1Q, W7Q, S11R,E17A, M19F, 33.6 4.71 R22T, K26R NV1G1141 NV1D2972 127 Y1Q, W7Q, S11A,M19F, V20S 34.1 6.2 NV1G1774 NV1D3347 179 Y1Q, K4T, W7Q, S11R, M19F,34.2 5.99 R22T, K26R NV1G1881 NV1D3257 167 Y1Q, W7Q, S11A, M19F 34.22.81 NV1G1915 NV1D3467 249 Y1Q, W7Q, S11R, E17G, M19F, 34.5 4 R22T, K26RNV1G1984 NV1D3806 348 Y1Q, W7Q, S11R, M19F, R22T, 35.1 4.56 K26RNV1G1716 NV1D3561 300 Y1A, W7Q, S11A, E12N, M19F, 35.6 5 V20S, R22T,NV1G1255 NV1D3014 137 Y1Q, W7Q, S11R, M19F, R22T 36.1 5.37 NV1G1959NV1D3818 357 Y1Q, W7Q, S11R, M19F, R22T, 36.3 204 K26R NV1G1825 NV1D3377206 Y1Q, W7Q, S11R, K14T, M19F, 36.4 4.83 R22T, K26R NV1G1723 NV1D3536276 W7Q, S11A, E12K, M19F, V20S, 37 5.4 R22T, K26R NV1G1732 NV1D3555 295Y1R, W7Q, S11A, M19F, V20S, 37.4 4.3 R22T, NV1G1983 NV1D3809 350 Y1Q,W7Q, S11R, M19F, R22T, 38.9 4.81 K26R NV1G1982 NV1D3805 347 Y1Q, W7Q,S11R, M19F, R22T, 41.2 5.44 K26R NV1G1785 NV1D3385 214 Y1Q, W7Q, S11R,E17T, M19F, 41.5 6.5 R22T, K26R NV1G1583 NV1D3030 144 Y1Q, W7Q, S11R,E12N, M19F, 41.9 5.15 R22T NV1G1729 NV1D3545 285 W7Q, S11R, E12N, M19F,V20S, 42.8 4.6 R22T, K26R NV1G1007 NV1D2775 56 Y1Q, W7Q, S11A, M19F 42.96.7 NV1G1734 NV1D3568 306 Q1A, W7Q, S11A, M19F, R22T 44 8.3 NV1G1683NV1D3523 263 Y1Q, W7Q, S11R, M19F, R22T, 44.7 K26R NV1G1834 NV1D3360 191Y1Q, W7Q, D10R, S11R, M19F, 45.2 3.79 R22T, K26R NV1G1795 NV1D3401 229Y1Q, W7Q, S11R, M19F, R22T, 45.5 6.58 K26R, K27R NV1G1689 NV1D3514 255Y1Q, W7Q, S11R, M19F, R22T, 46.4 K26R NV1G2043 NV1D3835 370 Y1Q, W7Q,S11R, M19F, R22T, 46.4 4.09 K26R NV1G1783 NV1D3384 213 Y1Q, W7Q, S11R,E17K, M19F, 46.8 7.39 R22T, K26R NV1G1239 NV1D3020 143 Y1Q, W7Q, S11A,M19F, R22T, 47.2 7.84 K26R NV1G1788 NV1D3399 227 Y1Q, W7Q, S11R, M19F,V20T, 47.3 6.36 R22T, K26R NV1G899 NV1D2774 52 Y1A, W7Q, S11A, M19F 50.515.2 NV1G2057 NV1D3799 341 Y1Q, W7Q, S11R, M19F, R22T, 50.6 6.33 K26RNV1G1738 NV1D3578 316 W7Q, S11A, M19F, V20S, 50.7 5.7 NV1G1713 NV1D3525265 Y1Q, W7Q, S11R, M19F, R22T, 52.3 K26R NV1G1765 NV1D3553 293 W7Q,S11R, M19F, V20S, R22T, 52.4 10 K26R NV1G1916 NV1D3465 247 Y1Q, W5F,W7Q, S11R, M19F, 52.8 10.3 R22T, K26R NV1G1977 NV1D3804 346 Y1Q, W7Q,S11R, M19F, R22T, 53.6 6.27 K26R NV1G1879 NV1D3259 168 Y1Q, W7Q, S11A,M19F 54.9 7.62 NV1G1884 NV1D3256 166 Y1Q, W7Q, S11A, M19F 55.7 10.5NV1G1986 NV1D3819 358 Y1Q, W7Q, S11R, M19F, R22T, 56 6.57 K26R NV1G1633NV1D3251 163 Y1Q, W7Q, S11A, M19F 56.1 13.9 NV1G1880 NV1D3261 170 Y1Q,W7Q, S11A, M19F 57 6.25 NV1G1985 NV1D3808 349 Y1Q, W7Q, S11R, M19F,R22T, 57 6.74 K26R NV1G1849 NV1D3400 228 Y1Q, W7Q, S11R, M19F, V20Q,57.3 9.52 R22T, K26R NV1G1883 NV1D3260 169 Y1Q, W7Q, S11A, M19F 57.66.91 NV1G1145 NV1D2970 125 Y1S, W7Q, S11A, M19F, R22T 58 18.8 NV1G1697NV1D3517 258 Y1Q, W7Q, S11R, M19F, R22T, 58.5 K26R NV1G1737 NV1D3579 317Y1A, W7Q, S11A, M19F, V20S 59.9 9.6 NV1G1978 NV1D3833 368 Y1Q, W7Q,S11R, M19F, R22T, 60.3 9.57 K26R NV1G1954 NV1D3800 342 Y1Q, W7Q, S11R,M19F, R22T, 60.9 6.43 K26R NV1G1989 NV1D3791 334 Y1Q, W7Q, S11R, M19F,R22T, 61.8 8.66 K26R NV1G1815 NV1D3380 209 Y1Q, K4E, W7Q, S11R, M19F, 6410.5 R22T, K26R NV1G1967 NV1D3793 336 Y1Q, W7Q, S11R, M19F, R22T, 64.68.19 K26R NV1G1869 NV1D3573 311 Y1R, W7Q, S11A, E12N, M19F, 64.7 50.7R22T NV1G1872 NV1D3777 330 Y1Q, W7Q, S11R, M19F, R22T, 64.9 15.3 K26RNV1G1979 NV1D3834 369 Y1Q, W7Q, S11R, M19F, R22T, 65.5 7.59 K26RNV1G1827 NV1D3365 195 Y1Q, W7Q, D10Q, S11R, M19F, 66.1 10.1 R22T, K26RNV1G1768 NV1D3341 174 Y1Q, Q3T, W7Q, S11R, M19F, 66.2 9.32 R22T, K26RNV1G911 NV1D2666 30 W7Q, M19F 66.5 36.7 NV1G1856 NV1D3397 225 Y1Q, W7Q,S11R, G18S, M19F, 66.7 7.31 R22T, K26R NV1G1973 NV1D3810 351 Y1Q, W7Q,S11R, M19F, R22T, 66.9 7.04 K26R NV1G1855 NV1D3398 226 Y1Q, W7Q, S11R,M19F, V20S, 67.3 11 R22T, K26R NV1G1961 NV1D3802 344 Y1Q, W7Q, S11R,M19F, R22T, 68 8.23 K26R NV1G1846 NV1D3431 244 Y1Q, K4E, W7Q, S11R,E17K, 68.6 13.9 M19F, R22T, K26R NV1G1771 NV1D3348 180 Y1Q, K4A, W7Q,S11R, M19F, 70.6 15.9 R22T, K26R NV1G1691 NV1D3520 261 Y1Q, W7Q, S11R,M19F, R22T, 71.4 K26R NV1G1681 NV1D3511 252 Y1Q, W7Q, S11R, M19F, R22T,71.5 K26R NV1G1968 NV1D3822 359 Y1Q, W7Q, S11R, M19F, R22T, 74.2 11.1K26R NV1G1813 NV1D3424 238 Y1Q, W7Q, D10K, S11R, E12K, 75.2 12.2 M19F,R22T, K26R NV1G1067 NV1D2893 57 Y1Q, W7Q, S11A, M19L 75.5 10.5 NV1G1867NV1D3546 286 Y1A, W7Q, S11R, E12N, M19F, 76 17.6 V20S, R22T, K26RNV1G1143 NV1D2971 126 Y1S, W7Q, S11A, M19F, V20S, 77.5 22.1 R22TNV1G1806 NV1D3409 232 Y1Q, W7Q, S11R, M19F, R22T, 79.1 11.3 K26R, K28TNV1G1061 NV1D2896 60 Y1R, W7Q, S11A, M19L 80.3 7.13 NV1G1793 NV1D3419236 Y1Q, W7Q, S11R, M19F, R22T, 80.9 11.9 K26R, W30D NV1G1613 NV1D3057157 Y1Q, W7Q, S11R, E12K, M19F, 83.4 16.6 K26R NV1G1585 NV1D3052 155Y1Q, W7Q, S11A, E12K, M19F, 84.8 28.8 K26R NV1G1707 NV1D3524 264 Y1Q,W7Q, S11R, M19F, R22T, 84.9 K26R NV1G1773 NV1D3350 182 Y1Q, K4E, W7Q,S11R, M19F, 85.6 14.4 R22T, K26R NV1G1949 NV1D3828 364 Y1Q, W7Q, S11R,M19F, R22T, 87.5 11 K26R NV1G1976 NV1D3811 352 Y1Q, W7Q, S11R, M19F,R22T, 87.7 15.7 K26R NV1G1956 NV1D3801 343 Y1Q, W7Q, S11R, M19F, R22T,88.1 11.4 K26R NV1G1975 NV1D3832 367 Y1Q, W7Q, S11R, M19F, R22T, 88.412.3 K26R NV1G1839 NV1D3774 328 Y1Q, W7Q, S11R, M19F, R22T, 88.6 19.6K26R NV1G1971 NV1D3830 366 Y1Q, W7Q, S11R, M19F, R22T, 88.6 9.88 K26RNV1G1882 NV1D3262 171 Y1Q, W7Q, S11A, M19F 89.2 8.32 NV1G1950 NV1D3797339 Y1Q, W7Q, S11R, M19F, R22T, 91.1 13.5 K26R NV1G1828 NV1D3363 194Y1Q, W7Q, D10A, S11R, M19F, 93.1 15.3 R22T, K26R NV1G1139 NV1D2973 128Y1Q, W7Q, S11A, M19F, R22T 93.9 19.5 NV1G1842 NV1D3430 243 Y1Q, K4D,W7Q, S11R, E17K, 93.9 14.1 M19F, R22T, K26R NV1G1948 NV1D3798 340 Y1Q,W7Q, S11R, M19F, R22T, 94.5 17.8 K26R NV1G1807 NV1D3408 231 Y1Q, W7Q,S11R, M19F, R22T, 94.8 17.8 K26R, K28R NV1G1137 NV1D2974 129 Y1Q, W7Q,S11A, M19F, V20S, 95.7 16.2 R22T NV1G1843 NV1D3432 245 Y1Q, K4E, W7Q,S11R, E17R, 95.9 10.4 M19F, R22T, K26R NV1G1822 NV1D3423 237 Y1Q, W7Q,D10R, S11R, E12R, 99.5 9.45 M19F, R22T, K26R NV1G1862 NV1D3556 296 W7Q,S11A, M19F, V20S, R22T 100 18.5 NV1G1969 NV1D3795 337 Y1Q, W7Q, S11R,M19F, R22T, 100 14.5 K26R NV1G1980 NV1D3812 353 Y1Q, W7Q, S11R, M19F,R22T, 101 23.6 K26R NV1G1850 NV1D3414 235 Y1Q, W7Q, S11R, M19F, R22T,102 19.4 K26R, K28S NV1G1981 NV1D3815 356 Y1Q, W7Q, S11R, M19F, R22T,102 13.5 K26R NV1G1851 NV1D3390 219 Y1Q, W7Q, S11R, G18R, M19F, 108 15.5R22T, K26R NV1G1922 NV1D3466 248 Y1Q, W7Q, S11E, M19F, R22T, 108 922K26R NV1G1778 NV1D3349 181 Y1Q, K4D, W7Q, S11R, M19F, 109 16 R22T, K26RNV1G1972 NV1D3824 361 Y1Q, W7Q, S11R, M19F, R22T, 110 16.1 K26R NV1G1974NV1D3796 338 Y1Q, W7Q, S11R, M19F, R22T, 110 19.6 K26R NV1G1826 NV1D3357188 Y1Q, W7Q, T8E, S11R, M19F, 111 15.1 R22T, K26R NV1G1892 NV1D3439 246Y1Q, W7Q, S11R, M19F, R22T, 112 13.2 K26R, W30G NV1G1819 NV1D3375 204Y1Q, W7Q, S11R, R13S, M19F, 113 1270 R22T, K26R NV1G1805 NV1D3410 233Y1Q, W7Q, S11R, M19F, R22T, 114 21.5 K26R, K28A NV1G1831 NV1D3374 203Y1Q, W7Q, S11R, R13Q, M19F, 114 1600 R22T, K26R NV1G1693 NV1D3512 253Y1Q, W7Q, S11R, M19F, R22T, 115.6 K26R NV1G1854 NV1D3392 221 Y1Q, W7Q,S11R, G18T, M19F, 117 21.8 R22T, K26R NV1G1951 NV1D3829 365 Y1Q, W7Q,S11R, M19F, R22T, 122 13.3 K26R NV1G1860 NV1D3393 222 Y1Q, W7Q, S11R,G18A, M19F, 125 24.8 R22T, K26R NV1G1099 NV1D2732 36 Y1Q, W7Q, S11A 12626.9 NV1G1705 NV1D3513 254 Y1Q, W7Q, S11R, M19F, R22T, 131.2 K26RNV1G1848 NV1D3426 240 Y1Q, W7Q, D10K, S11R, E12K, 135 39.9 R13D, M19F,R22T, K26R NV1G1952 NV1D3813 354 Y1Q, W7Q, S11R, M19F, R22T, 139 30.1K26R NV1G1631 NV1D3252 164 Y1Q, W7Q, S11A, M19F 145 53 NV1G1817 NV1D3371201 Y1Q, W7Q, S11R, R13A, M19F, 151 33.7 R22T, K26R NV1G1789 NV1D3394223 Y1Q, W7Q, S11R, G18D, M19F, 155 41.4 R22T, K26R NV1G1852 NV1D3391220 Y1Q, W7Q, S11R, G18K, M19F, 157 23.1 R22T, K26R NV1G1709 NV1D3510251 Y1Q, W7Q, S11R, M19F, R22T, 159 K26R NV1G1840 NV1D3425 239 Y1Q, W7Q,D10R, S11R, E12R, 161 27.9 R13D, M19F, R22T, K26R NV1G1809 NV1D3413 234Y1Q, W7Q, S11R, M19F, R22T, 164 43.7 K26R, K28Q NV1G1863 NV1D3356 187Y1Q, W7Q, T8D, S11R, M19F, 167 32.2 R22T, K26R NV1G1699 NV1D3527 267Y1Q, W7Q, S11R, M19F, R22T, 169.1 K26R NV1G1844 NV1D3428 242 Y1Q, W7Q,D10K, S11R, E12K, 180 52.4 R13E, M19F, R22T, K26R NV1G1853 NV1D3370 200Y1Q, W7Q, S11R, R13T, M19F, 181 25.1 R22T, K26R NV1G1946 NV1D3825 362Y1Q, W7Q, S11R, M19F, R22T, 194 28.4 K26R

The wild-type Protoxin-II inhibits Nav1.7 with an IC₅₀ value of about 4nM in FLIPR assay as described in Example 3. Variants retainingsignificant Nav1.7 potency were characterized further. FIG. 1 shows thesequence genus of generated Protoxin-II variants that inhibit Nav1.7with an IC₅₀ value of 30 nM or less.

Select Protoxin-II variants were tested for their inhibition of Nav1.7and for their selectivity against human Nav1.6 using QPatch. IC₅₀ valuesfor both Nav1.7 and Nav1.6 for select peptides obtained using QPatch areshown in FIG. 2. These peptides inhibited Nav1.7 with an IC₅₀ of 30 nMor less, and were at least 30-fold selective over Nav1.7 when comparedto Nav1.6.

The amino acid sequences of the peptides shown in FIG. 2 are shown inFIG. 3. All these peptides had W7Q and M19F substitutions when comparedto the wild type Protoxin-II.

The protoxin-II variants were expressed and purified as described inExample 1, or synthesized by standard solid phase synthesis methods. Theyields of the recombinant or synthetic peptides were compared to theyields of the wild-type protoxin. Table 12 shows that the yields of theselect protoxin-II variants were significantly higher than that ofprotoxin-II, indicating improved folding properties of the variants. Thescale of the solid-phase synthesis was 0.5 mmol.

TABLE 12 Solid phase synthesis Yield Yield Recombinant Total from Fromexpression Peptide yield Crude Linear % active isomer Protoxin-II 52 mg2.7% 7.3% 54.0% NV1D2775 84 mg 4.5% 18.7% 89.1% NV1D3034 149 mg  8.0%21.0% 85.2% NV1D3368 83 mg 4.0% 24.0% 93.8%

Example 5. Protoxin-II Variants are Efficient in In Vivo Models of PainMaterials and Methods Animals

Male C57Bl/6 mice (24-26 g), ordered from Charles River and housedindividually, were used for this study.

Behavioral Tests

Von Frey Test:

Mechanical (tactile) threshold was assessed by Von Frey Hairs followingthe Up-Down method (Dixon, 1980, Chaplan et al., 1994). 7 graded stimuli(von Frey filaments: 0.03, 0.07, 0.16, 0.4, 0.6, 1, 2 g; Stoelting, WoodDale, Ill.) were used. Von Frey hairs were presented perpendicularlyagainst the center plantar area (between toris) on a hindpaw. Sufficientforce was applied to bend the filament slightly and held for 3 seconds.Per the Chaplan paper, a positive response can be either 1) a sharpwithdrawal or 2) immediate flinching upon removal of the filament. SeeChaplan et al for more details. Mice were acclimated to the wire mesh inthe testing chamber for 30-60 minutes prior to testing.

Hargreaves Test:

A modified Hargreaves box was used to measure thermal paw withdrawallatency (PWL) (Hargreaves et al., 1988, Pain, 32:77-88; Dirig et al.,1997, J Neurosci. Methods, 76:183-191). This box consists of a chamberwith a raised glass floor maintained at a constant temperature (27° C.).The thermal nociceptive stimulus originates from a projection bulb lightbeam below the glass surface. The light beam is aimed at the areabetween toris (center plantar). The “start” button will turn on thelight and start the timer. Movements (such as a sudden withdrawal) ofthe stimulated paw will trigger the switch to turn off the light andstop the timer. The latency in seconds is displayed. If no movementoccurs, the bulb will be turned off after 20 seconds (cutoff) to preventtissue injury. The animals were allowed to habituate on the glasssurface for 30-60 minutes before PWL measurement. Constant amperage wasused throughout the study, which resulted in Pre-test paw withdrawallatencies between 8-12 seconds when averaged over 3 to 6 read-outs takenat least 5 minutes apart.

MPE % Calculation:

Percent maximum possible effect (MPE %)=(T₁−T₀)/(Tc−T₀)×100%. T₀:threshold on day0 (post-CFA, pre-pump); T₁: threshold on day1 post pumpimplantation; Tc: cut-off of the test (20 s for the Hargreaves test and2 g for the Von Frey test)

Hotplate Test:

Animals were placed on a 10″×10″ metal plate surrounded by 4 Plexiglaswalls (15 inches high). The plate was maintained at a temperature ofeither 50 or 55° C. The response latency (time when the animal firstflinches or licks its hind paw, jumps, or vocalizes) was measured andthe animal removed from the plate. Animals showing no response wereremoved from the plate after 40 s (50° C.) or 20 s (55° C.) to preventany possible tissue damage. This trial was repeated 2-5 times every15-60 minutes in a day.

Inflammatory Pain Models

CFA Model:

Animals were anesthetized with isoflurane (4% induction and 2%maintenance) and 20 μL of 100% Complete Freund's Adjuvant (CFA;Sigma-Aldrich; Saint Louis, Mo.) was injected into the center plantararea on one hind paw using a 27 gauge needle attached to a 50 μLHamilton syringe.

Carrageenan Model:

Animals were anesthetized with isoflurane (4% induction and 2%maintenance) and 25 μL of 2% λ-carrageenan (Sigma-Aldrich; Saint Louis,Mo.) dissolved in normal saline was injected into the center plantararea on hind paws using an insulin syringe (BD; Franklin Lakes, N.J.

Implantation of Mini Pumps

Alzet micro-osmotic mini pumps (Durect Corporation Model 1003D and2001D) were filled and primed per manufacturer's guide. Mice wereanesthetized with isoflurane (5% induction; 2% maintenance). Their backswere shaved, wiped down with isopropyl alcohol and povidone iodine, anda small incision was made between the scapulae. Using a pair of forcepsor hemostat, a small pocket was formed by spreading the subcutaneousconnective tissues apart. The pump was inserted into the pocket with theflow moderator pointing away from the incision. The skin incision wasthen closed using 7 mm staples and the animals were allowed to recoverin their home cages.

Data Analysis

Data are represented as mean±s.e.m. Prism (Graphpad Software Inc., LaJolla, Calif.) was used for graphing and statistical analysis. Forcomparison of threshold values over time, a two-way ANOVA followed byBonferroni's multiple comparison test was used with a significance levelof p<0.05. Hotplate and MPE % data were analyzed by one-way ANOVAfollowed by Bonferroni's multiple comparison test.

Results

Efficacy of variants NV1D3034-OH (NV1D3034-COOH), NV1D3368-OH(NV1D3368-COOH) and NV1D2775-OH (NV1D2775-COOH) was studied in the CFAmodel, a commonly used model of inflammatory pain. The injection of CFAin the hindpaw induced paw edema (not shown) and hypersensitivity tothermal stimuli (thermal hyperalgesia), as indicated by the loweredthermal latency in the injected paw on day0 (FIG. 6A). Thermalhyperalgesia was completely reversed by NV1D3034-OH at 684 and 1824μg/day, when administered by a subcutaneous osmotic mini-pump (FIGS. 4Aand 4B).

NV1D3368-OH fully reversed CFA-induced thermal hyperalgesia at 684 and1824 μg/day (FIGS. 5A and 5B). NV1D2775-OH demonstrated strong efficacyin the CFA model. Thermal latencies reached values close to the cut-offfollowing NV1D2775 administration (FIGS. 6A and 6B, 1824 μg/day),suggesting a strong analgesia effect on top of the anti-hyperalgesiaeffect. In addition, NV1D2775-OH reversed CFA-induced tactile allodynia(FIGS. 6C and 6D, 1824 μg/day). The anti-hyperalgesic effect ofNV1D2775-OH was seen as early as 4 hr post-pump implantation (FIG. 7A).The effect reached the maximum at 8 hr in both the thermal and tactiletests (FIGS. 7A and 7B), which was maintained at 24 hr. Thermal latencyand tactile threshold returned the control level by 48 h post pumpimplantation (approximately 24 h after the pumps were predicted to beempty) (FIGS. 7A and 7B).

CFA-induced thermal hyperalgesia was readily reversed by two additionalpeptides, NV1D3368-amide (NV1D3368-NH₂) and NV1D3034-N-methylamide(NV1D3034-NHMe). Thermal MPE % from the experiments is summarized inTable 13.

TABLE 13 Dose (μg/day/mouse) Peptide Vehicle (PBS) 228 684 1824NV1D3034-OH 20 ± 7 (11) 22 ± 6 (6) 48 ± 10* (8) 50 ± 6* (8) NV1D3368-OH13 ± 7 (8) 23 ± 8 (7) 42 ± 9* (7) 47 ± 6** (8) NV1D2775-OH 15 ± 4 (20)35 ± 8 (8) 57 ± 12*** (8) 85 ± 6**** (12) NV1D3368-NH₂ 15 ± 13 (6) 27 ±4 (4) 46 ± 9 (4) 55 ± 15 (6) NV1D3034-NHMe 5 ± 25 (3) 49 ± 17 (6) *P <0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001 vs. PBS, one-way ANOVAfollowed by Bonferroni's multiple comparison.

NV1D2775-OH also exhibited strong, dose-dependent efficacy in thehotplate test (FIG. 8). Latencies at 50 and 55° C. reached values nearcut-off following the administration of 1824 μg/day. At 228 μg/day,NV1D2775-OH produced a modest yet significant increase in the thermallatency, compared to the PBS control.

The efficacy of NV1D2775-OH was evaluated in another model ofinflammatory pain, the carrageenan model. Animals were implanted withNV1D2775-OH or PBS pumps. Thermal withdrawal latencies were measuredpre- and on day1 post-pump. λ-carrageenan was injected into the hindpawsand thermal latencies were measured again on 2, 3 and 4 hr followingcarrageenan. NV1D2775-OH at 1824 μg/day produced significant analgesia(FIG. 9). Injection of λ-carrageenan in the hindpaws inducedinflammation (not shown) and lowered thermal paw withdrawal latency inthe Hargreaves test over the 4 hr test-period (FIG. 9, PBS group).Animals pretreated with NV1D2775-OH at 1824 μg/day were fully protectedfrom carrageenan-induced hyperalgesia.

Example 6. Generation and Characterization of Combinatorial Protoxin-IIVariants

An amino acid scanning library was generated for Protoxin-II. At everynon-cysteine position in Protoxin-II (Tyr1, Gln3, Lys4, Trp5, Met6,Trp7, Thr8, Asp10, Ser11, Glu12, Arg13, Lys14, Glu17, Glyl8, Met19,Va120, Arg22, Leu23, Trp24, Lys26, Lys27, Lys28, Leu29 and Trp30) thefollowing residues were substituted in place of the native residue: Ala,Asp, Glu, Phe, Gly, His, Ile, Lys, Leu, Asn, Pro, Gln, Arg, Ser, Thr,Val, and Tyr.

Mutant peptides were expressed as recombinant fusions to human serumalbumin and site-specifically enzymatically cleaved using HRV3C togenerate Protoxin-II variants as described in Example 1. EachProtoxin-II variant, after cleavage from HSA had a residual N-terminalGP from the cleavage site. For each Protoxin-II variant, IC₅₀ valuesagainst human Nav1.7 were measured using FLIPR Tetra or Qpatch accordingto the protocols described in Example 3. Variants demonstrating IC₅₀≦100nM for human Nav1.7 were counter-screened for selectivity againstadditional hNav channels using Qpatch electrophysiology. Selective hitswere identified and used in the design of combinatorial peptidelibraries which were produced using both recombinant expression andsolid-phase peptide synthesis. Combinatorial variants were screenedusing the same strategy as detailed above.

Based on the results, positions that can be mutated to improveselectivity include Gln3, Ser11, Glu12, Lys14, Glu17, Glyl8, Leu29 andTrp30 (residues numbering according to SEQ ID NO: 1).

The solution structure of Protoxin-II was determined by NMR and is shownin FIG. 10 as a surface representation. The left hand side of the Figureshows the previously described (Park et al., J. Med. Chem. 2014,57:6623-6631) ring of Trp residues, W5/W7/W24, surrounding M6. On theopposite side of the molecule, using both mutagenesis and the NMRstructure, a selectivity face was identified in this study onProtoxin-II consisting of multiple amino acid positions which can bemutated to improve selectivity for hNav1.7 over other sodium channelisoforms. The residues residing on the selectivity face include residuesSer11, Glu12, Lys14, Glu17, Glyl8, Leu29 and Trp30 (residue numberingaccording to SEQ ID NO: 1). The identification of the selectivity faceand multiple positions within responsible for selectivity towards Nav1.7has not been described earlier.

Improved selectivity of Protoxin II variants with substitution at Ser11is unexpected as it has been earlier demonstrated that mutation of Ser11affect activity on multiple Nav channels, and therefore the residue wasconcluded not to play a role in Protoxin-II Nav1.7 selectivity (Park etal., J. Med. Chem. 2014, 57:6623-6631).

A key step in the synthetic production of Protoxin-II variants is theoxidative refolding of the linear peptide, where the disulfide pairingsare formed. The RP-HPLC trace for native Protoxin-II purificationfollowing refolding revealed multiple peaks at differing retention timesthat were of correct mass but demonstrated differing levels of activity,indicative of improper folding of the peptide.

The relative abundance of the RP-HPLC major peak, and therefore therelative abundance of correctly folded peptide could be improved bymaking substitutions at various Protoxin-II positions. Mutation of Trp7or Trp30 improved folding of the resulting Protoxin-II variant. Mutationof both Trp7 and Trp30 in combination further improved folding of theresulting Protoxin-II variant, and could rescue folding ofdifficult-to-refold Protoxin-II variants.

Production of combinatorial mutant peptides having one or moresubstitutions that improved selectivity (Gln3, Ser11, Glu12, Lys14,Glu17, Glyl8, and Leu29) as well as mutations at Trp7 and Trp30 resultedin peptides with both improved selectivity and improved refoldingproperties. Protoxin-II belongs to a family 3 of inhibitory cysteineknot peptides (Klint et. al., Toxicon 60:478-491, 2012). Trp7 isconserved in all family 3 members, and substitutions at this position aswell as at Trp5 and Met6 in Jingzhaotoxin-V, another family 3 inhibitorycysteine knot peptide, resulted in loss in potency, indicating thathydrophobic residues at positions 5, 6 and 7 in Jingzhaotoxin-V areessential to Jingzhaotoxin-V Nav1.7 inhibitory potency (Int. Pat. Publ.No. 2014/165277). Trp5/Met6/Trp7 is also conserved in Protoxin-II, andtherefore it was unexpected that polar substitutions at Trp7 can be madewithout loss of Protoxin-II activity with significantly improvedrefolding properties. Substitutions at Trp30 were shown tosimultaneously improve Nav1.7 selectivity and refolding properties ofthe variant peptide and were unexpected since individual advantageoussubstitutions typically only improve a single parameter.

Table 14 shows the amino acid sequences of the select generatedProtoxin-II variants.

TABLE 14 Protein Protein Name Substitution SEQ ID NO:Amino acid sequence NV1G2232 W30L 408 GPYCQKWMWTCDSERKCCEGMVCRLWCKKKLL-COOH NV1G2182 W30F 409 WPYCQKWMWTCDSERKCCEGMVCRLWCKKKL F-COOH NV1G2319W30Y 410 GPYCQKWMWTCDSERKCCEGMVCRLWCKKKL Y-COOH NV1G2329 W30G 411GPYCQKWMWTCDSERKCCEGMVCRLWCKKKL G-COOH NV1G2129 W30I 412GPYCQKWMWTCDSERKCCEGMVCRLWCKKKL I-COOH NV1G2291 W30V 413GPYCQKWMWTCDSERKCCEGMVCRLWCKKKL V-CCOH NV1G2156 W7Y 414GPYCQKWMYTCDSERKCCEGMVCRLWCKKKL W-COOH NV1G2082 W7E 415GPYCQKWMETCDSERKCCEGMVCRLWCKKKL W-COOH 63930841 W7Q 416GPYCQKWMQTCDSERKCCEGMVCRLWCKKKL W-COOH 64087946 (-GP) 417YCQKWMQTCDAERKCCEGFSC-(N-Me- W7Q, S11A, M19F, Arg)-LWCKKKLL-COOHV20S, R22Me, W30L 64053366 (-GP) W7Q S11D 418YCQKWMQTCDDERKCCEGMVCRLWCKKKLL- W30L COOH 64053340 (GP) W7Q K14F W30L419 YCQKWMQTCDSERFCCEGMVCRLWCKKKLL- COOH 64053236 W7Q, K14F W30L 420GPYCQKWMQTCDSERFCCEGMVCRLWCKKKL L-COOH 64053223 W7Q S11I W30L 421GPYCQKWMQTCDIERKCCEGMVCRLWCKKKL L-COOH 63955918 W7Q W30L 422GPYCQKSWMQTCDSERKCCEGMVCRLWCKKK LL-COOH 64053210 W7Q E17N W30L 423GPYCQKWMQTCDSERKCCNGMVCRLWCKKKL L-COOH 64087907 (-GP) W7Q 424YCQKWMQTCDSERKCCEGMVCRLWCKKKLW- COOH 64032488 (-GP) W7Q W30L 425YCQKWMQTCDSERKCCEGMVCRLWCKKKLL- COOH 64053301 W7Q S11V W30L 426GPYCQKSMQTCDVERKCCEGMVCRLWCKKKL L-COOH 64053275 W7Q E17L W30L 427GPYCQKWMQTCDSERKCCLGMVCRLWCKKKL L-COOH 64053327 (-GP) W7Q E17N 428YCQKWMQTCDSERKCCNGMVCRLWCKKKLL- W30L COOH NV1G2324 E17Y 429GPYCQKWMWTCDSERKCCYGMVCRLWCKKKL W-COOH NV1G2094 E17I 430GPYCQKWMWTCDSERKCCIGMVCRLWCKKKL W-COOH NV1G1996 E17L 431GPYCQKWMWTCDSERKCCLGMVCRLWCKKKL W-COOHSelect variants were characterized for their inhibition of Nav1.7 usingFLIPR Tetra or Qpatch as described in Example 3. Table 15 shows the IC₅₀values obtained. For some variants, % inhibition at certainconcentration was recorded for Qpatch results (% of Protoxin-II).

TABLE 15 Protein hNav1.7 Protein SEQ ID TETRA QP Name NO: IC50 (nM) se*IC50 (nM) % blk** se* NV1G2232 408 16.7 1.32 5.0 56.5% @ 10 nM 5.7NV1G2182 409 17.3 1.37 3.8 54.2% @ 10 nM 5.4 NV1G2319 410 20.7 2.3 9.743.2% @ 10 nM 6.2 NV1G2329 411 38 2.43E+00 NV1G2129 412 47.3 3.81 −6.5%@ 10 nM 6.5 NV1G2291 413 63.3 14.9 NV1G2156 414 90.5 6.88 NV1G2082 41590.8 11.4 63930841 416 20.9 64087946 417 23.8 20.7% @ 10 nM 10.964053366 418 22.1% @ 10 nM 3.5 64053340 419 26.8% @ 10 nM 3.7 64053236420 28.0% @ 10 nM 13.2 64053223 421 33.0% @ 10 nM 5.8 63955918 422 10.838.50% @ 10 nM  4.5 64053210 423 41.7% @ 10 nM 6.2 64087907 424 7.145.1% @ 10 nM 6.0 64032488 425 6.5 45.6% @ 10 nM 4.6 64053301 426 10.745.83% @ 10 nM  3.3 64053275 427 2.9 48.22% @ 10 nM  5.2 64053327 4287.9 51.9% @ 10 nM 2.6 NV1G2324 429 57.5% @ 10 nM 3.9 NV1G2094 430 63.2%@ 30 nM 6.2 NV1G1996 431 0.5 76.9% @ 10 nM 2.3 *se; standard error **%blk: QP: QPatch

Selectivity of select variants were tested against various human Nav1.xchannels. Table 16 shows the results of those experiments. IC50 valuesfor each channel were measured using QPatch.

TABLE 16 Protein Protein SEQ ID IC₅₀ (nM) Name Substitution NO: Nav1.1Nav1.2 Nav1.4 Nav1.6 NV1G2232 W30L 408 3847.0 562.7 NV1G2182 W30F 409239.6 732.2 253.1 NV1G2319 W30Y 410 1704.0 63930841 W7Q 416 543.164087946 (-GP) 417 2586.0 W7Q, S11A, M19F, V20S, R22Me, W30L 63955918W7Q W30L 422 1951.0 17000.0 1987.0 64087907 (-GP) W7Q 424 1460.064032488 (-GP) W7Q 425 1336.0 1842.0 W30L 64053301 W7Q S11V 426 15340.019350.0 2244.0 W30L 64053275 W7Q E17L 427 3868.0 136.7 2219.0 W30L64053327 (-GP) W7Q 428 6391.0 6656.0 3867.0 E17N W30L

Protoxin-II variants were expressed and purified as described in Example1, or synthesized by standard solid phase synthesis methods. The yieldsof the recombinant or synthetic peptides were compared to the yields ofthe wild-type protoxin. Table 17 shows that the yields of the selectprotoxin-II variants were significantly higher than that of protoxin-II,indicating improved folding properties of the variants. The scale of thesolid-phase synthesis was 0.1 mmol.

TABLE 17 total yield Protein name Substitution (mg) NV1D12 (Protoxin-IIwith 3.8 N-terminal GP) 63930841 W7Q 14.4 NV1G2232 W30L 14.5 63955918W7Q, W30L 16.2 NV1G1996 E17L 1.8 64053275 E17L W7Q W30L 13.0

Example 7. Protoxin-II Variants are Efficient in In Vivo Models of PainFollowing Intrathecal Administration

Efficacy of select Protoxin-II variants in reducing pain afterintrathecal administration was evaluated.

Peptides NV1D2775-OH, NV1D3034 and 63955918 were used in the studies.Animal models that measure acute thermal pain (tail flick and hot plate)and injury-induced pain (formalin flinching) were used.

Tail-Flick Test:

The animals were placed on a tail-flick device (Ugo Basile). The devicehas a focal infrared light heating area (diameter-5 mm). The tail (⅓-½way from distal end) of the animal was placed on the focal heating area.The temperature of the heat source was adjusted to elicit a tail-flickwithin 10 seconds in animals treated with vehicle. A 15 second cut-offtime was used to prevent tissue damage, as is standard in theliterature. The time elapsed between the start of the heat stimulus andany avoidance response was measured automatically and recorded for thetest groups.

Hot Plate Test:

The animal was placed on a 10″×10″ metal plate surrounded by 4 Plexiglaswalls (15 inches high) and maintained at a temperature of 48-55° C. Ifthe animal licked its hind paw, jumped, or vocalized, it was removedfrom the plate and the response latency was be documented. If the animaldid not show any response within 20-90 seconds (cut-off time), it was beremoved from the plate to prevent any possible tissue damage.

Formalin Flinching:

Hindpaw injection of formalin-induced pain behavior (i.e. paw flinches)was measured using an automated “flinch response” measuring device UCSD.The device detects any sudden movement of a metal band glued onto onehind paw of the animal using a motion sensor installed underneath thedevice floor. One-half to one hour prior to formalin injection, a smallmetal band was attached to the plantar surface of one hind paw using asmall drop of cyanoacrylate and the animal was placed in the testingchamber to be acclimatized. The attachment of the metal band did notappear to be irritating to the animal. Formalin (2.5%, 50 μL) wasinjected subcutaneously into the dorsum of the paw with the metal band.The animal was placed in the customized cylinder (25×10×20 cm, San DiegoInstrument) immediately after intraplantar formalin injection. Pawflinches were recorded automatically.

In the acute thermal pain models, Protoxin-II variant 63955918 producedpotent and prolonged analgesia as indicated by the elevated latency inthe tail flick test (FIG. 11A and FIG. 11B) and hot plate test (FIG.11C, FIG. 11D) after a single intrathecal administration. Thesignificance and duration of the analgesia was dose-dependent.

Hindpaw formalin injection is a commonly used model for injury-inducedpain. The injection induces a characteristic, bi-phasic flinchingbehavior, which indicates pain in test animals. As shown in FIG. 11E,animals pretreated with intrathecal injection of Protoxin-II variant63955918 demonstrated less flinches in the formalin test, suggesting aninhibition of injury-induced pain.

Similarly, peptides NV1D2775-OH and NV1D3034 demonstrated significantefficacy in the tail flick, hot plate and formalin test (FIG. 12A, FIG.12B, FIG. 12C, FIG. 12D, FIG. 12E, FIG. 13A, FIG. 13B, FIG. 13C, FIG.13D, FIG. 13E) following a single intrathecal administration.

We claim: 1) An isolated Protoxin-II variant, wherein the Protoxin-IIvariant inhibits human Nav1.7 activity with an IC₅₀ value of about1×10⁻⁷ M or less, about 1×10⁻⁸ M or less, about 1×10⁻⁹ M or less, about1×10⁻¹⁰ M or less, wherein the IC₅₀ value is measured using a FLIPR®Tetra membrane depolarization assay using fluorescence resonance energytransfer (FRET) in the presence of 25×10⁻⁶ M 3-veratroylveracevine inHEK293 cells stably expressing human Nav1.7, wherein the Protoxin-IIvariant has a W7Q and/or a W30L substitution, wherein residue numberingis according to SEQ ID NO:
 1. 2) The isolated Protoxin-II variant ofclaim 1, comprising the sequenceX₁X₂X₃CX₄X₅WX₆QX₇CX₈X₉X₁₀X₁₁X₁₂CCX₁₃X₁₄FX₁₅CX₁₆LWCX₁₇KKLL (SEQ ID NO:432), wherein X₁ is G, P, A or deleted; X₂ is P, A or deleted; X₃ is S,Q, A, R or Y; X₄ is Q, R, K, A or S; X₅ is K, S, Q or R; X₆ is M or F;X₇ is T, S, R, K or Q; X₈ is D or T; X₉ is S, A or R; X₁₀ is E, R, N, K,T or Q; X₁₁ is R or K; X₁₂ is K, Q, S or A; X₁₃ is E, Q or D; X₁₄ is Gor Q; X₁₅ is V or S; X₁₆ is R or T; and X₁₇ is K or R; optionally havingan N-terminal extension or a C-terminal extension, wherein thepolypeptide inhibits human Nav1.7 activity with an IC₅₀ value of about1×10⁻⁷ M or less, wherein the IC₅₀ value is measured using a FLIPR®Tetra membrane depolarization assay using fluorescence resonance energytransfer (FRET) in the presence of 25×10⁻⁶ M 3-veratroylveracevine inHEK293 cells stably expressing human Nav1.7. 3) The Protoxin-II variantof claim 2, wherein the N-terminal extension comprises the amino acidsequence of SEQ ID NOs: 372, 373, 374, 375, 376, 377, 378, 379, 380,381, 382, 383, 384 or 385 and/or the C-terminal extension comprises theamino acid sequence of SEQ ID NOs: 374, 386, 387, 388, 389, 390, 391,392, 393, 394, 395, 396 or
 397. 4) The Protoxin-II variant of claim 2,wherein the C-terminal extension comprises the amino acid sequence ofSEQ ID NOs: 374, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396or
 397. 5) The Protoxin-II variant of claim 3, wherein the N-terminaland/or the C-terminal extension is conjugated to the Protoxin-II variantvia a linker. 6) The Protoxin-II variant of claim 5, wherein the linkercomprises the amino acid sequence of SEQ ID NOs: 383, 392, 398, 399,400, 401 or
 402. 7) The isolated Protoxin-II variant of any of the claim1, comprising the amino acid sequence of SEQ ID NOs: 30, 40, 44, 52, 56,56, 59, 65, 78, 109, 110, 111, 114, 117, 118, 119, 120, 121, 122, 123,124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137,138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151,152, 153, 154, 155, 156, 157, 158, 159, 162, 165, 166, 167, 168, 169,170, 171, 172, 173, 174, 175, 177, 178, 179, 180, 182, 183, 184, 185,186, 189, 190, 193, 195, 197, 199, 206, 207, 208, 209, 210, 211, 212,213, 214, 215, 216, 217, 218, 224, 226, 227, 231, 232, 243, 244, 245,247, 249, 252, 255, 258, 261, 263, 264, 265, 266, 269, 270, 271, 272,273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286,287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300,301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314,315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 332, 334,335, 336, 337, 339, 340, 341, 342, 346, 351, 358, 359, 364, 366, 367,368, 369, 370, 371, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417,418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430 or 431.8) The isolated Protoxin-II variant of any of the claim 1, that inhibitshuman Nav1.7 activity with an IC₅₀ value of about 3×10⁻⁸ M or less. 9)The isolated Protoxin-II variant of claim 8 that inhibits human Nav1.7activity with an IC₅₀ value of between about 3×10⁻⁸ M to about 1×10⁻⁹ M.10) The isolated Protoxin-II variant of claim 8, comprising the aminoacid sequence GPQCX₁X₂WX₃QX₄CX₅X₆X₇X₈X₉CCX₁₀X₁₁FX₁₂CX₁₃LWCX₁₄KKLL (SEQID NO: 433), wherein X₁ is Q, R, K, A or S; X₂ is K, S, Q or R; X₃ is Mor F; X₄ is T, S, R, K or Q; X₅ is D or T; X₆ is S, A or R; X₇ is E, R,N, K, T or Q; X₈ is R or K; X₉ is K, Q, S or A; X₁₀ is E, Q or D; X₁₁ isG or Q; X₁₂ is V or S; X₁₃ is R or T; and X₁₄ is K or R. 11) Theisolated Protoxin-II variant of any of the claim 1, comprising the aminoacid sequence of SEQ ID NOs: 56, 78, 111, 114, 117, 118, 119, 122, 123,129, 130, 131, 132, 133, 134, 135, 136, 138, 139, 140, 141, 142, 145,146, 147, 149, 150, 151, 152, 153, 154, 156, 158, 159, 165, 172, 173,175, 177, 178, 183, 184, 185, 186, 189, 190, 193, 197, 199, 207, 210,211, 216, 217, 224, 266, 273, 282, 335, 408, 409, 410, 422, 424, 425,426, 427 and
 428. 12) An isolated Protoxin-II variant comprising theamino acid sequence that is 90%, identical to the amino acid sequence ofSEQ ID NO: 422 (GPYCQKWMQTCDSERKCCEGMVCRLWCKKKLL-COOH); wherein theProtoxin-II variant has Q at position 7 and L at position 30, whenresidue numbering is according to SEQ ID NO: 1; and the polypeptideinhibits human Nav1.7 activity with an IC₅₀ value of about 30×10⁻⁹ M orless, wherein the IC₅₀ value is measured using a FLIPR® Tetra membranedepolarization assay using fluorescence resonance energy transfer (FRET)in the presence of 25×10⁻⁶ M 3-veratroylveracevine in HEK293 cellsstably expressing human Nav1.7. 13) The isolated Protoxin-II variant ofany of the claim 1, having a free C-terminal carboxylic acid, amide,methylamide or butylamide group. 14) An isolated fusion proteincomprising the Protoxin-II variant of claim 1 conjugated to a half-lifeextending moiety. 15) The fusion protein of claim 14, wherein thehalf-life extending moiety is human serum albumin (HSA), albumin bindingdomain (ABD), Fc or polyethylene glycol (PEG). 16) An isolatedpolynucleotide encoding the Protoxin-II variant of claim
 12. 17) Avector comprising the isolated polynucleotide of claim
 16. 18) A hostcell comprising the vector of claim
 17. 19) A method of producing theisolated Protoxin-II variant, comprising culturing the host cell ofclaim 18 and recovering the Protoxin-II variant produced by the hostcell. 20) A pharmaceutical composition comprising the isolatedProtoxin-II variant or fusion protein of any of the claim 1 and apharmaceutically acceptable excipient. 21) A method of treatingNav1.7-mediated pain in a subject, comprising administering to a subjectin need thereof an effective amount of the Protoxin-II variant or thefusion protein of any of the claim 1 to treat the pain. 22) The methodof claim 21, wherein pain is chronic pain, acute pain, neuropathic pain,nociceptive pain, visceral pain, back pain, post-operative pain, thermalpain, phantom limb pain, or pain associated with inflammatoryconditions, primary erythemalgia (PE), paraoxysmal extreme pain disorder(PEPD), osteoarthritis, rheumatoid arthritis, lumbar discectomy,pancreatitis, fibromyalgia, painful diabetic neuropathy (PDN),post-herpetic neuropathy (PHN), trigeminal neuralgia (TN), spinal cordinjuries or multiple sclerosis. 23) The method of claim 22, wherein theProtoxin-II variant is administered peripherally. 24) The method ofclaim 23, wherein the Protoxin-II variant is administered locally to ajoint, spinal cord, surgical wound, sites of injury or trauma,peripheral nerve fibers, urogenital organs, or inflamed tissues. 25) Themethod of claim 24, wherein the subject is a human. 26) The Protoxin-IIvariant or fusion proteins of any of the claims 1-15 for use in treatingpain in a subject in need thereof.